primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
139113815,13911381,20,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q1,Blood pressure increased,,2019,Q1,5,F,2016.0,20190213.0,20170828,20190221,EXP,,CA-AMGEN-CANSP2016172409,AMGEN,,67.0,YR,E,M,Y,90.0,KG,20190221.0,,OT,CA,CA,2019,Q1,Elderly
139113815,13911381,20,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q1,Crohn's disease,,2019,Q1,5,F,2016.0,20190213.0,20170828,20190221,EXP,,CA-AMGEN-CANSP2016172409,AMGEN,,67.0,YR,E,M,Y,90.0,KG,20190221.0,,OT,CA,CA,2019,Q1,Elderly
139113815,13911381,20,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q1,Fatigue,,2019,Q1,5,F,2016.0,20190213.0,20170828,20190221,EXP,,CA-AMGEN-CANSP2016172409,AMGEN,,67.0,YR,E,M,Y,90.0,KG,20190221.0,,OT,CA,CA,2019,Q1,Elderly
139113815,13911381,20,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q1,Skin laceration,,2019,Q1,5,F,2016.0,20190213.0,20170828,20190221,EXP,,CA-AMGEN-CANSP2016172409,AMGEN,,67.0,YR,E,M,Y,90.0,KG,20190221.0,,OT,CA,CA,2019,Q1,Elderly
139113815,13911381,20,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q1,Type 1 diabetes mellitus,,2019,Q1,5,F,2016.0,20190213.0,20170828,20190221,EXP,,CA-AMGEN-CANSP2016172409,AMGEN,,67.0,YR,E,M,Y,90.0,KG,20190221.0,,OT,CA,CA,2019,Q1,Elderly
141686063,14168606,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ALSO RECEIVED 10 MG ON 15-NOV-2017,,,Y,,,,,,,TABLET,,2019,Q1,Acute kidney injury,,2019,Q1,3,F,20171010.0,20190129.0,20171108,20190212,EXP,GB-MHRA-ADR 24225544,GB-ACCORD-060710,ACCORD,,78.0,YR,,M,Y,,,20190212.0,,MD,GB,GB,2019,Q1,Elderly
141686063,14168606,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ALSO RECEIVED 10 MG ON 15-NOV-2017,,,Y,,,,,,,TABLET,,2019,Q1,Epididymitis,,2019,Q1,3,F,20171010.0,20190129.0,20171108,20190212,EXP,GB-MHRA-ADR 24225544,GB-ACCORD-060710,ACCORD,,78.0,YR,,M,Y,,,20190212.0,,MD,GB,GB,2019,Q1,Elderly
141686063,14168606,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ALSO RECEIVED 10 MG ON 15-NOV-2017,,,Y,,,,,,,TABLET,,2019,Q1,Feeling hot,,2019,Q1,3,F,20171010.0,20190129.0,20171108,20190212,EXP,GB-MHRA-ADR 24225544,GB-ACCORD-060710,ACCORD,,78.0,YR,,M,Y,,,20190212.0,,MD,GB,GB,2019,Q1,Elderly
141686063,14168606,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ALSO RECEIVED 10 MG ON 15-NOV-2017,,,Y,,,,,,,TABLET,,2019,Q1,Groin pain,,2019,Q1,3,F,20171010.0,20190129.0,20171108,20190212,EXP,GB-MHRA-ADR 24225544,GB-ACCORD-060710,ACCORD,,78.0,YR,,M,Y,,,20190212.0,,MD,GB,GB,2019,Q1,Elderly
141686063,14168606,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ALSO RECEIVED 10 MG ON 15-NOV-2017,,,Y,,,,,,,TABLET,,2019,Q1,Hypotension,,2019,Q1,3,F,20171010.0,20190129.0,20171108,20190212,EXP,GB-MHRA-ADR 24225544,GB-ACCORD-060710,ACCORD,,78.0,YR,,M,Y,,,20190212.0,,MD,GB,GB,2019,Q1,Elderly
1416873113,14168731,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q1,Diabetic metabolic decompensation,,2019,Q1,13,F,20140101.0,20190304.0,20171107,20190308,EXP,IT-MINISAL02-433704,IT-MYLANLABS-2017M1068934,MYLAN,BELVISO A.. DAPAGLIFLOZIN: OLTRE IL CONTROLLO GLICEMICO IN UN PAZIENTE DIABETICO SCOMPENSATO.. MEDIA.. 2017;17:162-163,63.0,YR,,F,Y,,,20190308.0,,CN,IT,IT,2019,Q1,Adult
145193493,14519349,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Myocardial infarction,,2019,Q1,3,F,20180208.0,20190218.0,20180212,20190221,EXP,,PL-ASTRAZENECA-2018SE17897,ASTRAZENECA,,25602.0,DY,,M,Y,,,20190221.0,,MD,PL,PL,2019,Q1,Elderly
145193493,14519349,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Myocardial infarction,,2019,Q1,3,F,20180208.0,20190218.0,20180212,20190221,EXP,,PL-ASTRAZENECA-2018SE17897,ASTRAZENECA,,25602.0,DY,,M,Y,,,20190221.0,,MD,PL,PL,2019,Q1,Elderly
145193493,14519349,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Myocardial infarction,,2019,Q1,3,F,20180208.0,20190218.0,20180212,20190221,EXP,,PL-ASTRAZENECA-2018SE17897,ASTRAZENECA,,25602.0,DY,,M,Y,,,20190221.0,,MD,PL,PL,2019,Q1,Elderly
146161933,14616193,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,5.0,MG,,BID,2019,Q1,General physical health deterioration,,2019,Q1,3,F,20180213.0,20190206.0,20180309,20190211,EXP,,ES-ROCHE-2082970,ROCHE,,65.0,YR,,M,Y,93.0,KG,20190211.0,,MD,ES,ES,2019,Q1,Elderly
146408002,14640800,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,2,F,,20190206.0,20180315,20190214,EXP,,GB-ASTRAZENECA-2016SF11955,ASTRAZENECA,,59.0,YR,,,Y,,,20190214.0,,OT,GB,GB,2019,Q1,Adult
146408002,14640800,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Off label use,,2019,Q1,2,F,,20190206.0,20180315,20190214,EXP,,GB-ASTRAZENECA-2016SF11955,ASTRAZENECA,,59.0,YR,,,Y,,,20190214.0,,OT,GB,GB,2019,Q1,Adult
146408002,14640800,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,2,F,,20190206.0,20180315,20190214,EXP,,GB-ASTRAZENECA-2016SF11955,ASTRAZENECA,,59.0,YR,,,Y,,,20190214.0,,OT,GB,GB,2019,Q1,Adult
146543553,14654355,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,3,F,,20190206.0,20180319,20190214,EXP,,GB-ASTRAZENECA-2016SF11966,ASTRAZENECA,,51.0,YR,,F,Y,,,20190214.0,,MD,GB,GB,2019,Q1,Adult
146543553,14654355,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Off label use,,2019,Q1,3,F,,20190206.0,20180319,20190214,EXP,,GB-ASTRAZENECA-2016SF11966,ASTRAZENECA,,51.0,YR,,F,Y,,,20190214.0,,MD,GB,GB,2019,Q1,Adult
146543553,14654355,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,3,F,,20190206.0,20180319,20190214,EXP,,GB-ASTRAZENECA-2016SF11966,ASTRAZENECA,,51.0,YR,,F,Y,,,20190214.0,,MD,GB,GB,2019,Q1,Adult
146831785,14683178,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Diabetic metabolic decompensation,,2019,Q1,5,F,20140101.0,20190219.0,20180327,20190303,EXP,IT-MINISAL02-435560,IT-ACCORD-065153,ACCORD,,63.0,YR,,F,Y,,,20190302.0,,OT,IT,IT,2019,Q1,Adult
149753274,14975327,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1600.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Cellulitis,,2019,Q1,4,F,20180430.0,20190117.0,20180605,20190124,EXP,,US-ASTRAZENECA-2018SE72104,ASTRAZENECA,,19478.0,DY,,M,Y,,,20190125.0,,MD,US,US,2019,Q1,Elderly
149753274,14975327,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1600.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Sepsis,,2019,Q1,4,F,20180430.0,20190117.0,20180605,20190124,EXP,,US-ASTRAZENECA-2018SE72104,ASTRAZENECA,,19478.0,DY,,M,Y,,,20190125.0,,MD,US,US,2019,Q1,Elderly
151346755,15134675,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, IN THE MORNING",,,U,,,,,10.0,MG,,,2019,Q1,Lower respiratory tract infection,,2019,Q1,5,F,20180102.0,20190128.0,20180712,20190201,EXP,,PHHO2018GB000903,NOVARTIS,,62.0,YR,,M,Y,99.1,KG,20190201.0,,OT,GB,GB,2019,Q1,Adult
151346755,15134675,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, IN THE MORNING",,,U,,,,,10.0,MG,,,2019,Q1,Pancreatitis acute,,2019,Q1,5,F,20180102.0,20190128.0,20180712,20190201,EXP,,PHHO2018GB000903,NOVARTIS,,62.0,YR,,M,Y,99.1,KG,20190201.0,,OT,GB,GB,2019,Q1,Adult
154328082,15432808,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Fournier's gangrene,,2019,Q1,2,F,20180817.0,20190110.0,20180927,20190115,EXP,,DE-ASTRAZENECA-2018SF23970,ASTRAZENECA,,39.0,YR,,M,Y,160.0,KG,20190115.0,,,DE,DE,2019,Q1,Adult
155004353,15500435,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Cardiac failure congestive,,2019,Q1,3,F,20181011.0,20190213.0,20181015,20190219,EXP,,IN-ASTRAZENECA-2018SF32909,ASTRAZENECA,,22047.0,DY,,M,Y,,,20190219.0,,MD,IN,IN,2019,Q1,Elderly
155004353,15500435,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Cardiac failure congestive,,2019,Q1,3,F,20181011.0,20190213.0,20181015,20190219,EXP,,IN-ASTRAZENECA-2018SF32909,ASTRAZENECA,,22047.0,DY,,M,Y,,,20190219.0,,MD,IN,IN,2019,Q1,Elderly
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Decreased vibratory sense,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Gastrointestinal disorder,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Limb discomfort,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Neuropathy peripheral,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Pain in extremity,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Sensory disturbance,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Sleep disorder,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Temperature perception test abnormal,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U, UNK,,,10.0,MG,TABLET,QD,2019,Q1,Visual impairment,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Decreased vibratory sense,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Gastrointestinal disorder,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Limb discomfort,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Neuropathy peripheral,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Pain in extremity,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Sensory disturbance,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Sleep disorder,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Temperature perception test abnormal,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U, UNK,,,,,TABLET,,2019,Q1,Visual impairment,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Decreased vibratory sense,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Gastrointestinal disorder,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Limb discomfort,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Neuropathy peripheral,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Pain in extremity,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Sensory disturbance,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Sleep disorder,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Temperature perception test abnormal,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155183717,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U, UNK,,,10.0,MG,TABLET,,2019,Q1,Visual impairment,,2019,Q1,7,F,2016.0,20190308.0,20181017,20190313,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20190313.0,,OT,DE,DE,2019,Q1,Adult
155986402,15598640,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,, UNK,,,,,,,2019,Q1,Acute myocardial infarction,,2019,Q1,2,F,,20181228.0,20181108,20190104,EXP,,GR-MYLANLABS-2018M1083934,MYLAN,DALIANIS A.. THE IMPORTANCE OF OPTIMAL TREATMENT IN TREATING PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CARDIOMYOPATHY. 3RD SYMPOSIUM ON CARDIO-ONCOLOGY AND HEART FAILURE (BOOK OF PROCEEDINGS).. 2018,43.0,YR,,M,Y,88.0,KG,20190104.0,,OT,GR,GR,2019,Q1,Adult
155986402,15598640,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,, UNK,,,,,,,2019,Q1,Cardiac failure,,2019,Q1,2,F,,20181228.0,20181108,20190104,EXP,,GR-MYLANLABS-2018M1083934,MYLAN,DALIANIS A.. THE IMPORTANCE OF OPTIMAL TREATMENT IN TREATING PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CARDIOMYOPATHY. 3RD SYMPOSIUM ON CARDIO-ONCOLOGY AND HEART FAILURE (BOOK OF PROCEEDINGS).. 2018,43.0,YR,,M,Y,88.0,KG,20190104.0,,OT,GR,GR,2019,Q1,Adult
155986402,15598640,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,, UNK,,,,,,,2019,Q1,Product use in unapproved indication,,2019,Q1,2,F,,20181228.0,20181108,20190104,EXP,,GR-MYLANLABS-2018M1083934,MYLAN,DALIANIS A.. THE IMPORTANCE OF OPTIMAL TREATMENT IN TREATING PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CARDIOMYOPATHY. 3RD SYMPOSIUM ON CARDIO-ONCOLOGY AND HEART FAILURE (BOOK OF PROCEEDINGS).. 2018,43.0,YR,,M,Y,88.0,KG,20190104.0,,OT,GR,GR,2019,Q1,Adult
156045065,15604506,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,TABLET,,2019,Q1,Chest pain,,2019,Q1,5,F,,20190311.0,20181110,20190314,EXP,,PHHY2018PT147150,SANDOZ,,54.0,YR,,F,Y,,,20190314.0,,OT,PT,PT,2019,Q1,Adult
156045065,15604506,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,TABLET,,2019,Q1,Headache,,2019,Q1,5,F,,20190311.0,20181110,20190314,EXP,,PHHY2018PT147150,SANDOZ,,54.0,YR,,F,Y,,,20190314.0,,OT,PT,PT,2019,Q1,Adult
156045065,15604506,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,TABLET,,2019,Q1,Ischaemic stroke,,2019,Q1,5,F,,20190311.0,20181110,20190314,EXP,,PHHY2018PT147150,SANDOZ,,54.0,YR,,F,Y,,,20190314.0,,OT,PT,PT,2019,Q1,Adult
156383792,15638379,18,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q1,Chest pain,,2019,Q1,2,F,2018.0,20190214.0,20181120,20190226,EXP,,PT-AMGEN-PRTSP2018165248,AMGEN,,54.0,YR,A,F,Y,110.0,KG,20190225.0,,OT,PT,PT,2019,Q1,Adult
156383792,15638379,18,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q1,Headache,,2019,Q1,2,F,2018.0,20190214.0,20181120,20190226,EXP,,PT-AMGEN-PRTSP2018165248,AMGEN,,54.0,YR,A,F,Y,110.0,KG,20190225.0,,OT,PT,PT,2019,Q1,Adult
156383792,15638379,18,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q1,Ischaemic stroke,,2019,Q1,2,F,2018.0,20190214.0,20181120,20190226,EXP,,PT-AMGEN-PRTSP2018165248,AMGEN,,54.0,YR,A,F,Y,110.0,KG,20190225.0,,OT,PT,PT,2019,Q1,Adult
156444348,15644434,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,202293.0,,,TABLET,,2019,Q1,Chest pain,,2019,Q1,8,F,,20190315.0,20181121,20190322,EXP,,PT-ASTRAZENECA-2018SF50815,ASTRAZENECA,,54.0,YR,,F,Y,,,20190322.0,,CN,PT,PT,2019,Q1,Adult
156444348,15644434,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,202293.0,,,TABLET,,2019,Q1,Headache,,2019,Q1,8,F,,20190315.0,20181121,20190322,EXP,,PT-ASTRAZENECA-2018SF50815,ASTRAZENECA,,54.0,YR,,F,Y,,,20190322.0,,CN,PT,PT,2019,Q1,Adult
156444348,15644434,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,202293.0,,,TABLET,,2019,Q1,Ischaemic stroke,,2019,Q1,8,F,,20190315.0,20181121,20190322,EXP,,PT-ASTRAZENECA-2018SF50815,ASTRAZENECA,,54.0,YR,,F,Y,,,20190322.0,,CN,PT,PT,2019,Q1,Adult
156579644,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q1,Chest pain,,2019,Q1,4,F,,20190312.0,20181126,20190318,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190318.0,,OT,PT,PT,2019,Q1,Adult
156579644,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q1,Headache,,2019,Q1,4,F,,20190312.0,20181126,20190318,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190318.0,,OT,PT,PT,2019,Q1,Adult
156579644,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q1,Ischaemic stroke,,2019,Q1,4,F,,20190312.0,20181126,20190318,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190318.0,,OT,PT,PT,2019,Q1,Adult
156659133,15665913,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q1,Chest pain,,2019,Q1,3,F,,20190213.0,20181128,20190218,EXP,PT-002147023-PHHY2018PT147150,PT-FRESENIUS KABI-FK201812057,FRESENIUS KABI,,54.0,YR,,F,Y,,,20190218.0,,OT,GB,PT,2019,Q1,Adult
156659133,15665913,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q1,Headache,,2019,Q1,3,F,,20190213.0,20181128,20190218,EXP,PT-002147023-PHHY2018PT147150,PT-FRESENIUS KABI-FK201812057,FRESENIUS KABI,,54.0,YR,,F,Y,,,20190218.0,,OT,GB,PT,2019,Q1,Adult
156659133,15665913,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q1,Ischaemic stroke,,2019,Q1,3,F,,20190213.0,20181128,20190218,EXP,PT-002147023-PHHY2018PT147150,PT-FRESENIUS KABI-FK201812057,FRESENIUS KABI,,54.0,YR,,F,Y,,,20190218.0,,OT,GB,PT,2019,Q1,Adult
156702895,15670289,11,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q1,Chest pain,,2019,Q1,5,F,,20190315.0,20181129,20190328,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20190328.0,,OT,PT,PT,2019,Q1,Adult
156702895,15670289,11,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q1,Headache,,2019,Q1,5,F,,20190315.0,20181129,20190328,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20190328.0,,OT,PT,PT,2019,Q1,Adult
156702895,15670289,11,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q1,Ischaemic stroke,,2019,Q1,5,F,,20190315.0,20181129,20190328,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20190328.0,,OT,PT,PT,2019,Q1,Adult
156770202,15677020,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,2,F,20181102.0,20190125.0,20181130,20190201,EXP,,GB-ASTRAZENECA-2018SF55656,ASTRAZENECA,,63.0,YR,,M,Y,85.5,KG,20190201.0,,,GB,GB,2019,Q1,Adult
156770202,15677020,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Vomiting,,2019,Q1,2,F,20181102.0,20190125.0,20181130,20190201,EXP,,GB-ASTRAZENECA-2018SF55656,ASTRAZENECA,,63.0,YR,,M,Y,85.5,KG,20190201.0,,,GB,GB,2019,Q1,Adult
156847432,15684743,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,8270.0,MG,D,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Cerebral infarction,,2019,Q1,2,F,20180301.0,20190107.0,20181204,20190118,EXP,,IN-ASTRAZENECA-2018SF58094,ASTRAZENECA,,28105.0,DY,,M,Y,74.0,KG,20190118.0,,MD,JP,JP,2019,Q1,Elderly
156847432,15684743,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,8270.0,MG,D,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Pneumonia,,2019,Q1,2,F,20180301.0,20190107.0,20181204,20190118,EXP,,IN-ASTRAZENECA-2018SF58094,ASTRAZENECA,,28105.0,DY,,M,Y,74.0,KG,20190118.0,,MD,JP,JP,2019,Q1,Elderly
157473962,15747396,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q1,Erectile dysfunction,,2019,Q1,2,F,,20190211.0,20181220,20190225,EXP,,RO-ELI_LILLY_AND_COMPANY-RO201812007263,ELI LILLY AND CO,,48.0,YR,,M,Y,,,20190225.0,,MD,RO,RO,2019,Q1,Adult
157473962,15747396,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q1,Neuropathy peripheral,,2019,Q1,2,F,,20190211.0,20181220,20190225,EXP,,RO-ELI_LILLY_AND_COMPANY-RO201812007263,ELI LILLY AND CO,,48.0,YR,,M,Y,,,20190225.0,,MD,RO,RO,2019,Q1,Adult
157484642,15748464,11,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2019,Q1,Chest pain,,2019,Q1,2,F,,20181224.0,20181221,20190102,EXP,,PT-TEVA-2018-PT-989694,TEVA,,54.0,YR,,F,Y,,,20190102.0,,OT,PT,PT,2019,Q1,Adult
157484642,15748464,11,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2019,Q1,Ischaemic stroke,,2019,Q1,2,F,,20181224.0,20181221,20190102,EXP,,PT-TEVA-2018-PT-989694,TEVA,,54.0,YR,,F,Y,,,20190102.0,,OT,PT,PT,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Alcohol abuse,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Amnesia,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Anxiety,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Asthenia,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Cerebrovascular accident,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Diabetes mellitus,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Diplopia,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Disturbance in attention,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Drug ineffective,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Feeling of despair,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Hypertension,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Nausea,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Negative thoughts,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Panic disorder,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Panic reaction,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Paraesthesia,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Psychiatric symptom,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Suicidal ideation,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Tearfulness,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Thinking abnormal,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157508702,15750870,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,TABLET,QD,2019,Q1,Treatment noncompliance,,2019,Q1,2,F,20170317.0,20180125.0,20181221,20190201,EXP,,GB-HERITAGE PHARMACEUTICALS-2018HTG00474,HERITAGE,,57.0,YR,,M,Y,88.0,KG,20190201.0,,CN,IN,GB,2019,Q1,Adult
157703352,15770335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,2,F,,20190110.0,20181228,20190117,EXP,,BR-ASTRAZENECA-2018SF69283,ASTRAZENECA,,40.0,YR,,F,Y,,,20190117.0,,MD,BR,BR,2019,Q1,Adult
157703352,15770335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,2,F,,20190110.0,20181228,20190117,EXP,,BR-ASTRAZENECA-2018SF69283,ASTRAZENECA,,40.0,YR,,F,Y,,,20190117.0,,MD,BR,BR,2019,Q1,Adult
157703352,15770335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Off label use,,2019,Q1,2,F,,20190110.0,20181228,20190117,EXP,,BR-ASTRAZENECA-2018SF69283,ASTRAZENECA,,40.0,YR,,F,Y,,,20190117.0,,MD,BR,BR,2019,Q1,Adult
157703352,15770335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,2,F,,20190110.0,20181228,20190117,EXP,,BR-ASTRAZENECA-2018SF69283,ASTRAZENECA,,40.0,YR,,F,Y,,,20190117.0,,MD,BR,BR,2019,Q1,Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Blood glucose increased,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Dehydration,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Infection,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Nausea,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Pain,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Stress,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Subcutaneous abscess,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Thirst,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Urine output increased,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157812263,15781226,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD AFTER LUNCH",,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Vomiting,,2019,Q1,3,F,20181020.0,20190228.0,20190102,20190305,EXP,,ZA-SA-2018SA307952,SANOFI AVENTIS,,32.0,YR,A,M,Y,,,20190305.0,,CN,ZA,ZA,2019,Q1,Young Adult
157815131,15781513,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Acute kidney injury,,2019,Q1,1,I,,20181224.0,20190102,20190102,EXP,,PT-ASTRAZENECA-2018SF71109,ASTRAZENECA,,46.0,YR,,F,Y,,,20190102.0,,OT,PT,PT,2019,Q1,Adult
157815131,15781513,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20181224.0,20190102,20190102,EXP,,PT-ASTRAZENECA-2018SF71109,ASTRAZENECA,,46.0,YR,,F,Y,,,20190102.0,,OT,PT,PT,2019,Q1,Adult
157815131,15781513,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20181224.0,20190102,20190102,EXP,,PT-ASTRAZENECA-2018SF71109,ASTRAZENECA,,46.0,YR,,F,Y,,,20190102.0,,OT,PT,PT,2019,Q1,Adult
157815131,15781513,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20181224.0,20190102,20190102,EXP,,PT-ASTRAZENECA-2018SF71109,ASTRAZENECA,,46.0,YR,,F,Y,,,20190102.0,,OT,PT,PT,2019,Q1,Adult
157827584,15782758,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2019,Q1,Chest pain,,2019,Q1,4,F,,20190204.0,20190102,20190301,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190301.0,,OT,PT,PT,2019,Q1,Adult
157827584,15782758,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2019,Q1,Headache,,2019,Q1,4,F,,20190204.0,20190102,20190301,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190301.0,,OT,PT,PT,2019,Q1,Adult
157827584,15782758,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2019,Q1,Ischaemic stroke,,2019,Q1,4,F,,20190204.0,20190102,20190301,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190301.0,,OT,PT,PT,2019,Q1,Adult
157981792,15798179,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,150.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Balanoposthitis,,2019,Q1,2,F,201808.0,20190109.0,20190108,20190207,PER,,US-ASTRAZENECA-2018SF68707,ASTRAZENECA,,906.0,MON,,M,Y,87.9,KG,20190207.0,,,US,US,2019,Q1,Elderly
157981792,15798179,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,150.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Candida infection,,2019,Q1,2,F,201808.0,20190109.0,20190108,20190207,PER,,US-ASTRAZENECA-2018SF68707,ASTRAZENECA,,906.0,MON,,M,Y,87.9,KG,20190207.0,,,US,US,2019,Q1,Elderly
157981792,15798179,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,150.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Intentional product misuse,,2019,Q1,2,F,201808.0,20190109.0,20190108,20190207,PER,,US-ASTRAZENECA-2018SF68707,ASTRAZENECA,,906.0,MON,,M,Y,87.9,KG,20190207.0,,,US,US,2019,Q1,Elderly
157981792,15798179,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,150.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Urinary tract infection,,2019,Q1,2,F,201808.0,20190109.0,20190108,20190207,PER,,US-ASTRAZENECA-2018SF68707,ASTRAZENECA,,906.0,MON,,M,Y,87.9,KG,20190207.0,,,US,US,2019,Q1,Elderly
158040371,15804037,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q1,Pancreatitis acute,,2019,Q1,1,I,,20190107.0,20190109,20190109,EXP,,PHHY2019GB002445,SANDOZ,,70.0,YR,,M,Y,76.0,KG,20190109.0,,OT,GB,GB,2019,Q1,Elderly
158065711,15806571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE AND FREQUENCY UNKNOWN,,,U,,,,202293.0,,,TABLET,,2019,Q1,Crying,,2019,Q1,1,I,,20181229.0,20190110,20190110,PER,,US-ASTRAZENECA-2019SE00910,ASTRAZENECA,,61.0,YR,,F,Y,,,20190110.0,,CN,US,US,2019,Q1,Adult
158065711,15806571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE AND FREQUENCY UNKNOWN,,,U,,,,202293.0,,,TABLET,,2019,Q1,Eye disorder,,2019,Q1,1,I,,20181229.0,20190110,20190110,PER,,US-ASTRAZENECA-2019SE00910,ASTRAZENECA,,61.0,YR,,F,Y,,,20190110.0,,CN,US,US,2019,Q1,Adult
158065711,15806571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE AND FREQUENCY UNKNOWN,,,U,,,,202293.0,,,TABLET,,2019,Q1,Fungal infection,,2019,Q1,1,I,,20181229.0,20190110,20190110,PER,,US-ASTRAZENECA-2019SE00910,ASTRAZENECA,,61.0,YR,,F,Y,,,20190110.0,,CN,US,US,2019,Q1,Adult
158065711,15806571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE AND FREQUENCY UNKNOWN,,,U,,,,202293.0,,,TABLET,,2019,Q1,Neck pain,,2019,Q1,1,I,,20181229.0,20190110,20190110,PER,,US-ASTRAZENECA-2019SE00910,ASTRAZENECA,,61.0,YR,,F,Y,,,20190110.0,,CN,US,US,2019,Q1,Adult
158065711,15806571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE AND FREQUENCY UNKNOWN,,,U,,,,202293.0,,,TABLET,,2019,Q1,Pruritus,,2019,Q1,1,I,,20181229.0,20190110,20190110,PER,,US-ASTRAZENECA-2019SE00910,ASTRAZENECA,,61.0,YR,,F,Y,,,20190110.0,,CN,US,US,2019,Q1,Adult
158092121,15809212,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,TABLET,QD,2019,Q1,Metabolic acidosis,,2019,Q1,1,I,,20190107.0,20190110,20190110,EXP,,DE-ASTRAZENECA-2019SE02227,ASTRAZENECA,,19.0,YR,,F,Y,,,20190111.0,,MD,DE,DE,2019,Q1,Youth
158092121,15809212,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,TABLET,QD,2019,Q1,Metabolic acidosis,,2019,Q1,1,I,,20190107.0,20190110,20190110,EXP,,DE-ASTRAZENECA-2019SE02227,ASTRAZENECA,,19.0,YR,,F,Y,,,20190111.0,,MD,DE,DE,2019,Q1,Youth
158092121,15809212,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,TABLET,QD,2019,Q1,Metabolic acidosis,,2019,Q1,1,I,,20190107.0,20190110,20190110,EXP,,DE-ASTRAZENECA-2019SE02227,ASTRAZENECA,,19.0,YR,,F,Y,,,20190111.0,,MD,DE,DE,2019,Q1,Youth
158107691,15810769,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2019,Q1,Diabetes mellitus,,2019,Q1,1,I,201701.0,20181229.0,20190111,20190111,EXP,,CZ-AUROBINDO-AUR-APL-2018-064084,AUROBINDO,RADOVA B.. AN EXPERIENCE WITH AN EARLY INITIATION OF A COMBINED FIXED THERAPY DEGLUDEC/LIRAGLUTIDE IN A PATIENT WITH THE TYPE 2 DIABETES MELLITUS.. KAZUISTIKY V DIABETOLOGII.. 2017;15(3):17-18.,50.0,YR,,M,Y,160.0,KG,20190111.0,,MD,CZ,CZ,2019,Q1,Adult
158107691,15810769,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2019,Q1,Glycosylated haemoglobin increased,,2019,Q1,1,I,201701.0,20181229.0,20190111,20190111,EXP,,CZ-AUROBINDO-AUR-APL-2018-064084,AUROBINDO,RADOVA B.. AN EXPERIENCE WITH AN EARLY INITIATION OF A COMBINED FIXED THERAPY DEGLUDEC/LIRAGLUTIDE IN A PATIENT WITH THE TYPE 2 DIABETES MELLITUS.. KAZUISTIKY V DIABETOLOGII.. 2017;15(3):17-18.,50.0,YR,,M,Y,160.0,KG,20190111.0,,MD,CZ,CZ,2019,Q1,Adult
158107691,15810769,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2019,Q1,Hyperglycaemia,,2019,Q1,1,I,201701.0,20181229.0,20190111,20190111,EXP,,CZ-AUROBINDO-AUR-APL-2018-064084,AUROBINDO,RADOVA B.. AN EXPERIENCE WITH AN EARLY INITIATION OF A COMBINED FIXED THERAPY DEGLUDEC/LIRAGLUTIDE IN A PATIENT WITH THE TYPE 2 DIABETES MELLITUS.. KAZUISTIKY V DIABETOLOGII.. 2017;15(3):17-18.,50.0,YR,,M,Y,160.0,KG,20190111.0,,MD,CZ,CZ,2019,Q1,Adult
158107821,15810782,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Dysgeusia,,2019,Q1,1,I,,20190108.0,20190111,20190111,EXP,GB-MHRA-EYC 00191941,GB-TEVA-2019-GB-997125,TEVA,,56.0,YR,,M,Y,122.0,KG,20190111.0,,CN,GB,GB,2019,Q1,Adult
158108911,15810891,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;,,,U,, UNKNOWN,,,10.0,MG,,,2019,Q1,Pancreatitis acute,,2019,Q1,1,I,,20190108.0,20190111,20190111,EXP,GB-MHRA-EYC 00192303,GB-TEVA-2019-GB-997229,TEVA,,70.0,YR,,M,Y,76.0,KG,20190111.0,,PH,GB,GB,2019,Q1,Elderly
158133341,15813334,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7585.209,MG,Y,, UNKNOWN,,,5.0,MG,TABLET,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20181204.0,20190108.0,20190111,20190111,EXP,,GB-ASTRAZENECA-2019SE03342,ASTRAZENECA,,50.0,YR,,F,Y,74.2,KG,20190111.0,,,GB,GB,2019,Q1,Adult
158186171,15818617,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Pancreatitis acute,,2019,Q1,1,I,,20190108.0,20190113,20190113,EXP,,GB-ASTRAZENECA-2019SE04168,ASTRAZENECA,,70.0,YR,,M,Y,76.0,KG,20190113.0,,,GB,GB,2019,Q1,Elderly
158195851,15819585,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2019,Q1,Urinary incontinence,,2019,Q1,1,I,20181129.0,20190108.0,20190114,20190114,EXP,GB-MHRA-EYC 00191910,GB-TEVA-2019-GB-998345,TEVA,,60.0,YR,,F,Y,70.0,KG,20190114.0,,CN,GB,GB,2019,Q1,Adult
158214371,15821437,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2019,Q1,Urinary incontinence,,2019,Q1,1,I,20181129.0,20190108.0,20190114,20190114,EXP,GB-MHRA-EYC 00191910,GB-JNJFOC-20190108704,JANSSEN,,60.0,YR,A,F,Y,70.0,KG,20190114.0,,CN,GB,GB,2019,Q1,Adult
158341971,15834197,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, PER DAY",,,U,,,,,10.0,MG,,,2019,Q1,Pancreatitis acute,,2019,Q1,1,I,,20190109.0,20190116,20190116,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-002403,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,76.0,KG,20190116.0,,PH,GB,GB,2019,Q1,Elderly
158362631,15836263,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2019,Q1,Pancreatitis acute,,2019,Q1,1,I,,20190109.0,20190117,20190117,EXP,,GB-ASTRAZENECA-2019SE06752,ASTRAZENECA,,70.0,YR,,M,Y,76.0,KG,20190117.0,,PH,GB,GB,2019,Q1,Elderly
158378851,15837885,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20181211.0,20190108.0,20190117,20190117,EXP,,GB-ASTRAZENECA-2019SE04035,ASTRAZENECA,,73.0,YR,,M,Y,,,20190117.0,,,GB,GB,2019,Q1,Elderly
158409051,15840905,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,, KL5136,,202293.0,5.0,MG,TABLET,QD,2019,Q1,Fungal infection,,2019,Q1,1,I,201812.0,20190102.0,20190118,20190118,PER,,US-ASTRAZENECA-2019SE01132,ASTRAZENECA,,672.0,MON,,F,Y,83.9,KG,20190118.0,,,US,US,2019,Q1,Elderly
158409051,15840905,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,, KL5136,,202293.0,5.0,MG,TABLET,QD,2019,Q1,Vulvovaginal erythema,,2019,Q1,1,I,201812.0,20190102.0,20190118,20190118,PER,,US-ASTRAZENECA-2019SE01132,ASTRAZENECA,,672.0,MON,,F,Y,83.9,KG,20190118.0,,,US,US,2019,Q1,Elderly
158409051,15840905,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,, KL5136,,202293.0,5.0,MG,TABLET,QD,2019,Q1,Vulvovaginal pruritus,,2019,Q1,1,I,201812.0,20190102.0,20190118,20190118,PER,,US-ASTRAZENECA-2019SE01132,ASTRAZENECA,,672.0,MON,,F,Y,83.9,KG,20190118.0,,,US,US,2019,Q1,Elderly
158409051,15840905,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,, KL5136,,202293.0,5.0,MG,TABLET,QD,2019,Q1,Vulvovaginal swelling,,2019,Q1,1,I,201812.0,20190102.0,20190118,20190118,PER,,US-ASTRAZENECA-2019SE01132,ASTRAZENECA,,672.0,MON,,F,Y,83.9,KG,20190118.0,,,US,US,2019,Q1,Elderly
158427311,15842731,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY,,,Y,,,,202293.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20181227.0,20190109.0,20190118,20190118,EXP,,GB-ASTRAZENECA-2019SE04888,ASTRAZENECA,,42.0,YR,,F,Y,,,20190118.0,,,GB,GB,2019,Q1,Adult
158428032,15842803,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE UNKNOWN,,,,U,,,202293.0,,,TABLET,,2019,Q1,Abdominal pain upper,,2019,Q1,2,F,,20190116.0,20190118,20190124,EXP,,JP-ASTRAZENECA-2019SE05788,ASTRAZENECA,NAKAMURA J.. SCIENTIFIC EXCHANGE MEETING IN CHIBA; 10-JAN-2019. 2019;,32.0,YR,,F,Y,63.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Young Adult
158428032,15842803,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE UNKNOWN,,,,U,,,202293.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,2,F,,20190116.0,20190118,20190124,EXP,,JP-ASTRAZENECA-2019SE05788,ASTRAZENECA,NAKAMURA J.. SCIENTIFIC EXCHANGE MEETING IN CHIBA; 10-JAN-2019. 2019;,32.0,YR,,F,Y,63.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Young Adult
158428032,15842803,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE UNKNOWN,,,,U,,,202293.0,,,TABLET,,2019,Q1,Pollakiuria,,2019,Q1,2,F,,20190116.0,20190118,20190124,EXP,,JP-ASTRAZENECA-2019SE05788,ASTRAZENECA,NAKAMURA J.. SCIENTIFIC EXCHANGE MEETING IN CHIBA; 10-JAN-2019. 2019;,32.0,YR,,F,Y,63.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Young Adult
158428032,15842803,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE UNKNOWN,,,,U,,,202293.0,,,TABLET,,2019,Q1,Weight decreased,,2019,Q1,2,F,,20190116.0,20190118,20190124,EXP,,JP-ASTRAZENECA-2019SE05788,ASTRAZENECA,NAKAMURA J.. SCIENTIFIC EXCHANGE MEETING IN CHIBA; 10-JAN-2019. 2019;,32.0,YR,,F,Y,63.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Young Adult
158475411,15847541,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, DAILY",,,U,U,,,,10.0,MG,,,2019,Q1,Pancreatitis acute,,2019,Q1,1,I,,20190107.0,20190121,20190121,EXP,,GB-AUROBINDO-AUR-APL-2019-002152,AUROBINDO,,70.0,YR,,M,Y,76.0,KG,20190121.0,,PH,GB,GB,2019,Q1,Elderly
158604221,15860422,17,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q1,Dyspnoea,,2019,Q1,1,I,,20190117.0,20190123,20190123,EXP,,PHHY2019GB012154,SANDOZ,,58.0,YR,,F,Y,104.0,KG,20190124.0,,OT,GB,GB,2019,Q1,Adult
158604221,15860422,17,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q1,Wheezing,,2019,Q1,1,I,,20190117.0,20190123,20190123,EXP,,PHHY2019GB012154,SANDOZ,,58.0,YR,,F,Y,104.0,KG,20190124.0,,OT,GB,GB,2019,Q1,Adult
158623831,15862383,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q1,Drug hypersensitivity,,2019,Q1,1,I,,20181021.0,20190124,20190124,PER,,US-PFIZER INC-2019029806,PFIZER,,64.0,YR,,F,Y,,,20190124.0,,MD,US,US,2019,Q1,Adult
158634881,15863488,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,5.0,MG,,QD,2019,Q1,Hyperglycaemia,,2019,Q1,1,I,,20190117.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-002725",BOEHRINGER INGELHEIM,"OHARA N, KOBAYASHI M, IKEDA Y, NAGANO O, TAKADA T, KODAMA M, ET AL. GLUTAMIC ACID DECARBOXYLASE AUTOANTIBODY-NEGATIVE SLOWLY PROGRESSIVE TYPE 1 DIABETES MELLITUS: A CASE REPORT AND LITERATURE REVIEW. INTERNAL MEDICINE (TOKYO). 2018;57:24:3581-3587.",61.0,YR,,F,Y,37.5,KG,20190124.0,,MD,JP,JP,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Cough,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Dyspnoea,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Heart rate increased,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Hyperhidrosis,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Pruritus generalised,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Throat tightness,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158801671,15880167,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Urticaria,,2019,Q1,1,I,20181218.0,,20190104,20190104,DIR,,,FDA-CTU,,40.0,YR,,F,N,99.3,KG,20190103.0,N,PH,US,US,2019,Q1,Adult
158896841,15889684,17,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,,,,, UNKNOWN,,,1.0,DF,,,2019,Q1,Dyspnoea,,2019,Q1,1,I,,20190121.0,20190130,20190130,EXP,GB-MHRA-TPP5410256C37451YC1546881454536,GB-TEVA-2019-GB-1004557,TEVA,,58.0,YR,,F,Y,104.0,KG,20190130.0,,MD,GB,GB,2019,Q1,Adult
158896841,15889684,17,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,,,,, UNKNOWN,,,1.0,DF,,,2019,Q1,Wheezing,,2019,Q1,1,I,,20190121.0,20190130,20190130,EXP,GB-MHRA-TPP5410256C37451YC1546881454536,GB-TEVA-2019-GB-1004557,TEVA,,58.0,YR,,F,Y,104.0,KG,20190130.0,,MD,GB,GB,2019,Q1,Adult
158918961,15891896,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, QD",248.042,DF,,,,,,,,,QD,2019,Q1,Headache,,2019,Q1,1,I,20190103.0,20190124.0,20190130,20190130,EXP,GB-MHRA-TPP19280447C5083309YC1546529787040,GB-TAKEDA-2019TEU000706,TAKEDA,,55.0,YR,,F,Y,76.0,KG,20190130.0,,OT,GB,GB,2019,Q1,Adult
158918961,15891896,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, QD",248.042,DF,,,,,,,,,QD,2019,Q1,Joint swelling,,2019,Q1,1,I,20190103.0,20190124.0,20190130,20190130,EXP,GB-MHRA-TPP19280447C5083309YC1546529787040,GB-TAKEDA-2019TEU000706,TAKEDA,,55.0,YR,,F,Y,76.0,KG,20190130.0,,OT,GB,GB,2019,Q1,Adult
158953021,15895302,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20190110.0,20190125.0,20190131,20190131,EXP,,GB-ASTRAZENECA-2019SE15520,ASTRAZENECA,,52.0,YR,,F,Y,84.6,KG,20190131.0,,,GB,GB,2019,Q1,Adult
158953021,15895302,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diabetic ketosis,,2019,Q1,1,I,20190110.0,20190125.0,20190131,20190131,EXP,,GB-ASTRAZENECA-2019SE15520,ASTRAZENECA,,52.0,YR,,F,Y,84.6,KG,20190131.0,,,GB,GB,2019,Q1,Adult
159007661,15900766,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20190109.0,20190124.0,20190201,20190201,EXP,,GB-ASTRAZENECA-2019SE14793,ASTRAZENECA,,54.0,YR,,F,Y,,,20190201.0,,,GB,GB,2019,Q1,Adult
159007661,15900766,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Diarrhoea,,2019,Q1,1,I,20190109.0,20190124.0,20190201,20190201,EXP,,GB-ASTRAZENECA-2019SE14793,ASTRAZENECA,,54.0,YR,,F,Y,,,20190201.0,,,GB,GB,2019,Q1,Adult
159007661,15900766,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Malaise,,2019,Q1,1,I,20190109.0,20190124.0,20190201,20190201,EXP,,GB-ASTRAZENECA-2019SE14793,ASTRAZENECA,,54.0,YR,,F,Y,,,20190201.0,,,GB,GB,2019,Q1,Adult
159057821,15905782,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190128.0,20190204,20190204,EXP,,GB-ASTRAZENECA-2019SE17195,ASTRAZENECA,,42.0,YR,,M,Y,,,20190204.0,,,GB,GB,2019,Q1,Adult
159196311,15919631,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG ONCE/SINGLE ADMINISTRATION,10.0,MG,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Abdominal pain,,2019,Q1,1,I,20190117.0,20190131.0,20190205,20190205,EXP,,GB-ASTRAZENECA-2019SE18257,ASTRAZENECA,,50.0,YR,,F,Y,104.0,KG,20190205.0,,OT,GB,GB,2019,Q1,Adult
159196311,15919631,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG ONCE/SINGLE ADMINISTRATION,10.0,MG,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diarrhoea,,2019,Q1,1,I,20190117.0,20190131.0,20190205,20190205,EXP,,GB-ASTRAZENECA-2019SE18257,ASTRAZENECA,,50.0,YR,,F,Y,104.0,KG,20190205.0,,OT,GB,GB,2019,Q1,Adult
159196311,15919631,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG ONCE/SINGLE ADMINISTRATION,10.0,MG,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Dry mouth,,2019,Q1,1,I,20190117.0,20190131.0,20190205,20190205,EXP,,GB-ASTRAZENECA-2019SE18257,ASTRAZENECA,,50.0,YR,,F,Y,104.0,KG,20190205.0,,OT,GB,GB,2019,Q1,Adult
159196311,15919631,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG ONCE/SINGLE ADMINISTRATION,10.0,MG,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Nausea,,2019,Q1,1,I,20190117.0,20190131.0,20190205,20190205,EXP,,GB-ASTRAZENECA-2019SE18257,ASTRAZENECA,,50.0,YR,,F,Y,104.0,KG,20190205.0,,OT,GB,GB,2019,Q1,Adult
159371341,15937134,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10320.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Necrotising fasciitis,,2019,Q1,1,I,20190105.0,20190201.0,20190208,20190208,EXP,,GB-ASTRAZENECA-2019SE20253,ASTRAZENECA,,40.0,YR,,F,Y,54.0,KG,20190208.0,,,GB,GB,2019,Q1,Adult
159534051,15953405,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20180827.0,20190204.0,20190212,20190212,EXP,,GB-ASTRAZENECA-2019SE20528,ASTRAZENECA,,61.0,YR,,M,Y,88.0,KG,20190212.0,,MD,GB,GB,2019,Q1,Adult
159534051,15953405,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diarrhoea,,2019,Q1,1,I,20180827.0,20190204.0,20190212,20190212,EXP,,GB-ASTRAZENECA-2019SE20528,ASTRAZENECA,,61.0,YR,,M,Y,88.0,KG,20190212.0,,MD,GB,GB,2019,Q1,Adult
159534051,15953405,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Vomiting,,2019,Q1,1,I,20180827.0,20190204.0,20190212,20190212,EXP,,GB-ASTRAZENECA-2019SE20528,ASTRAZENECA,,61.0,YR,,M,Y,88.0,KG,20190212.0,,MD,GB,GB,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Back pain,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Blood glucose decreased,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Bronchitis,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Dizziness,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Dyspnoea,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,General physical health deterioration,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Glycosylated haemoglobin increased,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Hypoglycaemia,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Influenza,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159594301,15959430,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q1,Nasopharyngitis,,2019,Q1,1,I,20180920.0,20181002.0,20190214,20190214,EXP,,ZA-SA-2018SA274615,SANOFI AVENTIS,,63.0,YR,A,F,Y,,,20190214.0,,CN,ZA,ZA,2019,Q1,Adult
159611182,15961118,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"5 MILLIGRAM, QD",,,,,,,,5.0,MG,,QD,2019,Q1,Cerebrovascular accident,,2019,Q1,2,F,20190208.0,20190219.0,20190214,20190226,EXP,,GB-MYLANLABS-2019M1013964,MYLAN,,70.0,YR,,M,Y,108.2,KG,20190226.0,,MD,GB,GB,2019,Q1,Elderly
159761011,15976101,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,20190129.0,20190211.0,20190218,20190218,EXP,,PT-ASTRAZENECA-2019SE24925,ASTRAZENECA,,24535.0,DY,,M,Y,,,20190218.0,,,PT,PT,2019,Q1,Elderly
159801981,15980198,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1120.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q1,Diarrhoea,,2019,Q1,1,I,,20190213.0,20190219,20190219,EXP,,GB-ASTRAZENECA-2019SE25680,ASTRAZENECA,,65.0,YR,,M,Y,101.0,KG,20190219.0,,,GB,GB,2019,Q1,Elderly
159801981,15980198,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1120.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q1,Malaise,,2019,Q1,1,I,,20190213.0,20190219,20190219,EXP,,GB-ASTRAZENECA-2019SE25680,ASTRAZENECA,,65.0,YR,,M,Y,101.0,KG,20190219.0,,,GB,GB,2019,Q1,Elderly
159860911,15986091,6,C,DAPAGLIFLOZIN;METFORMIN,,2,,,,,,,,,,,,,,2019,Q1,Pancreatic carcinoma,,2019,Q1,1,I,,20190214.0,20190220,20190220,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201902007000,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20190220.0,,CN,ES,ES,2019,Q1,Elderly
159864811,15986481,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2019,Q1,Drug hypersensitivity,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2019,Q1,Epistaxis,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2019,Q1,Renal cyst haemorrhage,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2019,Q1,Thrombocytopenia,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2019,Q1,Upper gastrointestinal haemorrhage,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,RECOMMENCED AFTER 39 DAYS,,,Y,U,,,,,,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,RECOMMENCED AFTER 39 DAYS,,,Y,U,,,,,,TABLET,,2019,Q1,Drug hypersensitivity,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,RECOMMENCED AFTER 39 DAYS,,,Y,U,,,,,,TABLET,,2019,Q1,Epistaxis,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,RECOMMENCED AFTER 39 DAYS,,,Y,U,,,,,,TABLET,,2019,Q1,Renal cyst haemorrhage,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,RECOMMENCED AFTER 39 DAYS,,,Y,U,,,,,,TABLET,,2019,Q1,Thrombocytopenia,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159864811,15986481,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,RECOMMENCED AFTER 39 DAYS,,,Y,U,,,,,,TABLET,,2019,Q1,Upper gastrointestinal haemorrhage,,2019,Q1,1,I,,20190212.0,20190220,20190220,EXP,,US-ASTRAZENECA-2019SE24623,ASTRAZENECA,,55.0,YR,,M,Y,,,20190220.0,,OT,US,US,2019,Q1,Adult
159905751,15990575,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7760.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Bleeding varicose vein,,2019,Q1,1,I,20181225.0,20190213.0,20190221,20190221,EXP,,ES-ASTRAZENECA-2019SE25005,ASTRAZENECA,,47.0,YR,,M,Y,137.0,KG,20190221.0,,PH,ES,ES,2019,Q1,Adult
159905751,15990575,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7760.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Hypovolaemic shock,,2019,Q1,1,I,20181225.0,20190213.0,20190221,20190221,EXP,,ES-ASTRAZENECA-2019SE25005,ASTRAZENECA,,47.0,YR,,M,Y,137.0,KG,20190221.0,,PH,ES,ES,2019,Q1,Adult
159905751,15990575,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7760.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Varicose ulceration,,2019,Q1,1,I,20181225.0,20190213.0,20190221,20190221,EXP,,ES-ASTRAZENECA-2019SE25005,ASTRAZENECA,,47.0,YR,,M,Y,137.0,KG,20190221.0,,PH,ES,ES,2019,Q1,Adult
160002351,16000235,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Drug ineffective for unapproved indication,,2019,Q1,1,I,,20190218.0,20190225,20190225,PER,,US-AMGEN-USASP2019026598,AMGEN,"DOI: 10.1002/AJH.25382 VALLATHARASU Y.; HAYASHI-TANNER Y.; POLEWSKI P. J. ET. AL. SEVERE, PROLONGED THROMBOCYTOPENIA IN A PATIENT SENSITIVE TO EXENATIDE. AJH. 2018;E78-E80",55.0,YR,A,M,Y,,,20190225.0,,OT,US,US,2019,Q1,Adult
160002351,16000235,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Marrow hyperplasia,,2019,Q1,1,I,,20190218.0,20190225,20190225,PER,,US-AMGEN-USASP2019026598,AMGEN,"DOI: 10.1002/AJH.25382 VALLATHARASU Y.; HAYASHI-TANNER Y.; POLEWSKI P. J. ET. AL. SEVERE, PROLONGED THROMBOCYTOPENIA IN A PATIENT SENSITIVE TO EXENATIDE. AJH. 2018;E78-E80",55.0,YR,A,M,Y,,,20190225.0,,OT,US,US,2019,Q1,Adult
160014931,16001493,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,1,I,,20190220.0,20190225,20190225,EXP,,US-009507513-1902USA008476,MERCK,"VALLATHARASU YAZHINI, HAYASHI-TANNER Y, POLEWSKI P J, BOTTNER WA., ROSENSTEIN LJ., UPRETY D, ET AL. SEVERE, PROLONGED THROMBOCYTOPENIA IN A PATIENT SENSITIVE TO EXENATIDE. AMERICAN JOURNAL OF HEMATOLOGY. 2019;94 (3):E78?80",55.0,YR,,M,Y,,,20190225.0,,OT,US,US,2019,Q1,Adult
160134621,16013462,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,1 COMPRIMIDO CADA DIA,6910.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Skin ulcer,,2019,Q1,1,I,20181228.0,20190218.0,20190227,20190227,EXP,,ES-ASTRAZENECA-2019SE28151,ASTRAZENECA,,53.0,YR,,M,Y,98.0,KG,20190227.0,,PH,ES,ES,2019,Q1,Adult
160156681,16015668,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,630.0,MG,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Anxiety,,2019,Q1,1,I,20190206.0,20190220.0,20190228,20190228,EXP,,GB-ASTRAZENECA-2019SE30090,ASTRAZENECA,,66.0,YR,,M,Y,104.0,KG,20190228.0,,,GB,GB,2019,Q1,Elderly
160156681,16015668,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,63.0,DF,,,,,,1.0,DF,,QD,2019,Q1,Anxiety,,2019,Q1,1,I,20190206.0,20190220.0,20190228,20190228,EXP,,GB-ASTRAZENECA-2019SE30090,ASTRAZENECA,,66.0,YR,,M,Y,104.0,KG,20190228.0,,,GB,GB,2019,Q1,Elderly
160232241,16023224,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7010.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20190204.0,20190220.0,20190301,20190301,EXP,,GB-ASTRAZENECA-2019SE30071,ASTRAZENECA,,54.0,YR,,F,Y,50.0,KG,20190301.0,,,GB,GB,2019,Q1,Adult
160271412,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q1,Cellulitis,,2019,Q1,2,F,20181225.0,20190308.0,20190303,20190318,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190318.0,,OT,DE,DE,2019,Q1,Adult
160271412,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q1,Lymphangitis,,2019,Q1,2,F,20181225.0,20190308.0,20190303,20190318,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190318.0,,OT,DE,DE,2019,Q1,Adult
160271412,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q1,Necrosis,,2019,Q1,2,F,20181225.0,20190308.0,20190303,20190318,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190318.0,,OT,DE,DE,2019,Q1,Adult
160271412,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q1,Soft tissue infection,,2019,Q1,2,F,20181225.0,20190308.0,20190303,20190318,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190318.0,,OT,DE,DE,2019,Q1,Adult
160355321,16035532,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Body height decreased,,2019,Q1,1,I,20180623.0,20180821.0,20190305,20190305,PER,,US-ALLERGAN-1841027US,ALLERGAN,,78.0,YR,,M,Y,92.97,KG,20190305.0,,MD,US,US,2019,Q1,Elderly
160355321,16035532,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Product dose omission,,2019,Q1,1,I,20180623.0,20180821.0,20190305,20190305,PER,,US-ALLERGAN-1841027US,ALLERGAN,,78.0,YR,,M,Y,92.97,KG,20190305.0,,MD,US,US,2019,Q1,Elderly
160433841,16043384,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"5 MILLIGRAM, QD",,,,, UNK,,,5.0,MG,TABLET,QD,2019,Q1,Atrial fibrillation,,2019,Q1,1,I,,20190301.0,20190306,20190306,EXP,GB-MHRA-MIDB-04AA736C-88D2-4BC6-B34D-1EBC7B351F5E,GB-MYLANLABS-2019M1020574,MYLAN,,63.0,YR,,M,Y,,,20190306.0,,PH,GB,GB,2019,Q1,Adult
160433841,16043384,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"5 MILLIGRAM, QD",,,,, UNK,,,5.0,MG,TABLET,QD,2019,Q1,Nodal arrhythmia,,2019,Q1,1,I,,20190301.0,20190306,20190306,EXP,GB-MHRA-MIDB-04AA736C-88D2-4BC6-B34D-1EBC7B351F5E,GB-MYLANLABS-2019M1020574,MYLAN,,63.0,YR,,M,Y,,,20190306.0,,PH,GB,GB,2019,Q1,Adult
160472161,16047216,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Necrotising fasciitis,,2019,Q1,1,I,,20190227.0,20190307,20190307,EXP,,GB-ASTRAZENECA-2019SE33734,ASTRAZENECA,,34.0,YR,,F,Y,,,20190307.0,,,GB,GB,2019,Q1,Young Adult
160519521,16051952,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, EVERY MORNING",,,Y,U,,,202293.0,,,TABLET,,2019,Q1,Foot amputation,,2019,Q1,1,I,20190212.0,20190301.0,20190308,20190308,EXP,,GB-ASTRAZENECA-2019SE35594,ASTRAZENECA,,56.0,YR,,M,Y,,,20190308.0,,PH,GB,GB,2019,Q1,Adult
160525611,16052561,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, KJ0244,,,5.0,MG,TABLET,QD,2019,Q1,Dehydration,,2019,Q1,1,I,201801.0,20190301.0,20190308,20190308,EXP,,US-ASTRAZENECA-2019SE37140,ASTRAZENECA,,761.0,MON,,F,Y,70.3,KG,20190308.0,,CN,US,US,2019,Q1,Elderly
160525611,16052561,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, KJ0244,,,5.0,MG,TABLET,QD,2019,Q1,Dizziness,,2019,Q1,1,I,201801.0,20190301.0,20190308,20190308,EXP,,US-ASTRAZENECA-2019SE37140,ASTRAZENECA,,761.0,MON,,F,Y,70.3,KG,20190308.0,,CN,US,US,2019,Q1,Elderly
160525611,16052561,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, KJ0244,,,5.0,MG,TABLET,QD,2019,Q1,Pancreatitis,,2019,Q1,1,I,201801.0,20190301.0,20190308,20190308,EXP,,US-ASTRAZENECA-2019SE37140,ASTRAZENECA,,761.0,MON,,F,Y,70.3,KG,20190308.0,,CN,US,US,2019,Q1,Elderly
160525611,16052561,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, KJ0244,,,5.0,MG,TABLET,QD,2019,Q1,Vaginal infection,,2019,Q1,1,I,201801.0,20190301.0,20190308,20190308,EXP,,US-ASTRAZENECA-2019SE37140,ASTRAZENECA,,761.0,MON,,F,Y,70.3,KG,20190308.0,,CN,US,US,2019,Q1,Elderly
160525611,16052561,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, KJ0244,,,5.0,MG,TABLET,QD,2019,Q1,Vulvovaginal disorder,,2019,Q1,1,I,201801.0,20190301.0,20190308,20190308,EXP,,US-ASTRAZENECA-2019SE37140,ASTRAZENECA,,761.0,MON,,F,Y,70.3,KG,20190308.0,,CN,US,US,2019,Q1,Elderly
160528241,16052824,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,,20190305.0,20190308,20190308,EXP,,KR-ASTRAZENECA-2019SE38325,ASTRAZENECA,,23.0,YR,,F,Y,,,20190308.0,,MD,KR,KR,2019,Q1,Youth
160528241,16052824,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Shock,,2019,Q1,1,I,,20190305.0,20190308,20190308,EXP,,KR-ASTRAZENECA-2019SE38325,ASTRAZENECA,,23.0,YR,,F,Y,,,20190308.0,,MD,KR,KR,2019,Q1,Youth
160529221,16052922,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,,,2019,Q1,Decreased appetite,,2019,Q1,1,I,20190211.0,20190228.0,20190308,20190308,EXP,,GB-ASTRAZENECA-2019SE34148,ASTRAZENECA,,63.0,YR,,M,Y,,,20190308.0,,OT,GB,GB,2019,Q1,Adult
160529221,16052922,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20190211.0,20190228.0,20190308,20190308,EXP,,GB-ASTRAZENECA-2019SE34148,ASTRAZENECA,,63.0,YR,,M,Y,,,20190308.0,,OT,GB,GB,2019,Q1,Adult
160529221,16052922,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,,,2019,Q1,Oropharyngeal pain,,2019,Q1,1,I,20190211.0,20190228.0,20190308,20190308,EXP,,GB-ASTRAZENECA-2019SE34148,ASTRAZENECA,,63.0,YR,,M,Y,,,20190308.0,,OT,GB,GB,2019,Q1,Adult
160529221,16052922,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,,,2019,Q1,Vertigo,,2019,Q1,1,I,20190211.0,20190228.0,20190308,20190308,EXP,,GB-ASTRAZENECA-2019SE34148,ASTRAZENECA,,63.0,YR,,M,Y,,,20190308.0,,OT,GB,GB,2019,Q1,Adult
160591081,16059108,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q1,Myocardial infarction,,2019,Q1,1,I,20190212.0,20190306.0,20190311,20190311,EXP,,PHHY2019PH052948,NOVARTIS,,85.0,YR,,F,Y,,,20190311.0,,CN,COUNTRY NOT SPECIFIED,PH,2019,Q1,Elderly
160591081,16059108,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q1,Product prescribing error,,2019,Q1,1,I,20190212.0,20190306.0,20190311,20190311,EXP,,PHHY2019PH052948,NOVARTIS,,85.0,YR,,F,Y,,,20190311.0,,CN,COUNTRY NOT SPECIFIED,PH,2019,Q1,Elderly
160591081,16059108,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q1,Wrong technique in product usage process,,2019,Q1,1,I,20190212.0,20190306.0,20190311,20190311,EXP,,PHHY2019PH052948,NOVARTIS,,85.0,YR,,F,Y,,,20190311.0,,CN,COUNTRY NOT SPECIFIED,PH,2019,Q1,Elderly
160630341,16063034,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Dehydration,,2019,Q1,1,I,20190214.0,20190305.0,20190312,20190312,EXP,,GB-ASTRAZENECA-2019SE37275,ASTRAZENECA,,72.0,YR,,M,Y,,,20190312.0,,,GB,GB,2019,Q1,Elderly
160630341,16063034,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20190214.0,20190305.0,20190312,20190312,EXP,,GB-ASTRAZENECA-2019SE37275,ASTRAZENECA,,72.0,YR,,M,Y,,,20190312.0,,,GB,GB,2019,Q1,Elderly
160662961,16066296,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6350.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Abscess,,2019,Q1,1,I,20190119.0,20190305.0,20190313,20190313,EXP,,IT-ASTRAZENECA-2019SE37446,ASTRAZENECA,,76.0,YR,,M,Y,100.0,KG,20190313.0,,MD,IT,IT,2019,Q1,Elderly
160662961,16066296,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6350.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Blister,,2019,Q1,1,I,20190119.0,20190305.0,20190313,20190313,EXP,,IT-ASTRAZENECA-2019SE37446,ASTRAZENECA,,76.0,YR,,M,Y,100.0,KG,20190313.0,,MD,IT,IT,2019,Q1,Elderly
160662961,16066296,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6350.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Erythema,,2019,Q1,1,I,20190119.0,20190305.0,20190313,20190313,EXP,,IT-ASTRAZENECA-2019SE37446,ASTRAZENECA,,76.0,YR,,M,Y,100.0,KG,20190313.0,,MD,IT,IT,2019,Q1,Elderly
160662961,16066296,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6350.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Fournier's gangrene,,2019,Q1,1,I,20190119.0,20190305.0,20190313,20190313,EXP,,IT-ASTRAZENECA-2019SE37446,ASTRAZENECA,,76.0,YR,,M,Y,100.0,KG,20190313.0,,MD,IT,IT,2019,Q1,Elderly
160662961,16066296,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6350.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Testicular swelling,,2019,Q1,1,I,20190119.0,20190305.0,20190313,20190313,EXP,,IT-ASTRAZENECA-2019SE37446,ASTRAZENECA,,76.0,YR,,M,Y,100.0,KG,20190313.0,,MD,IT,IT,2019,Q1,Elderly
160797451,16079745,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,201810.0,20190311.0,20190315,20190315,EXP,,GB-ASTRAZENECA-2019SE39926,ASTRAZENECA,,59.0,YR,,F,Y,64.0,KG,20190315.0,,,GB,GB,2019,Q1,Adult
160797451,16079745,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Intestinal ischaemia,,2019,Q1,1,I,201810.0,20190311.0,20190315,20190315,EXP,,GB-ASTRAZENECA-2019SE39926,ASTRAZENECA,,59.0,YR,,F,Y,64.0,KG,20190315.0,,,GB,GB,2019,Q1,Adult
160797451,16079745,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q1,Sepsis,,2019,Q1,1,I,201810.0,20190311.0,20190315,20190315,EXP,,GB-ASTRAZENECA-2019SE39926,ASTRAZENECA,,59.0,YR,,F,Y,64.0,KG,20190315.0,,,GB,GB,2019,Q1,Adult
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Blood pressure systolic increased,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Cough,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Dyspnoea,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Fall,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Gait disturbance,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Lower respiratory tract infection,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Musculoskeletal discomfort,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Pneumonia,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Spinal column stenosis,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160809441,16080944,9,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, 1 EVERY 1 DAY(S)",,,U,U,,,,1.0,DF,,,2019,Q1,Weight decreased,,2019,Q1,1,I,,20190301.0,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013863,AUROBINDO,,68.0,YR,,F,Y,,,20190316.0,,OT,CA,CA,2019,Q1,Elderly
160901481,16090148,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,U,,,202293.0,10.0,MG,TABLET,,2019,Q1,Fournier's gangrene,,2019,Q1,1,I,20190213.0,20190314.0,20190319,20190319,EXP,,GB-ASTRAZENECA-2019SE42128,ASTRAZENECA,,58.0,YR,,M,Y,78.0,KG,20190319.0,,,GB,GB,2019,Q1,Adult
160901481,16090148,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,U,,,202293.0,10.0,MG,TABLET,,2019,Q1,Septic shock,,2019,Q1,1,I,20190213.0,20190314.0,20190319,20190319,EXP,,GB-ASTRAZENECA-2019SE42128,ASTRAZENECA,,58.0,YR,,M,Y,78.0,KG,20190319.0,,,GB,GB,2019,Q1,Adult
160912861,16091286,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY(0-1-0),,,U,,,,202293.0,,,TABLET,,2019,Q1,Dizziness,,2019,Q1,1,I,,20190218.0,20190319,20190319,EXP,,ES-ASTRAZENECA-2019SE28746,ASTRAZENECA,,59.0,YR,,F,Y,,,20190319.0,,CN,ES,ES,2019,Q1,Adult
160912861,16091286,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY(0-1-0),,,U,,,,202293.0,,,TABLET,,2019,Q1,Glycosylated haemoglobin increased,,2019,Q1,1,I,,20190218.0,20190319,20190319,EXP,,ES-ASTRAZENECA-2019SE28746,ASTRAZENECA,,59.0,YR,,F,Y,,,20190319.0,,CN,ES,ES,2019,Q1,Adult
160912861,16091286,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY(0-1-0),,,U,,,,202293.0,,,TABLET,,2019,Q1,Poisoning,,2019,Q1,1,I,,20190218.0,20190319,20190319,EXP,,ES-ASTRAZENECA-2019SE28746,ASTRAZENECA,,59.0,YR,,F,Y,,,20190319.0,,CN,ES,ES,2019,Q1,Adult
160977081,16097708,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,5.0,MG,,BID,2019,Q1,Diabetic retinopathy,,2019,Q1,1,I,,20190312.0,20190320,20190320,EXP,,PHHY2019PT062196,SANDOZ,"AMARAL M., FERREIRA C. BACELAR C.. DIABETES MELLITUS: QUANDO. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1 SUPPL):80",58.0,YR,,F,Y,81.0,KG,20190320.0,,OT,PT,PT,2019,Q1,Adult
160977081,16097708,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,5.0,MG,,BID,2019,Q1,Macular oedema,,2019,Q1,1,I,,20190312.0,20190320,20190320,EXP,,PHHY2019PT062196,SANDOZ,"AMARAL M., FERREIRA C. BACELAR C.. DIABETES MELLITUS: QUANDO. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1 SUPPL):80",58.0,YR,,F,Y,81.0,KG,20190320.0,,OT,PT,PT,2019,Q1,Adult
160999141,16099914,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190313.0,20190321,20190321,EXP,,JP-ASTRAZENECA-2019SE42497,ASTRAZENECA,"IWASAKI Y, ET AL.. O4-2 THREE CASES OF PERIOPERATIVE KETOACIDOSIS CONSIDERED TO BE CAUSED BY SODIUM GLUCOSE CO-TRANSPORTER2 INHIBITORS.. THE 46TH ANNUAL MEETING OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE 2019;",70.0,YR,,M,Y,,,20190321.0,,OT,JP,JP,2019,Q1,Elderly
161046961,16104696,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190318.0,20190322,20190322,EXP,,PT-ASTRAZENECA-2019SE44506,ASTRAZENECA,,69.0,YR,,M,Y,,,20190322.0,,OT,PT,PT,2019,Q1,Elderly
161166251,16116625,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q1,Chest pain,,2019,Q1,1,I,,20190315.0,20190326,20190326,EXP,PT-EMA-DD-20181213-KUMARVN_P-153457,PT-ACCORD-115341,ACCORD,,54.0,YR,,F,Y,,,20190326.0,,OT,PT,PT,2019,Q1,Adult
161166251,16116625,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q1,Ischaemic stroke,,2019,Q1,1,I,,20190315.0,20190326,20190326,EXP,PT-EMA-DD-20181213-KUMARVN_P-153457,PT-ACCORD-115341,ACCORD,,54.0,YR,,F,Y,,,20190326.0,,OT,PT,PT,2019,Q1,Adult
161219161,16121916,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,ES-ASTRAZENECA-2019SE44303,ASTRAZENECA,,62.0,YR,,M,Y,,,20190327.0,,OT,ES,ES,2019,Q1,Adult
161219161,16121916,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,ES-ASTRAZENECA-2019SE44303,ASTRAZENECA,,62.0,YR,,M,Y,,,20190327.0,,OT,ES,ES,2019,Q1,Adult
161219171,16121917,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,ES-ASTRAZENECA-2019SE44425,ASTRAZENECA,,53.0,YR,,M,Y,,,20190327.0,,OT,ES,ES,2019,Q1,Adult
161219171,16121917,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,ES-ASTRAZENECA-2019SE44425,ASTRAZENECA,,53.0,YR,,M,Y,,,20190327.0,,OT,ES,ES,2019,Q1,Adult
161339211,16133921,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,310.0,MG,,, NOT REPORTED,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Device leakage,,2019,Q1,1,I,201902.0,20190301.0,20190329,20190329,PER,,US-ASTRAZENECA-2019SE37320,ASTRAZENECA,,659.0,MON,,F,Y,72.6,KG,20190329.0,,CN,US,US,2019,Q1,Elderly
161339211,16133921,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,310.0,MG,,, NOT REPORTED,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Injection site bruising,,2019,Q1,1,I,201902.0,20190301.0,20190329,20190329,PER,,US-ASTRAZENECA-2019SE37320,ASTRAZENECA,,659.0,MON,,F,Y,72.6,KG,20190329.0,,CN,US,US,2019,Q1,Elderly
161339211,16133921,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,310.0,MG,,, NOT REPORTED,,202293.0,10.0,MG,TABLET,QD,2019,Q1,Injection site erythema,,2019,Q1,1,I,201902.0,20190301.0,20190329,20190329,PER,,US-ASTRAZENECA-2019SE37320,ASTRAZENECA,,659.0,MON,,F,Y,72.6,KG,20190329.0,,CN,US,US,2019,Q1,Elderly
141145802,14114580,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10,,,U,U,,,202293.0,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190529.0,20171023,20190605,EXP,,GB-ASTRAZENECA-2017SF05480,ASTRAZENECA,,70.0,YR,,F,Y,,,20190605.0,,MD,GB,GB,2019,Q2,Elderly
141415172,14141517,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 (UNSPECIFIED UNITS),,,U,U,,,,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190529.0,20171030,20190605,EXP,,PHFR2017GB008354,SANDOZ,,70.0,YR,,F,Y,,,20190605.0,,OT,GB,GB,2019,Q2,Elderly
141674652,14167465,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 ABSENT,,,U,,,,,10.0,DF,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190517.0,20171107,20190531,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-099836,BRISTOL MYERS SQUIBB,,70.0,YR,,F,Y,,,20190531.0,,MD,GB,GB,2019,Q2,Elderly
144381975,14438197,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Acute kidney injury,,2019,Q2,5,F,20171001.0,20190527.0,20180125,20190530,EXP,,CA-ASTRAZENECA-2018SE01524,ASTRAZENECA,,28824.0,DY,,F,Y,,,20190530.0,,MD,CA,CA,2019,Q2,Elderly
144381975,14438197,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Gangrene,,2019,Q2,5,F,20171001.0,20190527.0,20180125,20190530,EXP,,CA-ASTRAZENECA-2018SE01524,ASTRAZENECA,,28824.0,DY,,F,Y,,,20190530.0,,MD,CA,CA,2019,Q2,Elderly
144381975,14438197,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Acute kidney injury,,2019,Q2,5,F,20171001.0,20190527.0,20180125,20190530,EXP,,CA-ASTRAZENECA-2018SE01524,ASTRAZENECA,,28824.0,DY,,F,Y,,,20190530.0,,MD,CA,CA,2019,Q2,Elderly
144381975,14438197,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Gangrene,,2019,Q2,5,F,20171001.0,20190527.0,20180125,20190530,EXP,,CA-ASTRAZENECA-2018SE01524,ASTRAZENECA,,28824.0,DY,,F,Y,,,20190530.0,,MD,CA,CA,2019,Q2,Elderly
1561839711,15618397,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNKNOWN",,,U,U,,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,11,F,,20190329.0,20181114,20190410,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201811005909,ELI LILLY AND CO,,54.0,YR,,F,Y,,,20190410.0,,CN,PT,PT,2019,Q2,Adult
1561839711,15618397,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNKNOWN",,,U,U,,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,11,F,,20190329.0,20181114,20190410,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201811005909,ELI LILLY AND CO,,54.0,YR,,F,Y,,,20190410.0,,CN,PT,PT,2019,Q2,Adult
1561839711,15618397,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNKNOWN",,,U,U,,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,11,F,,20190329.0,20181114,20190410,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201811005909,ELI LILLY AND CO,,54.0,YR,,F,Y,,,20190410.0,,CN,PT,PT,2019,Q2,Adult
1564428128,15644281,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,28,F,,20190611.0,20181121,20190625,EXP,,PT-PFIZER INC-2018477132,PFIZER,,54.0,YR,,F,Y,,,20190625.0,,CN,PT,PT,2019,Q2,Adult
1564428128,15644281,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,28,F,,20190611.0,20181121,20190625,EXP,,PT-PFIZER INC-2018477132,PFIZER,,54.0,YR,,F,Y,,,20190625.0,,CN,PT,PT,2019,Q2,Adult
1564428128,15644281,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,28,F,,20190611.0,20181121,20190625,EXP,,PT-PFIZER INC-2018477132,PFIZER,,54.0,YR,,F,Y,,,20190625.0,,CN,PT,PT,2019,Q2,Adult
156579647,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNK",,,U,,,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,7,F,,20190611.0,20181126,20190621,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190621.0,,OT,PT,PT,2019,Q2,Adult
156579647,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNK",,,U,,,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,7,F,,20190611.0,20181126,20190621,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190621.0,,OT,PT,PT,2019,Q2,Adult
156579647,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNK",,,U,,,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,7,F,,20190611.0,20181126,20190621,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190621.0,,OT,PT,PT,2019,Q2,Adult
156659134,15665913,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,, UNK,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,4,F,,20190605.0,20181128,20190611,EXP,PT-002147023-PHHY2018PT147150,PT-FRESENIUS KABI-FK201812057,FRESENIUS KABI,,54.0,YR,,F,Y,,,20190611.0,,OT,GB,PT,2019,Q2,Adult
156659134,15665913,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,, UNK,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,4,F,,20190605.0,20181128,20190611,EXP,PT-002147023-PHHY2018PT147150,PT-FRESENIUS KABI-FK201812057,FRESENIUS KABI,,54.0,YR,,F,Y,,,20190611.0,,OT,GB,PT,2019,Q2,Adult
156659134,15665913,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,, UNK,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,4,F,,20190605.0,20181128,20190611,EXP,PT-002147023-PHHY2018PT147150,PT-FRESENIUS KABI-FK201812057,FRESENIUS KABI,,54.0,YR,,F,Y,,,20190611.0,,OT,GB,PT,2019,Q2,Adult
156702899,15670289,13,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U, UNK,,,,,,,2019,Q2,Chest pain,,2019,Q2,9,F,,20190612.0,20181129,20190620,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20190620.0,,OT,PT,PT,2019,Q2,Adult
156702899,15670289,13,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U, UNK,,,,,,,2019,Q2,Headache,,2019,Q2,9,F,,20190612.0,20181129,20190620,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20190620.0,,OT,PT,PT,2019,Q2,Adult
156702899,15670289,13,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U, UNK,,,,,,,2019,Q2,Ischaemic stroke,,2019,Q2,9,F,,20190612.0,20181129,20190620,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20190620.0,,OT,PT,PT,2019,Q2,Adult
156847433,15684743,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,8270.0,MG,D,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Cerebral infarction,,2019,Q2,3,F,20180301.0,20190422.0,20181204,20190426,EXP,,IN-ASTRAZENECA-2018SF58094,ASTRAZENECA,,28105.0,DY,,M,Y,74.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Elderly
156847433,15684743,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,8270.0,MG,D,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Pneumonia,,2019,Q2,3,F,20180301.0,20190422.0,20181204,20190426,EXP,,IN-ASTRAZENECA-2018SF58094,ASTRAZENECA,,28105.0,DY,,M,Y,74.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Elderly
157041065,15704106,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,5,F,,20190402.0,20181210,20190410,EXP,,PHHY2018PT173656,NOVARTIS,,54.0,YR,,F,Y,,,20190410.0,,OT,PT,PT,2019,Q2,Adult
157041065,15704106,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,5,F,,20190402.0,20181210,20190410,EXP,,PHHY2018PT173656,NOVARTIS,,54.0,YR,,F,Y,,,20190410.0,,OT,PT,PT,2019,Q2,Adult
157041065,15704106,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,5,F,,20190402.0,20181210,20190410,EXP,,PHHY2018PT173656,NOVARTIS,,54.0,YR,,F,Y,,,20190410.0,,OT,PT,PT,2019,Q2,Adult
157473963,15747396,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Erectile dysfunction,,2019,Q2,3,F,,20190517.0,20181220,20190528,EXP,,RO-ELI_LILLY_AND_COMPANY-RO201812007263,ELI LILLY AND CO,,48.0,YR,,M,Y,,,20190528.0,,MD,RO,RO,2019,Q2,Adult
157473963,15747396,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Neuropathy peripheral,,2019,Q2,3,F,,20190517.0,20181220,20190528,EXP,,RO-ELI_LILLY_AND_COMPANY-RO201812007263,ELI LILLY AND CO,,48.0,YR,,M,Y,,,20190528.0,,MD,RO,RO,2019,Q2,Adult
157827586,15782758,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,6,F,,20190619.0,20190102,20190627,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190627.0,,OT,PT,PT,2019,Q2,Adult
157827586,15782758,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,6,F,,20190619.0,20190102,20190627,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190627.0,,OT,PT,PT,2019,Q2,Adult
157827586,15782758,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,6,F,,20190619.0,20190102,20190627,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190627.0,,OT,PT,PT,2019,Q2,Adult
159004822,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q2,Blister,,2019,Q2,2,F,20190101.0,20190409.0,20190201,20190417,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20190417.0,,,GB,GB,2019,Q2,Adult
159004822,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q2,Peripheral swelling,,2019,Q2,2,F,20190101.0,20190409.0,20190201,20190417,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20190417.0,,,GB,GB,2019,Q2,Adult
159004822,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q2,Purpura,,2019,Q2,2,F,20190101.0,20190409.0,20190201,20190417,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20190417.0,,,GB,GB,2019,Q2,Adult
159004822,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q2,Vasculitis,,2019,Q2,2,F,20190101.0,20190409.0,20190201,20190417,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20190417.0,,,GB,GB,2019,Q2,Adult
160014932,16001493,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,2,F,,20190501.0,20190225,20190506,EXP,,US-009507513-1902USA008476,MERCK,"VALLATHARASU Y, HAYASHI-TANNER Y, POLEWSKI P J, BOTTNER WA., ROSENSTEIN LJ, UPRETY D, ET AL. SEVERE, PROLONGED THROMBOCYTOPENIA IN A PATIENT SENSITIVE TO EXENATIDE. AMERICAN JOURNAL OF HEMATOLOGY. 2019;94(3):E78-80",55.0,YR,,M,Y,,,20190506.0,,MD,US,US,2019,Q2,Adult
1601002811,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q2,Chest pain,,2019,Q2,11,F,,20190607.0,20190225,20190626,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190626.0,,CN,PT,PT,2019,Q2,Adult
1601002811,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,11,F,,20190607.0,20190225,20190626,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190626.0,,CN,PT,PT,2019,Q2,Adult
1601002811,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q2,Ischaemic stroke,,2019,Q2,11,F,,20190607.0,20190225,20190626,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190626.0,,CN,PT,PT,2019,Q2,Adult
160169492,16016949,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6910.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Osteitis,,2019,Q2,2,F,20181228.0,20190507.0,20190228,20190514,EXP,,ES-ASTRAZENECA-2019SE28701,ASTRAZENECA,,53.0,YR,,M,Y,95.0,KG,20190514.0,,PH,ES,ES,2019,Q2,Adult
160169492,16016949,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,6910.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Skin ulcer,,2019,Q2,2,F,20181228.0,20190507.0,20190228,20190514,EXP,,ES-ASTRAZENECA-2019SE28701,ASTRAZENECA,,53.0,YR,,M,Y,95.0,KG,20190514.0,,PH,ES,ES,2019,Q2,Adult
160271414,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q2,Cellulitis,,2019,Q2,4,F,20181224.0,20190508.0,20190303,20190510,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190510.0,,OT,DE,DE,2019,Q2,Adult
160271414,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q2,Lymphangitis,,2019,Q2,4,F,20181224.0,20190508.0,20190303,20190510,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190510.0,,OT,DE,DE,2019,Q2,Adult
160271414,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q2,Necrosis,,2019,Q2,4,F,20181224.0,20190508.0,20190303,20190510,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190510.0,,OT,DE,DE,2019,Q2,Adult
160271414,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q2,Soft tissue infection,,2019,Q2,4,F,20181224.0,20190508.0,20190303,20190510,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20190510.0,,OT,DE,DE,2019,Q2,Adult
160545663,16054566,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q2,Creatinine urine increased,,2019,Q2,3,F,20181220.0,20190619.0,20190309,20190626,EXP,,PHHY2019GB049975,SANDOZ,,59.0,YR,,F,Y,79.4,KG,20190626.0,,MD,GB,GB,2019,Q2,Adult
160545663,16054566,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q2,Glycosylated haemoglobin increased,,2019,Q2,3,F,20181220.0,20190619.0,20190309,20190626,EXP,,PHHY2019GB049975,SANDOZ,,59.0,YR,,F,Y,79.4,KG,20190626.0,,MD,GB,GB,2019,Q2,Adult
160545663,16054566,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q2,Hepatic enzyme increased,,2019,Q2,3,F,20181220.0,20190619.0,20190309,20190626,EXP,,PHHY2019GB049975,SANDOZ,,59.0,YR,,F,Y,79.4,KG,20190626.0,,MD,GB,GB,2019,Q2,Adult
160545663,16054566,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q2,Hepatic function abnormal,,2019,Q2,3,F,20181220.0,20190619.0,20190309,20190626,EXP,,PHHY2019GB049975,SANDOZ,,59.0,YR,,F,Y,79.4,KG,20190626.0,,MD,GB,GB,2019,Q2,Adult
160545663,16054566,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q2,Red blood cell sedimentation rate increased,,2019,Q2,3,F,20181220.0,20190619.0,20190309,20190626,EXP,,PHHY2019GB049975,SANDOZ,,59.0,YR,,F,Y,79.4,KG,20190626.0,,MD,GB,GB,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Abdominal pain lower,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Abdominal pain upper,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Bladder transitional cell carcinoma,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Cystitis haemorrhagic,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Diarrhoea,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Haematuria,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Hypersplenism,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Pancytopenia,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Renal failure,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Splenomegaly,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Abdominal pain lower,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Abdominal pain upper,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Bladder transitional cell carcinoma,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Cystitis haemorrhagic,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Diarrhoea,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Haematuria,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Hypersplenism,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Pancytopenia,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Renal failure,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Splenomegaly,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
160913444,16091344,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAPAGLAIFLOZIN (TRIAL MEDICATION) UNKNOWN,,,U,, UNKNOWN,,,,,TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,4,F,2014.0,20190414.0,20190319,20190524,EXP,,ZA-ASTRAZENECA-2019SE41099,ASTRAZENECA,,64.0,YR,,M,Y,70.0,KG,20190524.0,,,ZA,ZA,2019,Q2,Adult
161166252,16116625,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Chest pain,,2019,Q2,2,F,,20190502.0,20190326,20190508,EXP,PT-EMA-DD-20181213-KUMARVN_P-153457,PT-ACCORD-115341,ACCORD,,54.0,YR,,F,Y,,,20190508.0,,OT,PT,PT,2019,Q2,Adult
161166252,16116625,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Ischaemic stroke,,2019,Q2,2,F,,20190502.0,20190326,20190508,EXP,PT-EMA-DD-20181213-KUMARVN_P-153457,PT-ACCORD-115341,ACCORD,,54.0,YR,,F,Y,,,20190508.0,,OT,PT,PT,2019,Q2,Adult
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Cardiac failure,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Diabetic metabolic decompensation,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Drug ineffective,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Drug interaction,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Fatigue,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Food refusal,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Hypernatraemia,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Metabolic acidosis,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Off label use,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161403713,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q2,Urine ketone body present,,2019,Q2,3,F,,20190527.0,20190401,20190530,EXP,,PHHY2019PT072916,SANDOZ,,69.0,YR,,F,Y,,,20190530.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Abdominal pain,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Acetonaemia,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Cholecystitis acute,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Ketonuria,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Nervous system disorder,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,Vomiting,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161410531,16141053,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U, UNK,,,,,,,2019,Q2,White blood cell count increased,,2019,Q2,1,I,,20190322.0,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028474,MYLAN,"FERREIRA JL, PRINCIPE RM, GUEDES C. POSTERS. CONGRESSO PORTUGUES DE ENDOCRINOLOGIA - 69 REUNIAO ANUAL DA SPEDM",66.0,YR,,M,Y,,,20190401.0,,OT,PT,PT,2019,Q2,Elderly
161494791,16149479,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG/24 H DAILY,,,Y,,,,202293.0,,,TABLET,,2019,Q2,Fournier's gangrene,,2019,Q2,1,I,20190121.0,20190328.0,20190402,20190402,EXP,,ES-ASTRAZENECA-2019SE49469,ASTRAZENECA,,47.0,YR,,M,Y,,,20190402.0,,MD,ES,ES,2019,Q2,Adult
161578721,16157872,1,PS,DAPAGLIFLOZIN 10 MG,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q2,Bladder cancer,,2019,Q2,1,I,20190126.0,,20190301,20190301,DIR,,,FDA-CTU,,65.0,YR,,M,N,231.0,LBS,20190227.0,N,MD,US,US,2019,Q2,Elderly
161578721,16157872,1,PS,DAPAGLIFLOZIN 10 MG,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q2,Bladder transitional cell carcinoma,,2019,Q2,1,I,20190126.0,,20190301,20190301,DIR,,,FDA-CTU,,65.0,YR,,M,N,231.0,LBS,20190227.0,N,MD,US,US,2019,Q2,Elderly
161649461,16164946,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,, UNK,,,10.0,MG,TABLET,QD,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,20141013.0,20190401.0,20190405,20190405,EXP,,NL-MYLANLABS-2019M1031411,MYLAN,,58.0,YR,,F,Y,,,20190405.0,,CN,US,NL,2019,Q2,Adult
161649461,16164946,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,, UNK,,,10.0,MG,TABLET,QD,2019,Q2,Hypoglycaemia,,2019,Q2,1,I,20141013.0,20190401.0,20190405,20190405,EXP,,NL-MYLANLABS-2019M1031411,MYLAN,,58.0,YR,,F,Y,,,20190405.0,,CN,US,NL,2019,Q2,Adult
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Cardiac failure,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Diabetic metabolic decompensation,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Drug ineffective,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Drug interaction,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Off label use,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Cardiac failure,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Diabetic metabolic decompensation,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Drug ineffective,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Drug interaction,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161652032,16165203,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Off label use,,2019,Q2,2,F,,20190419.0,20190405,20190429,EXP,,PT-BAUSCH-BL-2019-009685,BAUSCH AND LOMB,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J, CARVALHO A, PEREIRA M, FERREIRA L, FREITAS C, DORES J, AMARAL C, CARDOSO H. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS TO BEAR IN MIND. PORTUGUESE JOURNAL ON DIABETES. 2019;14(SUPPL 1):79.",69.0,YR,,F,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161795501,16179550,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, QD",,,Y,, UNK,,,5.0,MG,,QD,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,1,I,,20190328.0,20190410,20190410,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-032957,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,,,20190410.0,,OT,IT,IT,2019,Q2,Adult
161795501,16179550,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, QD",,,Y,, UNK,,,5.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,,20190328.0,20190410,20190410,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-032957,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,,,20190410.0,,OT,IT,IT,2019,Q2,Adult
161795531,16179553,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,,,,,10.0,MG,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,,20190328.0,20190410,20190410,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-033029,BRISTOL MYERS SQUIBB,,47.0,YR,,F,Y,,,20190410.0,,OT,IT,IT,2019,Q2,Adult
161835452,16183545,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,2,F,,20190429.0,20190411,20190507,EXP,,IT-ASTRAZENECA-2019SE52283,ASTRAZENECA,,50.0,YR,,F,Y,,,20190507.0,,OT,IT,IT,2019,Q2,Adult
161835452,16183545,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190429.0,20190411,20190507,EXP,,IT-ASTRAZENECA-2019SE52283,ASTRAZENECA,,50.0,YR,,F,Y,,,20190507.0,,OT,IT,IT,2019,Q2,Adult
161861491,16186149,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q2,Hypoglycaemia,,2019,Q2,1,I,20160713.0,20190109.0,20190411,20190411,EXP,,PT-SA-2019SA009069,SANOFI AVENTIS,,83.0,YR,E,M,Y,,,20190411.0,,OT,PT,PT,2019,Q2,Elderly
161861491,16186149,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q2,Inappropriate schedule of product administration,,2019,Q2,1,I,20160713.0,20190109.0,20190411,20190411,EXP,,PT-SA-2019SA009069,SANOFI AVENTIS,,83.0,YR,E,M,Y,,,20190411.0,,OT,PT,PT,2019,Q2,Elderly
161861491,16186149,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q2,Syncope,,2019,Q2,1,I,20160713.0,20190109.0,20190411,20190411,EXP,,PT-SA-2019SA009069,SANOFI AVENTIS,,83.0,YR,E,M,Y,,,20190411.0,,OT,PT,PT,2019,Q2,Elderly
161888061,16188806,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Blood glucose increased,,2019,Q2,1,I,201810.0,20190409.0,20190412,20190412,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201904006016,ELI LILLY AND CO,,57.0,YR,,M,Y,75.0,KG,20190412.0,,CN,CN,CN,2019,Q2,Adult
161916511,16191651,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1220.0,MG,,,,,,10.0,MG,TABLET,QD,2019,Q2,Device malfunction,,2019,Q2,1,I,201805.0,20190318.0,20190412,20190412,PER,,US-ASTRAZENECA-2019SE45774,ASTRAZENECA,,486.0,MON,,M,Y,70.3,KG,20190412.0,,CN,US,US,2019,Q2,Elderly
161916511,16191651,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1220.0,MG,,,,,,10.0,MG,TABLET,QD,2019,Q2,Injection site pain,,2019,Q2,1,I,201805.0,20190318.0,20190412,20190412,PER,,US-ASTRAZENECA-2019SE45774,ASTRAZENECA,,486.0,MON,,M,Y,70.3,KG,20190412.0,,CN,US,US,2019,Q2,Elderly
161968631,16196863,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190404.0,20190415,20190415,EXP,,GB-ASTRAZENECA-2019SE53952,ASTRAZENECA,,65.0,YR,,M,Y,,,20190415.0,,MD,GB,GB,2019,Q2,Elderly
161968742,16196874,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY DOSE: 10 MG MILLGRAM(S) EVERY DAYS,,,U,,,,,10.0,MG,,,2019,Q2,Blood glucose increased,,2019,Q2,2,F,20190328.0,20190430.0,20190415,20190505,EXP,DE-DCGMA-19180813,DE-TORRENT-00013776,TORRENT,,70.0,YR,E,M,Y,70.0,KG,20190505.0,,MD,DE,DE,2019,Q2,Elderly
161968742,16196874,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY DOSE: 10 MG MILLGRAM(S) EVERY DAYS,,,U,,,,,10.0,MG,,,2019,Q2,Depressed level of consciousness,,2019,Q2,2,F,20190328.0,20190430.0,20190415,20190505,EXP,DE-DCGMA-19180813,DE-TORRENT-00013776,TORRENT,,70.0,YR,E,M,Y,70.0,KG,20190505.0,,MD,DE,DE,2019,Q2,Elderly
161968742,16196874,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY DOSE: 10 MG MILLGRAM(S) EVERY DAYS,,,U,,,,,10.0,MG,,,2019,Q2,Ketoacidosis,,2019,Q2,2,F,20190328.0,20190430.0,20190415,20190505,EXP,DE-DCGMA-19180813,DE-TORRENT-00013776,TORRENT,,70.0,YR,E,M,Y,70.0,KG,20190505.0,,MD,DE,DE,2019,Q2,Elderly
161968742,16196874,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY DOSE: 10 MG MILLGRAM(S) EVERY DAYS,,,U,,,,,10.0,MG,,,2019,Q2,Lactic acidosis,,2019,Q2,2,F,20190328.0,20190430.0,20190415,20190505,EXP,DE-DCGMA-19180813,DE-TORRENT-00013776,TORRENT,,70.0,YR,E,M,Y,70.0,KG,20190505.0,,MD,DE,DE,2019,Q2,Elderly
162016851,16201685,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q2,Hypertriglyceridaemia,,2019,Q2,1,I,,20190402.0,20190416,20190416,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-02258,HIKMA,"SEUNG KIM D, O^HAYER P, RUBENFIRE M, BROOK R. HYPERTRIGLYCERIDAEMIA-INDUCED PANCREATITIS PROMPTED BY ACUTE CORTICOSTEROID TREATMENT: CAUTION FOR CLINICIANS. INTERNAL MEDICINE JOURNAL; DOI:10.1111/IMJ.14228. 2019;49:3:411-412.",41.0,YR,,F,Y,,,20190416.0,,MD,US,US,2019,Q2,Adult
162016851,16201685,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q2,Pancreatitis acute,,2019,Q2,1,I,,20190402.0,20190416,20190416,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-02258,HIKMA,"SEUNG KIM D, O^HAYER P, RUBENFIRE M, BROOK R. HYPERTRIGLYCERIDAEMIA-INDUCED PANCREATITIS PROMPTED BY ACUTE CORTICOSTEROID TREATMENT: CAUTION FOR CLINICIANS. INTERNAL MEDICINE JOURNAL; DOI:10.1111/IMJ.14228. 2019;49:3:411-412.",41.0,YR,,F,Y,,,20190416.0,,MD,US,US,2019,Q2,Adult
162060752,16206075,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Cerebrovascular accident,,2019,Q2,2,F,,20190606.0,20190417,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017403",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
162060752,16206075,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Drug interaction,,2019,Q2,2,F,,20190606.0,20190417,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017403",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
162060752,16206075,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Off label use,,2019,Q2,2,F,,20190606.0,20190417,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017403",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
162066021,16206602,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q2,Toe amputation,,2019,Q2,1,I,20181128.0,,20190416,20190416,DIR,,,FDA-CTU,,51.0,YR,,M,N,119.7,KG,20190416.0,N,PH,US,US,2019,Q2,Adult
162100072,16210007,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,Y,,,,,5.0,MG,,QD,2019,Q2,Asthenia,,2019,Q2,2,F,,20190509.0,20190417,20190518,EXP,,PHHY2019IT088937,SANDOZ,,50.0,YR,,F,Y,,,20190518.0,,OT,IT,IT,2019,Q2,Adult
162100072,16210007,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,Y,,,,,5.0,MG,,QD,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,2,F,,20190509.0,20190417,20190518,EXP,,PHHY2019IT088937,SANDOZ,,50.0,YR,,F,Y,,,20190518.0,,OT,IT,IT,2019,Q2,Adult
162100072,16210007,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,Y,,,,,5.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190509.0,20190417,20190518,EXP,,PHHY2019IT088937,SANDOZ,,50.0,YR,,F,Y,,,20190518.0,,OT,IT,IT,2019,Q2,Adult
162100072,16210007,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,Y,,,,,5.0,MG,,QD,2019,Q2,Nausea,,2019,Q2,2,F,,20190509.0,20190417,20190518,EXP,,PHHY2019IT088937,SANDOZ,,50.0,YR,,F,Y,,,20190518.0,,OT,IT,IT,2019,Q2,Adult
162100072,16210007,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,Y,,,,,5.0,MG,,QD,2019,Q2,Vomiting,,2019,Q2,2,F,,20190509.0,20190417,20190518,EXP,,PHHY2019IT088937,SANDOZ,,50.0,YR,,F,Y,,,20190518.0,,OT,IT,IT,2019,Q2,Adult
162129511,16212951,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, NOT REPORTED,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Bladder cancer,,2019,Q2,1,I,,20190410.0,20190418,20190418,PER,,US-ASTRAZENECA-2019SE56998,ASTRAZENECA,,55.0,YR,,M,Y,,,20190418.0,,MD,US,US,2019,Q2,Adult
162135011,16213501,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Blood glucose increased,,2019,Q2,1,I,20190328.0,20190412.0,20190418,20190418,EXP,,DE-ASTRAZENECA-2019SE57040,ASTRAZENECA,,70.0,YR,,M,Y,70.0,KG,20190418.0,,MD,DE,DE,2019,Q2,Elderly
162135011,16213501,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Depressed level of consciousness,,2019,Q2,1,I,20190328.0,20190412.0,20190418,20190418,EXP,,DE-ASTRAZENECA-2019SE57040,ASTRAZENECA,,70.0,YR,,M,Y,70.0,KG,20190418.0,,MD,DE,DE,2019,Q2,Elderly
162135011,16213501,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Ketoacidosis,,2019,Q2,1,I,20190328.0,20190412.0,20190418,20190418,EXP,,DE-ASTRAZENECA-2019SE57040,ASTRAZENECA,,70.0,YR,,M,Y,70.0,KG,20190418.0,,MD,DE,DE,2019,Q2,Elderly
162135011,16213501,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Lactic acidosis,,2019,Q2,1,I,20190328.0,20190412.0,20190418,20190418,EXP,,DE-ASTRAZENECA-2019SE57040,ASTRAZENECA,,70.0,YR,,M,Y,70.0,KG,20190418.0,,MD,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Blood glucose increased,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Depressed level of consciousness,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Hyperglycaemia,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Hypoinsulinaemia,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Ketoacidosis,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Lactic acidosis,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Weight decreased,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Blood glucose increased,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Depressed level of consciousness,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Hyperglycaemia,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Hypoinsulinaemia,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Ketoacidosis,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Lactic acidosis,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162146702,16214670,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, BID",,,Y,,,,,5.0,MG,,BID,2019,Q2,Weight decreased,,2019,Q2,2,F,2016.0,20190520.0,20190418,20190527,EXP,,PHHY2019DE086651,SANDOZ,,70.0,YR,,M,Y,70.0,KG,20190528.0,,OT,DE,DE,2019,Q2,Elderly
162184761,16218476,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,CREST syndrome,,2019,Q2,1,I,,20190417.0,20190419,20190419,EXP,,PHHY2019ES090502,SANDOZ,,50.0,YR,,F,Y,,,20190419.0,,OT,ES,ES,2019,Q2,Adult
162189081,16218908,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2019,Q2,Blood glucose increased,,2019,Q2,1,I,20190328.0,20190412.0,20190419,20190419,EXP,DE-DCGMA-19180813,DE-BAUSCH-BL-2019-011361,BAUSCH AND LOMB,,70.0,YR,,M,Y,70.0,KG,20190419.0,,MD,DE,DE,2019,Q2,Elderly
162189081,16218908,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2019,Q2,Depressed level of consciousness,,2019,Q2,1,I,20190328.0,20190412.0,20190419,20190419,EXP,DE-DCGMA-19180813,DE-BAUSCH-BL-2019-011361,BAUSCH AND LOMB,,70.0,YR,,M,Y,70.0,KG,20190419.0,,MD,DE,DE,2019,Q2,Elderly
162189081,16218908,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2019,Q2,Ketoacidosis,,2019,Q2,1,I,20190328.0,20190412.0,20190419,20190419,EXP,DE-DCGMA-19180813,DE-BAUSCH-BL-2019-011361,BAUSCH AND LOMB,,70.0,YR,,M,Y,70.0,KG,20190419.0,,MD,DE,DE,2019,Q2,Elderly
162189081,16218908,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,QD,2019,Q2,Lactic acidosis,,2019,Q2,1,I,20190328.0,20190412.0,20190419,20190419,EXP,DE-DCGMA-19180813,DE-BAUSCH-BL-2019-011361,BAUSCH AND LOMB,,70.0,YR,,M,Y,70.0,KG,20190419.0,,MD,DE,DE,2019,Q2,Elderly
162250621,16225062,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,,10.0,MG,,QD,2019,Q2,Asthma,,2019,Q2,1,I,20190324.0,20190413.0,20190422,20190422,EXP,GB-MHRA-EYC 00197580,GB-BAUSCH-BL-2019-011492,BAUSCH AND LOMB,,68.0,YR,,M,Y,,,20190422.0,,PH,GB,GB,2019,Q2,Elderly
162250621,16225062,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,,10.0,MG,,QD,2019,Q2,Dyspnoea,,2019,Q2,1,I,20190324.0,20190413.0,20190422,20190422,EXP,GB-MHRA-EYC 00197580,GB-BAUSCH-BL-2019-011492,BAUSCH AND LOMB,,68.0,YR,,M,Y,,,20190422.0,,PH,GB,GB,2019,Q2,Elderly
162250621,16225062,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,,10.0,MG,,QD,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,20190324.0,20190413.0,20190422,20190422,EXP,GB-MHRA-EYC 00197580,GB-BAUSCH-BL-2019-011492,BAUSCH AND LOMB,,68.0,YR,,M,Y,,,20190422.0,,PH,GB,GB,2019,Q2,Elderly
162250621,16225062,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,,10.0,MG,,QD,2019,Q2,Wheezing,,2019,Q2,1,I,20190324.0,20190413.0,20190422,20190422,EXP,GB-MHRA-EYC 00197580,GB-BAUSCH-BL-2019-011492,BAUSCH AND LOMB,,68.0,YR,,M,Y,,,20190422.0,,PH,GB,GB,2019,Q2,Elderly
162269961,16226996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Asthenia,,2019,Q2,1,I,201903.0,20190415.0,20190423,20190423,EXP,,CN-ASTRAZENECA-2019SE60339,ASTRAZENECA,,864.0,MON,,M,Y,103.0,KG,20190423.0,,CN,CN,CN,2019,Q2,Elderly
162269961,16226996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Cough,,2019,Q2,1,I,201903.0,20190415.0,20190423,20190423,EXP,,CN-ASTRAZENECA-2019SE60339,ASTRAZENECA,,864.0,MON,,M,Y,103.0,KG,20190423.0,,CN,CN,CN,2019,Q2,Elderly
162269961,16226996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Decreased appetite,,2019,Q2,1,I,201903.0,20190415.0,20190423,20190423,EXP,,CN-ASTRAZENECA-2019SE60339,ASTRAZENECA,,864.0,MON,,M,Y,103.0,KG,20190423.0,,CN,CN,CN,2019,Q2,Elderly
162296431,16229643,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Blood glucose increased,,2019,Q2,1,I,20190328.0,20190410.0,20190423,20190423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038946,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,70.0,KG,20190423.0,,MD,DE,DE,2019,Q2,Elderly
162296431,16229643,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Depressed level of consciousness,,2019,Q2,1,I,20190328.0,20190410.0,20190423,20190423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038946,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,70.0,KG,20190423.0,,MD,DE,DE,2019,Q2,Elderly
162296431,16229643,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Ketoacidosis,,2019,Q2,1,I,20190328.0,20190410.0,20190423,20190423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038946,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,70.0,KG,20190423.0,,MD,DE,DE,2019,Q2,Elderly
162296431,16229643,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Lactic acidosis,,2019,Q2,1,I,20190328.0,20190410.0,20190423,20190423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038946,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,70.0,KG,20190423.0,,MD,DE,DE,2019,Q2,Elderly
162296911,16229691,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,410.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Ketosis,,2019,Q2,1,I,,20190415.0,20190423,20190423,EXP,,GB-ASTRAZENECA-2019SE57564,ASTRAZENECA,,46.0,YR,,M,Y,87.0,KG,20190423.0,,,GB,GB,2019,Q2,Adult
162303351,16230335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Asthma,,2019,Q2,1,I,20190324.0,20190415.0,20190423,20190423,EXP,,GB-ASTRAZENECA-2019SE57551,ASTRAZENECA,,68.0,YR,,M,Y,,,20190423.0,,,GB,GB,2019,Q2,Elderly
162303351,16230335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Dyspnoea,,2019,Q2,1,I,20190324.0,20190415.0,20190423,20190423,EXP,,GB-ASTRAZENECA-2019SE57551,ASTRAZENECA,,68.0,YR,,M,Y,,,20190423.0,,,GB,GB,2019,Q2,Elderly
162303351,16230335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,20190324.0,20190415.0,20190423,20190423,EXP,,GB-ASTRAZENECA-2019SE57551,ASTRAZENECA,,68.0,YR,,M,Y,,,20190423.0,,,GB,GB,2019,Q2,Elderly
162303351,16230335,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,650.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Wheezing,,2019,Q2,1,I,20190324.0,20190415.0,20190423,20190423,EXP,,GB-ASTRAZENECA-2019SE57551,ASTRAZENECA,,68.0,YR,,M,Y,,,20190423.0,,,GB,GB,2019,Q2,Elderly
162369922,16236992,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Pancreatitis acute,,2019,Q2,2,F,,20190506.0,20190425,20190513,EXP,,US-TEVA-2019-US-1041303,TEVA,"KIM DS, O^HAYER PJ, RUBENFIRE M, BROOK RD. HYPERTRIGLYCERIDAEMIA-INDUCED PANCREATITIS PROMPTED BY ACUTE CORTICOSTEROID TREATMENT: CAUTION FOR CLINICIANS. INTERN-MED-J 2019;49(3):411-412.",41.0,YR,,F,Y,,,20190514.0,,OT,US,US,2019,Q2,Adult
162370491,16237049,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Scrotal abscess,,2019,Q2,1,I,,20190417.0,20190425,20190425,EXP,,GB-ASTRAZENECA-2019SE59132,ASTRAZENECA,,53.0,YR,,M,Y,,,20190425.0,,,GB,GB,2019,Q2,Adult
162406403,16240640,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,3,F,,20190513.0,20190425,20190521,EXP,,PHHY2019IT094679,SANDOZ,,47.0,YR,,F,Y,,,20190521.0,,OT,IT,IT,2019,Q2,Adult
162406403,16240640,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,3,F,,20190513.0,20190425,20190521,EXP,,PHHY2019IT094679,SANDOZ,,47.0,YR,,F,Y,,,20190521.0,,OT,IT,IT,2019,Q2,Adult
162523861,16252386,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2019,Q2,Asthma,,2019,Q2,1,I,20190324.0,20190416.0,20190429,20190429,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038943,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,,,20190429.0,,PH,GB,GB,2019,Q2,Elderly
162523861,16252386,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2019,Q2,Dyspnoea,,2019,Q2,1,I,20190324.0,20190416.0,20190429,20190429,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038943,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,,,20190429.0,,PH,GB,GB,2019,Q2,Elderly
162523861,16252386,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,20190324.0,20190416.0,20190429,20190429,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038943,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,,,20190429.0,,PH,GB,GB,2019,Q2,Elderly
162523861,16252386,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2019,Q2,Wheezing,,2019,Q2,1,I,20190324.0,20190416.0,20190429,20190429,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-038943,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,,,20190429.0,,PH,GB,GB,2019,Q2,Elderly
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Acute coronary syndrome,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Angina unstable,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Blood cholesterol increased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Blood creatine phosphokinase increased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Blood parathyroid hormone increased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Blood triglycerides increased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Coronary artery stenosis,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,High density lipoprotein decreased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Low density lipoprotein increased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Muscular weakness,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Myalgia,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Myopathy,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162547231,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q2,Total cholesterol/HDL ratio increased,,2019,Q2,1,I,,20190422.0,20190430,20190430,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190430.0,,MD,CA,CA,2019,Q2,Adult
162594121,16259412,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;,650.0,MG,Y,, UNKNOWN,,,10.0,MG,,,2019,Q2,Asthma,,2019,Q2,1,I,20190324.0,20190422.0,20190501,20190501,EXP,GB-MHRA-EYC 00197580,GB-TEVA-2019-GB-1045169,TEVA,,68.0,YR,,M,Y,,,20190501.0,,PH,GB,GB,2019,Q2,Elderly
162594121,16259412,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;,650.0,MG,Y,, UNKNOWN,,,10.0,MG,,,2019,Q2,Dyspnoea,,2019,Q2,1,I,20190324.0,20190422.0,20190501,20190501,EXP,GB-MHRA-EYC 00197580,GB-TEVA-2019-GB-1045169,TEVA,,68.0,YR,,M,Y,,,20190501.0,,PH,GB,GB,2019,Q2,Elderly
162594121,16259412,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;,650.0,MG,Y,, UNKNOWN,,,10.0,MG,,,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,20190324.0,20190422.0,20190501,20190501,EXP,GB-MHRA-EYC 00197580,GB-TEVA-2019-GB-1045169,TEVA,,68.0,YR,,M,Y,,,20190501.0,,PH,GB,GB,2019,Q2,Elderly
162594121,16259412,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;,650.0,MG,Y,, UNKNOWN,,,10.0,MG,,,2019,Q2,Wheezing,,2019,Q2,1,I,20190324.0,20190422.0,20190501,20190501,EXP,GB-MHRA-EYC 00197580,GB-TEVA-2019-GB-1045169,TEVA,,68.0,YR,,M,Y,,,20190501.0,,PH,GB,GB,2019,Q2,Elderly
162617771,16261777,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 MG, QD",,,U,U,,,,1.0,MG,,QD,2019,Q2,Diverticulum intestinal,,2019,Q2,1,I,,20190424.0,20190501,20190501,EXP,,CA-NOVOPROD-659792,NOVO NORDISK,,58.0,YR,,F,Y,,,20190501.0,,CN,CA,CA,2019,Q2,Adult
162617771,16261777,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 MG, QD",,,U,U,,,,1.0,MG,,QD,2019,Q2,Nephrolithiasis,,2019,Q2,1,I,,20190424.0,20190501,20190501,EXP,,CA-NOVOPROD-659792,NOVO NORDISK,,58.0,YR,,F,Y,,,20190501.0,,CN,CA,CA,2019,Q2,Adult
162647111,16264711,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,12350.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Pancreatitis acute,,2019,Q2,1,I,20190323.0,20190424.0,20190502,20190502,EXP,,GB-ASTRAZENECA-2019SE63226,ASTRAZENECA,,59.0,YR,,F,Y,79.0,KG,20190502.0,,,GB,GB,2019,Q2,Adult
162691091,16269109,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,60.0,MG,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190424.0,20190503,20190503,EXP,,CN-ASTRAZENECA-2019SE65006,ASTRAZENECA,,20.0,YR,,F,Y,58.1,KG,20190503.0,,CN,CN,CN,2019,Q2,Youth
162693711,16269371,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2180.417,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Fournier's gangrene,,2019,Q2,1,I,20190212.0,20190502.0,20190503,20190503,EXP,,GB-ASTRAZENECA-2019SE67223,ASTRAZENECA,,59.0,YR,,M,Y,74.0,KG,20190503.0,,,GB,GB,2019,Q2,Adult
162713882,16271388,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Atrioventricular block complete,,2019,Q2,2,F,20190422.0,20190514.0,20190503,20190522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-043250,BRISTOL MYERS SQUIBB,,61.0,YR,,F,Y,92.0,KG,20190522.0,,OT,US,US,2019,Q2,Adult
162713882,16271388,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Cardiac arrest,,2019,Q2,2,F,20190422.0,20190514.0,20190503,20190522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-043250,BRISTOL MYERS SQUIBB,,61.0,YR,,F,Y,92.0,KG,20190522.0,,OT,US,US,2019,Q2,Adult
162780691,16278069,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,11090.0,MG,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Necrotising fasciitis,,2019,Q2,1,I,20181014.0,20190430.0,20190506,20190506,EXP,,GB-ASTRAZENECA-2019SE65810,ASTRAZENECA,,42.0,YR,,F,Y,,,20190506.0,,PH,GB,GB,2019,Q2,Adult
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Blood cholesterol increased,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Blood triglycerides increased,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Fatigue,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Hyperglycaemia,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Hypertension,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Overdose,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162785082,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q2,Treatment noncompliance,,2019,Q2,2,F,,20190528.0,20190506,20190611,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
162801641,16280164,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190423.0,20190507,20190507,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-043483,BRISTOL MYERS SQUIBB,,63.0,YR,,F,Y,,,20190507.0,,OT,GB,GB,2019,Q2,Adult
162801641,16280164,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Pneumonia,,2019,Q2,1,I,,20190423.0,20190507,20190507,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-043483,BRISTOL MYERS SQUIBB,,63.0,YR,,F,Y,,,20190507.0,,OT,GB,GB,2019,Q2,Adult
162868271,16286827,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,STRENGTH: 10 MG,,,,,,,,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Pulmonary hypertension,,2019,Q2,1,I,201903.0,20190506.0,20190508,20190508,EXP,DK-DKMA-WBS-0022038,DK-009507513-1905DNK001939,MERCK,,71.0,YR,,M,Y,,,20190508.0,,MD,DK,DK,2019,Q2,Elderly
162868462,16286846,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,TABLET,QD,2019,Q2,Lung infection,,2019,Q2,2,F,201812.0,20190604.0,20190508,20190614,EXP,,BR-UCBSA-2019017162,UCB,,74.0,YR,,F,Y,96.0,KG,20190614.0,,CN,BR,BR,2019,Q2,Elderly
162868462,16286846,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,TABLET,QD,2019,Q2,Pharyngitis,,2019,Q2,2,F,201812.0,20190604.0,20190508,20190614,EXP,,BR-UCBSA-2019017162,UCB,,74.0,YR,,F,Y,96.0,KG,20190614.0,,CN,BR,BR,2019,Q2,Elderly
162868462,16286846,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,TABLET,QD,2019,Q2,Urinary tract infection,,2019,Q2,2,F,201812.0,20190604.0,20190508,20190614,EXP,,BR-UCBSA-2019017162,UCB,,74.0,YR,,F,Y,96.0,KG,20190614.0,,CN,BR,BR,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Blood pressure systolic increased,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Cough,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Dyspnoea,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Fall,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Gait disturbance,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Lower respiratory tract infection,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Musculoskeletal discomfort,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Pneumonia,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Spinal stenosis,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162890491,16289049,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"1 DF, QD",,,U,U,,,,1.0,DF,,,2019,Q2,Weight decreased,,2019,Q2,1,I,,20190429.0,20190509,20190509,EXP,,CA-APOTEX-2019AP013370,APOTEX,,68.0,YR,,F,Y,,,20190509.0,,CN,CA,CA,2019,Q2,Elderly
162979251,16297925,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,U,,,202293.0,10.0,MG,,,2019,Q2,Back pain,,2019,Q2,1,I,,20190503.0,20190510,20190510,EXP,,GB-ASTRAZENECA-2019SE68115,ASTRAZENECA,,46.0,YR,,F,Y,90.0,KG,20190510.0,,,GB,GB,2019,Q2,Adult
162979251,16297925,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,U,,,202293.0,10.0,MG,,,2019,Q2,Renal papillary necrosis,,2019,Q2,1,I,,20190503.0,20190510,20190510,EXP,,GB-ASTRAZENECA-2019SE68115,ASTRAZENECA,,46.0,YR,,F,Y,90.0,KG,20190510.0,,,GB,GB,2019,Q2,Adult
163000821,16300082,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q2,Necrotising fasciitis,,2019,Q2,1,I,20190312.0,20190507.0,20190510,20190510,EXP,,GB-ASTRAZENECA-2019SE69877,ASTRAZENECA,,57.0,YR,,F,Y,158.0,KG,20190510.0,,,GB,GB,2019,Q2,Adult
163017131,16301713,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190309.0,20190507.0,20190511,20190511,EXP,,GB-ASTRAZENECA-2019SE69939,ASTRAZENECA,,55.0,YR,,M,Y,103.0,KG,20190512.0,,,GB,GB,2019,Q2,Adult
163087161,16308716,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NK,,202293.0,10.0,MG,TABLET,,2019,Q2,Blood pressure increased,,2019,Q2,1,I,20190403.0,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70901,ASTRAZENECA,,59.0,YR,,M,Y,89.0,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163087161,16308716,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NK,,202293.0,10.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190403.0,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70901,ASTRAZENECA,,59.0,YR,,M,Y,89.0,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163087161,16308716,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NK,,202293.0,10.0,MG,TABLET,,2019,Q2,Ketonuria,,2019,Q2,1,I,20190403.0,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70901,ASTRAZENECA,,59.0,YR,,M,Y,89.0,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163087161,16308716,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NK,,202293.0,10.0,MG,TABLET,,2019,Q2,Kussmaul respiration,,2019,Q2,1,I,20190403.0,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70901,ASTRAZENECA,,59.0,YR,,M,Y,89.0,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163087161,16308716,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NK,,202293.0,10.0,MG,TABLET,,2019,Q2,Tachycardia,,2019,Q2,1,I,20190403.0,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70901,ASTRAZENECA,,59.0,YR,,M,Y,89.0,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163087161,16308716,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NK,,202293.0,10.0,MG,TABLET,,2019,Q2,Vomiting,,2019,Q2,1,I,20190403.0,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70901,ASTRAZENECA,,59.0,YR,,M,Y,89.0,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163087171,16308717,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Leg amputation,,2019,Q2,1,I,,20190509.0,20190514,20190514,EXP,,GB-ASTRAZENECA-2019SE70855,ASTRAZENECA,,46.0,YR,,M,Y,65.8,KG,20190514.0,,,GB,GB,2019,Q2,Adult
163148011,16314801,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Asthenia,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69747,ASTRAZENECA,,67.0,YR,,F,Y,76.3,KG,20190515.0,,,GB,GB,2019,Q2,Elderly
163148011,16314801,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Confusional state,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69747,ASTRAZENECA,,67.0,YR,,F,Y,76.3,KG,20190515.0,,,GB,GB,2019,Q2,Elderly
163148011,16314801,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69747,ASTRAZENECA,,67.0,YR,,F,Y,76.3,KG,20190515.0,,,GB,GB,2019,Q2,Elderly
163148011,16314801,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Diarrhoea,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69747,ASTRAZENECA,,67.0,YR,,F,Y,76.3,KG,20190515.0,,,GB,GB,2019,Q2,Elderly
163148011,16314801,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Hypotension,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69747,ASTRAZENECA,,67.0,YR,,F,Y,76.3,KG,20190515.0,,,GB,GB,2019,Q2,Elderly
163148011,16314801,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q2,Incontinence,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69747,ASTRAZENECA,,67.0,YR,,F,Y,76.3,KG,20190515.0,,,GB,GB,2019,Q2,Elderly
163148051,16314805,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69521,ASTRAZENECA,,63.0,YR,,F,Y,,,20190515.0,,OT,GB,GB,2019,Q2,Adult
163148051,16314805,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q2,Pneumonia,,2019,Q2,1,I,,20190507.0,20190515,20190515,EXP,,GB-ASTRAZENECA-2019SE69521,ASTRAZENECA,,63.0,YR,,F,Y,,,20190515.0,,OT,GB,GB,2019,Q2,Adult
163183541,16318354,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Polycythaemia,,2019,Q2,1,I,,20190315.0,20190516,20190516,PER,,IT-LUPIN PHARMACEUTICALS INC.-2019-01789,LUPIN,,68.0,YR,,M,Y,,,20190516.0,,OT,IT,IT,2019,Q2,Elderly
163204041,16320404,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5.0MG UNKNOWN,,,Y,U,,,202293.0,5.0,MG,TABLET,,2019,Q2,Depression,,2019,Q2,1,I,,20190508.0,20190516,20190516,EXP,,GB-ASTRAZENECA-2019SE69994,ASTRAZENECA,,50.0,YR,,M,Y,,,20190516.0,,MD,GB,GB,2019,Q2,Adult
163204041,16320404,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5.0MG UNKNOWN,,,Y,U,,,202293.0,5.0,MG,TABLET,,2019,Q2,Suicidal ideation,,2019,Q2,1,I,,20190508.0,20190516,20190516,EXP,,GB-ASTRAZENECA-2019SE69994,ASTRAZENECA,,50.0,YR,,M,Y,,,20190516.0,,MD,GB,GB,2019,Q2,Adult
163208331,16320833,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,5.0,MG,TABLET,BID,2019,Q2,Angina pectoris,,2019,Q2,1,I,,20190508.0,20190516,20190516,EXP,,DE-ASTRAZENECA-2019SE72128,ASTRAZENECA,,68.0,YR,,M,Y,,,20190516.0,,MD,DE,DE,2019,Q2,Elderly
163208331,16320833,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,5.0,MG,TABLET,BID,2019,Q2,Coronary artery stenosis,,2019,Q2,1,I,,20190508.0,20190516,20190516,EXP,,DE-ASTRAZENECA-2019SE72128,ASTRAZENECA,,68.0,YR,,M,Y,,,20190516.0,,MD,DE,DE,2019,Q2,Elderly
163208331,16320833,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,5.0,MG,TABLET,BID,2019,Q2,Myocardial ischaemia,,2019,Q2,1,I,,20190508.0,20190516,20190516,EXP,,DE-ASTRAZENECA-2019SE72128,ASTRAZENECA,,68.0,YR,,M,Y,,,20190516.0,,MD,DE,DE,2019,Q2,Elderly
163381261,16338126,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 UNSPECIFIED,,,U,,,,,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190516.0,20190521,20190521,EXP,,GB-BAUSCH-BL-2019-014517,BAUSCH AND LOMB,,70.0,YR,,F,Y,,,20190521.0,,MD,GB,GB,2019,Q2,Elderly
163389961,16338996,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, UNK",,,U,,,,,5.0,MG,TABLET,,2019,Q2,Asthenia,,2019,Q2,1,I,,20180914.0,20190521,20190521,EXP,,PHHY2018ES102449,SANDOZ,,72.0,YR,,M,Y,,,20190521.0,,OT,ES,ES,2019,Q2,Elderly
163428402,16342840,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190530.0,20190522,20190603,EXP,,GB-BAUSCH-BL-2019-014845,BAUSCH AND LOMB,"KANDASWAMY L, AL-SALIHI A, SINGH K, RANGAN S, MOULIK K. KETOACIDOSIS IN PATIENTS ON SGLT2 INHIBITOR: EXPERIENCE FROM A DISTRICT GENERAL HOSPITAL.. DIABETIC MEDICINE. 2019;36(1):174-174.",63.0,YR,,F,Y,,,20190603.0,,OT,GB,GB,2019,Q2,Adult
163428402,16342840,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q2,Pneumonia,,2019,Q2,2,F,,20190530.0,20190522,20190603,EXP,,GB-BAUSCH-BL-2019-014845,BAUSCH AND LOMB,"KANDASWAMY L, AL-SALIHI A, SINGH K, RANGAN S, MOULIK K. KETOACIDOSIS IN PATIENTS ON SGLT2 INHIBITOR: EXPERIENCE FROM A DISTRICT GENERAL HOSPITAL.. DIABETIC MEDICINE. 2019;36(1):174-174.",63.0,YR,,F,Y,,,20190603.0,,OT,GB,GB,2019,Q2,Adult
163432921,16343292,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,99.0,,,,QD,2019,Q2,Candida infection,,2019,Q2,1,I,20190501.0,,20190521,20190521,DIR,,,FDA-CTU,,65.0,YR,,F,N,72.0,KG,20190521.0,N,MD,PK,PK,2019,Q2,Elderly
163432921,16343292,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,99.0,,,,QD,2019,Q2,Urinary tract infection,,2019,Q2,1,I,20190501.0,,20190521,20190521,DIR,,,FDA-CTU,,65.0,YR,,F,N,72.0,KG,20190521.0,N,MD,PK,PK,2019,Q2,Elderly
163472241,16347224,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190414.0,20190514.0,20190523,20190523,EXP,,GB-ASTRAZENECA-2019SE72493,ASTRAZENECA,,41.0,YR,,M,Y,112.0,KG,20190523.0,,,GB,GB,2019,Q2,Adult
163472321,16347232,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,Y,,,,202293.0,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190415.0,20190517.0,20190523,20190523,EXP,,GB-ASTRAZENECA-2019SE75295,ASTRAZENECA,,57.0,YR,,F,Y,80.0,KG,20190523.0,,,GB,GB,2019,Q2,Adult
163512501,16351250,2,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,1,I,,20190424.0,20190524,20190524,EXP,,PHHY2019GB098445,SANDOZ,,63.0,YR,,F,Y,,,20190524.0,,OT,GB,GB,2019,Q2,Adult
163512501,16351250,2,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190424.0,20190524,20190524,EXP,,PHHY2019GB098445,SANDOZ,,63.0,YR,,F,Y,,,20190524.0,,OT,GB,GB,2019,Q2,Adult
163512501,16351250,2,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q2,Pneumonia,,2019,Q2,1,I,,20190424.0,20190524,20190524,EXP,,PHHY2019GB098445,SANDOZ,,63.0,YR,,F,Y,,,20190524.0,,OT,GB,GB,2019,Q2,Adult
163637421,16363742,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,N,,,,,,,,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,1,I,2017.0,20190520.0,20190528,20190528,EXP,,PHHY2019AE119150,SANDOZ,,50.0,YR,,M,Y,61.0,KG,20190528.0,,MD,AE,AE,2019,Q2,Adult
163637421,16363742,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,N,,,,,,,,,2019,Q2,Drug intolerance,,2019,Q2,1,I,2017.0,20190520.0,20190528,20190528,EXP,,PHHY2019AE119150,SANDOZ,,50.0,YR,,M,Y,61.0,KG,20190528.0,,MD,AE,AE,2019,Q2,Adult
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Acute kidney injury,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Cardiac failure,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Diabetic metabolic decompensation,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Drug ineffective,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Drug interaction,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163642771,16364277,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,TABLET,QD,2019,Q2,Off label use,,2019,Q2,1,I,,20190514.0,20190528,20190528,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050909,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,,,20190528.0,,OT,PT,PT,2019,Q2,Elderly
163704951,16370495,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20181015.0,20190524.0,20190530,20190530,EXP,,GB-ASTRAZENECA-2019SE78325,ASTRAZENECA,,59.0,YR,,F,Y,64.0,KG,20190530.0,,,GB,GB,2019,Q2,Adult
163803821,16380382,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,Y,,,,,10.0,MG,TABLET,QD,2019,Q2,Abdominal pain upper,,2019,Q2,1,I,20190224.0,20190529.0,20190601,20190601,EXP,,GB-ASTRAZENECA-2019SE79537,ASTRAZENECA,,66.0,YR,,F,Y,,,20190601.0,,,GB,GB,2019,Q2,Elderly
163819461,16381946,9,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q2,Meningitis aseptic,,2019,Q2,1,I,20190417.0,20190521.0,20190603,20190603,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050189,BRISTOL MYERS SQUIBB,,55.0,YR,,M,Y,98.0,KG,20190603.0,,PH,GB,GB,2019,Q2,Adult
163843421,16384342,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Abdominal pain upper,,2019,Q2,1,I,20190224.0,20190529.0,20190603,20190603,EXP,,GB-ASTRAZENECA-2019SE79736,ASTRAZENECA,,66.0,YR,,F,Y,,,20190603.0,,PH,GB,GB,2019,Q2,Elderly
163854001,16385400,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Anaemia,,2019,Q2,1,I,20190218.0,20190527.0,20190603,20190603,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190603.0,,OT,DE,DE,2019,Q2,Elderly
163854001,16385400,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,1,I,20190218.0,20190527.0,20190603,20190603,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190603.0,,OT,DE,DE,2019,Q2,Elderly
163854001,16385400,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Pneumonia,,2019,Q2,1,I,20190218.0,20190527.0,20190603,20190603,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190603.0,,OT,DE,DE,2019,Q2,Elderly
163854001,16385400,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Thrombocytopenia,,2019,Q2,1,I,20190218.0,20190527.0,20190603,20190603,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190603.0,,OT,DE,DE,2019,Q2,Elderly
163854001,16385400,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Vertigo,,2019,Q2,1,I,20190218.0,20190527.0,20190603,20190603,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190603.0,,OT,DE,DE,2019,Q2,Elderly
163933491,16393349,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2019,Q2,Fatigue,,2019,Q2,1,I,20170601.0,20190529.0,20190605,20190605,EXP,,GB-ASTRAZENECA-2019SE79661,ASTRAZENECA,,71.0,YR,,M,Y,80.0,KG,20190605.0,,MD,GB,GB,2019,Q2,Elderly
163933491,16393349,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2019,Q2,Polyuria,,2019,Q2,1,I,20170601.0,20190529.0,20190605,20190605,EXP,,GB-ASTRAZENECA-2019SE79661,ASTRAZENECA,,71.0,YR,,M,Y,80.0,KG,20190605.0,,MD,GB,GB,2019,Q2,Elderly
164073541,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Drug interaction,,2019,Q2,1,I,,20190415.0,20190608,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
164073541,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Ischaemic stroke,,2019,Q2,1,I,,20190415.0,20190608,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
164073541,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Off label use,,2019,Q2,1,I,,20190415.0,20190608,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
164073541,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Sinus rhythm,,2019,Q2,1,I,,20190415.0,20190608,20190608,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,,,20190608.0,,PH,HR,HR,2019,Q2,Elderly
164128471,16412847,3,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q2,Blood cholesterol increased,,2019,Q2,1,I,,20190527.0,20190611,20190611,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ZYDUS-037461,ZYDUS PHARM,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
164128471,16412847,3,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q2,Blood triglycerides increased,,2019,Q2,1,I,,20190527.0,20190611,20190611,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ZYDUS-037461,ZYDUS PHARM,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
164128471,16412847,3,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q2,Fatigue,,2019,Q2,1,I,,20190527.0,20190611,20190611,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ZYDUS-037461,ZYDUS PHARM,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
164128471,16412847,3,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,,20190527.0,20190611,20190611,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ZYDUS-037461,ZYDUS PHARM,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
164128471,16412847,3,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q2,Hypertension,,2019,Q2,1,I,,20190527.0,20190611,20190611,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ZYDUS-037461,ZYDUS PHARM,,72.0,YR,,M,Y,,,20190611.0,,PH,ES,ES,2019,Q2,Elderly
164146321,16414632,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,D,,,,5.0,MG,,QD,2019,Q2,Asthenia,,2019,Q2,1,I,20190106.0,,20190610,20190610,DIR,,,FDA-CTU,,43.0,YR,,F,N,93.0,KG,20190610.0,N,PH,US,US,2019,Q2,Adult
164146321,16414632,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,D,,,,5.0,MG,,QD,2019,Q2,Blood potassium decreased,,2019,Q2,1,I,20190106.0,,20190610,20190610,DIR,,,FDA-CTU,,43.0,YR,,F,N,93.0,KG,20190610.0,N,PH,US,US,2019,Q2,Adult
164146321,16414632,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,D,,,,5.0,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190106.0,,20190610,20190610,DIR,,,FDA-CTU,,43.0,YR,,F,N,93.0,KG,20190610.0,N,PH,US,US,2019,Q2,Adult
164146321,16414632,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,D,,,,5.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,1,I,20190106.0,,20190610,20190610,DIR,,,FDA-CTU,,43.0,YR,,F,N,93.0,KG,20190610.0,N,PH,US,US,2019,Q2,Adult
164146321,16414632,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,D,,,,5.0,MG,,QD,2019,Q2,Weight decreased,,2019,Q2,1,I,20190106.0,,20190610,20190610,DIR,,,FDA-CTU,,43.0,YR,,F,N,93.0,KG,20190610.0,N,PH,US,US,2019,Q2,Adult
164199081,16419908,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,549.583,MG,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Dry mouth,,2019,Q2,1,I,20190509.0,20190604.0,20190612,20190612,EXP,,GB-ASTRAZENECA-2019SE82703,ASTRAZENECA,,73.0,YR,,M,Y,75.0,KG,20190612.0,,,GB,GB,2019,Q2,Elderly
164199081,16419908,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,549.583,MG,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Polyuria,,2019,Q2,1,I,20190509.0,20190604.0,20190612,20190612,EXP,,GB-ASTRAZENECA-2019SE82703,ASTRAZENECA,,73.0,YR,,M,Y,75.0,KG,20190612.0,,,GB,GB,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Blood cholesterol increased,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Blood triglycerides increased,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Fatigue,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Hypertension,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Overdose,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164226061,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID",,,U,, ASKQ,,,1.0,DF,,,2019,Q2,Treatment noncompliance,,2019,Q2,1,I,,20190603.0,20190612,20190612,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20190612.0,,PH,ES,ES,2019,Q2,Elderly
164260901,16426090,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q2,Cerebrovascular accident,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135750,NOVARTIS,,65.0,YR,,F,Y,,,20190613.0,,OT,HR,HR,2019,Q2,Elderly
164260901,16426090,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q2,Drug interaction,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135750,NOVARTIS,,65.0,YR,,F,Y,,,20190613.0,,OT,HR,HR,2019,Q2,Elderly
164260901,16426090,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q2,Off label use,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135750,NOVARTIS,,65.0,YR,,F,Y,,,20190613.0,,OT,HR,HR,2019,Q2,Elderly
164273901,16427390,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2019,Q2,Vulvovaginal discomfort,,2019,Q2,1,I,20160725.0,20190605.0,20190613,20190613,EXP,,GB-ASTRAZENECA-2019SE83549,ASTRAZENECA,,62.0,YR,,F,Y,112.0,KG,20190613.0,,MD,GB,GB,2019,Q2,Adult
164280881,16428088,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,(AT BREAKFAST),70.0,MG,,,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,1,I,20170221.0,20190603.0,20190613,20190613,EXP,GB-MHRA-INPF8A8C7F3-A401-4499-8632-329B92FCD14F,GB-ELI_LILLY_AND_COMPANY-GB201906001218,ELI LILLY AND CO,,66.0,YR,,F,Y,140.2,KG,20190613.0,,CN,GB,GB,2019,Q2,Elderly
164280881,16428088,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,(AT BREAKFAST),70.0,MG,,,,,,10.0,MG,,QD,2019,Q2,Nausea,,2019,Q2,1,I,20170221.0,20190603.0,20190613,20190613,EXP,GB-MHRA-INPF8A8C7F3-A401-4499-8632-329B92FCD14F,GB-ELI_LILLY_AND_COMPANY-GB201906001218,ELI LILLY AND CO,,66.0,YR,,F,Y,140.2,KG,20190613.0,,CN,GB,GB,2019,Q2,Elderly
164288791,16428879,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Drug interaction,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20190614.0,,OT,HR,HR,2019,Q2,Elderly
164288791,16428879,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Ischaemic stroke,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20190614.0,,OT,HR,HR,2019,Q2,Elderly
164288791,16428879,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Off label use,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20190614.0,,OT,HR,HR,2019,Q2,Elderly
164288791,16428879,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q2,Sinus rhythm,,2019,Q2,1,I,,20190612.0,20190613,20190613,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20190614.0,,OT,HR,HR,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Blood cholesterol increased,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Blood triglycerides increased,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Fatigue,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Hypertension,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Overdose,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164305471,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q2,Treatment noncompliance,,2019,Q2,1,I,,20190531.0,20190614,20190614,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20190614.0,,OT,NL,ES,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Acute kidney injury,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Cardiac failure,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Dehydration,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Diabetic metabolic decompensation,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Drug ineffective,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Drug interaction,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Fatigue,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Food refusal,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Hypernatraemia,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164375421,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,1,I,,20190605.0,20190615,20190615,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20190615.0,,MD,PT,PT,2019,Q2,Elderly
164416931,16441693,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Blood insulin increased,,2019,Q2,1,I,,20190611.0,20190617,20190617,EXP,,CN-SA-2019SA161710,SANOFI AVENTIS,"YU-XIN T., LI-CHAO G., HUI G.,. EXOGENOUS INSULIN AUTOIMMUNE SYNDROME: ONE CASE REPORT. THE JOURNAL OF PRACTICAL MEDICINE. 2019;35(3):505-508",61.0,YR,A,M,Y,,,20190617.0,,MD,CN,CN,2019,Q2,Adult
164416931,16441693,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,1,I,,20190611.0,20190617,20190617,EXP,,CN-SA-2019SA161710,SANOFI AVENTIS,"YU-XIN T., LI-CHAO G., HUI G.,. EXOGENOUS INSULIN AUTOIMMUNE SYNDROME: ONE CASE REPORT. THE JOURNAL OF PRACTICAL MEDICINE. 2019;35(3):505-508",61.0,YR,A,M,Y,,,20190617.0,,MD,CN,CN,2019,Q2,Adult
164416931,16441693,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Insulin autoimmune syndrome,,2019,Q2,1,I,,20190611.0,20190617,20190617,EXP,,CN-SA-2019SA161710,SANOFI AVENTIS,"YU-XIN T., LI-CHAO G., HUI G.,. EXOGENOUS INSULIN AUTOIMMUNE SYNDROME: ONE CASE REPORT. THE JOURNAL OF PRACTICAL MEDICINE. 2019;35(3):505-508",61.0,YR,A,M,Y,,,20190617.0,,MD,CN,CN,2019,Q2,Adult
164416931,16441693,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Vomiting,,2019,Q2,1,I,,20190611.0,20190617,20190617,EXP,,CN-SA-2019SA161710,SANOFI AVENTIS,"YU-XIN T., LI-CHAO G., HUI G.,. EXOGENOUS INSULIN AUTOIMMUNE SYNDROME: ONE CASE REPORT. THE JOURNAL OF PRACTICAL MEDICINE. 2019;35(3):505-508",61.0,YR,A,M,Y,,,20190617.0,,MD,CN,CN,2019,Q2,Adult
164473121,16447312,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10MG,,,,,,,202293.0,,,TABLET,,2019,Q2,Fungal infection,,2019,Q2,1,I,2019.0,20190606.0,20190618,20190618,PER,,US-ASTRAZENECA-2019SE85669,ASTRAZENECA,,48.0,YR,,F,Y,,,20190619.0,,MD,US,US,2019,Q2,Adult
164495481,16449548,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Confusional state,,2019,Q2,1,I,20190509.0,20190612.0,20190619,20190619,EXP,,GB-ASTRAZENECA-2019SE86411,ASTRAZENECA,,56.0,YR,,F,Y,,,20190619.0,,PH,GB,GB,2019,Q2,Adult
164495481,16449548,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190509.0,20190612.0,20190619,20190619,EXP,,GB-ASTRAZENECA-2019SE86411,ASTRAZENECA,,56.0,YR,,F,Y,,,20190619.0,,PH,GB,GB,2019,Q2,Adult
164495481,16449548,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Unresponsive to stimuli,,2019,Q2,1,I,20190509.0,20190612.0,20190619,20190619,EXP,,GB-ASTRAZENECA-2019SE86411,ASTRAZENECA,,56.0,YR,,F,Y,,,20190619.0,,PH,GB,GB,2019,Q2,Adult
164591441,16459144,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,U, UNK,,,10.0,MG,,QD,2019,Q2,Pancreatitis acute,,2019,Q2,1,I,,20190610.0,20190620,20190620,EXP,GB-MHRA-EYC 00192303,GB-MYLANLABS-2019M1057062,MYLAN,,70.0,YR,,M,Y,76.0,KG,20190620.0,,PH,GB,GB,2019,Q2,Elderly
164631051,16463105,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,TABLET,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190511.0,20190612.0,20190621,20190621,EXP,,GB-ASTRAZENECA-2019SE86405,ASTRAZENECA,,42.0,YR,,F,Y,,,20190621.0,,,GB,GB,2019,Q2,Adult
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Blood cholesterol increased,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Blood triglycerides increased,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Fatigue,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Hypertension,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Overdose,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164648341,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2019,Q2,Treatment noncompliance,,2019,Q2,1,I,,20190530.0,20190621,20190621,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20190621.0,,PH,COUNTRY NOT SPECIFIED,ES,2019,Q2,Elderly
164900371,16490037,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,,,2019,Q2,Necrotising fasciitis,,2019,Q2,1,I,20180408.0,20190621.0,20190628,20190628,EXP,,GB-ASTRAZENECA-2019SE91031,ASTRAZENECA,,51.0,YR,,F,Y,165.0,KG,20190628.0,,,GB,GB,2019,Q2,Adult
164906221,16490622,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U, V1077B,,202293.0,10.0,MG,,,2019,Q2,Abdominal pain upper,,2019,Q2,1,I,20190504.0,20190621.0,20190628,20190628,EXP,,GB-ASTRAZENECA-2019SE91044,ASTRAZENECA,,57.0,YR,,M,Y,105.0,KG,20190628.0,,,GB,GB,2019,Q2,Adult
164906221,16490622,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U, V1077B,,202293.0,10.0,MG,,,2019,Q2,Back pain,,2019,Q2,1,I,20190504.0,20190621.0,20190628,20190628,EXP,,GB-ASTRAZENECA-2019SE91044,ASTRAZENECA,,57.0,YR,,M,Y,105.0,KG,20190628.0,,,GB,GB,2019,Q2,Adult
164906221,16490622,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U, V1077B,,202293.0,10.0,MG,,,2019,Q2,Headache,,2019,Q2,1,I,20190504.0,20190621.0,20190628,20190628,EXP,,GB-ASTRAZENECA-2019SE91044,ASTRAZENECA,,57.0,YR,,M,Y,105.0,KG,20190628.0,,,GB,GB,2019,Q2,Adult
164906221,16490622,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U, V1077B,,202293.0,10.0,MG,,,2019,Q2,Urine output increased,,2019,Q2,1,I,20190504.0,20190621.0,20190628,20190628,EXP,,GB-ASTRAZENECA-2019SE91044,ASTRAZENECA,,57.0,YR,,M,Y,105.0,KG,20190628.0,,,GB,GB,2019,Q2,Adult
130308722,13030872,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Blister,,2019,Q3,2,F,,20190619.0,20161215,20190702,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-107065,BRISTOL MYERS SQUIBB,LTO. A CASE OF BULLOUS PEMPHIGOID WHICH DEVELOPED AFTER ADMINISTRATION OF DPP-4 INHIBITOR. 54TH KYUSHU LOCAL MEETING OF THE JAPAN DIABETES SOCIETY. 2016;144,82.0,YR,,F,Y,,,20190702.0,,MD,JP,JP,2019,Q3,Elderly
130308722,13030872,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Erythema,,2019,Q3,2,F,,20190619.0,20161215,20190702,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-107065,BRISTOL MYERS SQUIBB,LTO. A CASE OF BULLOUS PEMPHIGOID WHICH DEVELOPED AFTER ADMINISTRATION OF DPP-4 INHIBITOR. 54TH KYUSHU LOCAL MEETING OF THE JAPAN DIABETES SOCIETY. 2016;144,82.0,YR,,F,Y,,,20190702.0,,MD,JP,JP,2019,Q3,Elderly
130308722,13030872,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Pemphigoid,,2019,Q3,2,F,,20190619.0,20161215,20190702,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-107065,BRISTOL MYERS SQUIBB,LTO. A CASE OF BULLOUS PEMPHIGOID WHICH DEVELOPED AFTER ADMINISTRATION OF DPP-4 INHIBITOR. 54TH KYUSHU LOCAL MEETING OF THE JAPAN DIABETES SOCIETY. 2016;144,82.0,YR,,F,Y,,,20190702.0,,MD,JP,JP,2019,Q3,Elderly
130308722,13030872,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Rash,,2019,Q3,2,F,,20190619.0,20161215,20190702,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-107065,BRISTOL MYERS SQUIBB,LTO. A CASE OF BULLOUS PEMPHIGOID WHICH DEVELOPED AFTER ADMINISTRATION OF DPP-4 INHIBITOR. 54TH KYUSHU LOCAL MEETING OF THE JAPAN DIABETES SOCIETY. 2016;144,82.0,YR,,F,Y,,,20190702.0,,MD,JP,JP,2019,Q3,Elderly
137694352,13769435,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,250.0,MG,,,,,,10.0,MG,TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,2,F,20170603.0,20190701.0,20170719,20190709,EXP,,NL-ASTRAZENECA-2017SE72817,ASTRAZENECA,,1007.0,MON,,M,Y,,,20190709.0,,MD,NL,NL,2019,Q3,Elderly
137694352,13769435,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,250.0,MG,,,,,,10.0,MG,TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,2,F,20170603.0,20190701.0,20170719,20190709,EXP,,NL-ASTRAZENECA-2017SE72817,ASTRAZENECA,,1007.0,MON,,M,Y,,,20190709.0,,MD,NL,NL,2019,Q3,Elderly
141145804,14114580,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10,,,U,U,,,202293.0,,,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,4,F,,20190813.0,20171023,20190828,EXP,,GB-ASTRAZENECA-2017SF05480,ASTRAZENECA,,70.0,YR,,F,Y,,,20190828.0,,MD,GB,GB,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Abdominal pain,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Anaphylactic reaction,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Dysphagia,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Dysphonia,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Palatal oedema,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Throat tightness,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Urticaria,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
143926922,14392692,3,C,"METFORMIN, DAPAGLIFLOZIN",,2,,,,,,,,,,,,,,2019,Q3,Vomiting,,2019,Q3,2,F,201703.0,20190911.0,20180116,20190919,EXP,,PT-ASTRAZENECA-2018SE04407,ASTRAZENECA,,66.0,YR,,F,Y,,,20190919.0,,OT,PT,PT,2019,Q3,Elderly
144754202,14475420,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,140.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Urinary tract infection,,2019,Q3,2,F,20170906.0,20190701.0,20180201,20190704,EXP,,BR-ASTRAZENECA-2017SE96260,ASTRAZENECA,,25028.0,DY,,M,Y,,,20190704.0,,MD,BR,BR,2019,Q3,Elderly
152311972,15231197,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD IN THE MORNING",,,U,,,,,10.0,MG,,QD,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,2009.0,20190823.0,20180802,20190829,EXP,,PHHY2018SK056999,SANDOZ,,67.0,YR,,M,Y,85.0,KG,20190829.0,,OT,SK,SK,2019,Q3,Elderly
152311972,15231197,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD IN THE MORNING",,,U,,,,,10.0,MG,,QD,2019,Q3,Diabetic metabolic decompensation,,2019,Q3,2,F,2009.0,20190823.0,20180802,20190829,EXP,,PHHY2018SK056999,SANDOZ,,67.0,YR,,M,Y,85.0,KG,20190829.0,,OT,SK,SK,2019,Q3,Elderly
152311972,15231197,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD IN THE MORNING",,,U,,,,,10.0,MG,,QD,2019,Q3,Diarrhoea,,2019,Q3,2,F,2009.0,20190823.0,20180802,20190829,EXP,,PHHY2018SK056999,SANDOZ,,67.0,YR,,M,Y,85.0,KG,20190829.0,,OT,SK,SK,2019,Q3,Elderly
152311972,15231197,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD IN THE MORNING",,,U,,,,,10.0,MG,,QD,2019,Q3,Hypertension,,2019,Q3,2,F,2009.0,20190823.0,20180802,20190829,EXP,,PHHY2018SK056999,SANDOZ,,67.0,YR,,M,Y,85.0,KG,20190829.0,,OT,SK,SK,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Abdominal pain,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Acetonaemia,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cholecystitis acute,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Ketonuria,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Metabolic acidosis,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Nervous system disorder,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Vomiting,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
154576422,15457642,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,White blood cell count increased,,2019,Q3,2,F,,20190629.0,20181003,20190704,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088987,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20190704.0,,OT,PT,PT,2019,Q3,Elderly
155518272,15551827,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Haemorrhagic transformation stroke,,2019,Q3,2,F,20181007.0,20190710.0,20181025,20190712,EXP,,BR-ASTRAZENECA-2018SF39200,ASTRAZENECA,,27767.0,DY,,M,Y,,,20190712.0,,MD,BR,BR,2019,Q3,Elderly
155518272,15551827,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Subdural haematoma,,2019,Q3,2,F,20181007.0,20190710.0,20181025,20190712,EXP,,BR-ASTRAZENECA-2018SF39200,ASTRAZENECA,,27767.0,DY,,M,Y,,,20190712.0,,MD,BR,BR,2019,Q3,Elderly
155518272,15551827,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Haemorrhagic transformation stroke,,2019,Q3,2,F,20181007.0,20190710.0,20181025,20190712,EXP,,BR-ASTRAZENECA-2018SF39200,ASTRAZENECA,,27767.0,DY,,M,Y,,,20190712.0,,MD,BR,BR,2019,Q3,Elderly
155518272,15551827,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Subdural haematoma,,2019,Q3,2,F,20181007.0,20190710.0,20181025,20190712,EXP,,BR-ASTRAZENECA-2018SF39200,ASTRAZENECA,,27767.0,DY,,M,Y,,,20190712.0,,MD,BR,BR,2019,Q3,Elderly
1560450611,15604506,17,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q3,Chest pain,,2019,Q3,11,F,,20190729.0,20181110,20190801,EXP,,PHHY2018PT147150,NOVARTIS,,54.0,YR,,F,Y,,,20190801.0,,OT,PT,PT,2019,Q3,Adult
1560450611,15604506,17,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q3,Headache,,2019,Q3,11,F,,20190729.0,20181110,20190801,EXP,,PHHY2018PT147150,NOVARTIS,,54.0,YR,,F,Y,,,20190801.0,,OT,PT,PT,2019,Q3,Adult
1560450611,15604506,17,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q3,Ischaemic stroke,,2019,Q3,11,F,,20190729.0,20181110,20190801,EXP,,PHHY2018PT147150,NOVARTIS,,54.0,YR,,F,Y,,,20190801.0,,OT,PT,PT,2019,Q3,Adult
1564428129,15644281,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2019,Q3,Chest pain,,2019,Q3,29,F,,20190702.0,20181121,20190716,EXP,,PT-PFIZER INC-2018477132,PFIZER,,54.0,YR,,F,Y,,,20190716.0,,CN,PT,PT,2019,Q3,Adult
1564428129,15644281,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2019,Q3,Headache,,2019,Q3,29,F,,20190702.0,20181121,20190716,EXP,,PT-PFIZER INC-2018477132,PFIZER,,54.0,YR,,F,Y,,,20190716.0,,CN,PT,PT,2019,Q3,Adult
1564428129,15644281,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2019,Q3,Ischaemic stroke,,2019,Q3,29,F,,20190702.0,20181121,20190716,EXP,,PT-PFIZER INC-2018477132,PFIZER,,54.0,YR,,F,Y,,,20190716.0,,CN,PT,PT,2019,Q3,Adult
156579648,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNK",,,U,,,,,,,TABLET,,2019,Q3,Chest pain,,2019,Q3,8,F,,20190702.0,20181126,20190712,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190712.0,,OT,PT,PT,2019,Q3,Adult
156579648,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNK",,,U,,,,,,,TABLET,,2019,Q3,Headache,,2019,Q3,8,F,,20190702.0,20181126,20190712,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190712.0,,OT,PT,PT,2019,Q3,Adult
156579648,15657964,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, UNK",,,U,,,,,,,TABLET,,2019,Q3,Ischaemic stroke,,2019,Q3,8,F,,20190702.0,20181126,20190712,EXP,,PT-SA-2018SA322867,SANOFI AVENTIS,,54.0,YR,A,F,Y,,,20190712.0,,OT,PT,PT,2019,Q3,Adult
156930682,15693068,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Immune-mediated hepatitis,,2019,Q3,2,F,,20190725.0,20181206,20190801,EXP,,CA-TEVA-2018-CA-983715,TEVA,,65.0,YR,,M,Y,,,20190801.0,,MD,CA,CA,2019,Q3,Elderly
157827588,15782758,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q3,Chest pain,,2019,Q3,8,F,,20190711.0,20190102,20190719,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190719.0,,OT,PT,PT,2019,Q3,Adult
157827588,15782758,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q3,Headache,,2019,Q3,8,F,,20190711.0,20190102,20190719,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190719.0,,OT,PT,PT,2019,Q3,Adult
157827588,15782758,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q3,Ischaemic stroke,,2019,Q3,8,F,,20190711.0,20190102,20190719,EXP,,PT-BAUSCH-BL-2018-036015,BAUSCH AND LOMB,,54.0,YR,,F,Y,,,20190719.0,,OT,PT,PT,2019,Q3,Adult
1601002813,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q3,Chest pain,,2019,Q3,13,F,,20190717.0,20190225,20190729,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190729.0,,CN,PT,PT,2019,Q3,Adult
1601002813,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q3,Headache,,2019,Q3,13,F,,20190717.0,20190225,20190729,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190729.0,,CN,PT,PT,2019,Q3,Adult
1601002813,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q3,Infection,,2019,Q3,13,F,,20190717.0,20190225,20190729,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190729.0,,CN,PT,PT,2019,Q3,Adult
1601002813,16010028,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U, UNKNOWN,,,,,TABLET,,2019,Q3,Ischaemic stroke,,2019,Q3,13,F,,20190717.0,20190225,20190729,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112421,BRISTOL MYERS SQUIBB,,54.0,YR,,F,Y,110.0,KG,20190729.0,,CN,PT,PT,2019,Q3,Adult
160794412,16079441,47,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Fluid overload,,2019,Q3,2,F,20190120.0,20190709.0,20190315,20190718,EXP,,US-SHIRE-US201907966,SHIRE,,58.0,YR,,M,Y,115.3,KG,20190718.0,,OT,US,US,2019,Q3,Adult
160794412,16079441,47,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Hypokalaemia,,2019,Q3,2,F,20190120.0,20190709.0,20190315,20190718,EXP,,US-SHIRE-US201907966,SHIRE,,58.0,YR,,M,Y,115.3,KG,20190718.0,,OT,US,US,2019,Q3,Adult
160794412,16079441,47,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Myocardial infarction,,2019,Q3,2,F,20190120.0,20190709.0,20190315,20190718,EXP,,US-SHIRE-US201907966,SHIRE,,58.0,YR,,M,Y,115.3,KG,20190718.0,,OT,US,US,2019,Q3,Adult
160794412,16079441,47,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,2,F,20190120.0,20190709.0,20190315,20190718,EXP,,US-SHIRE-US201907966,SHIRE,,58.0,YR,,M,Y,115.3,KG,20190718.0,,OT,US,US,2019,Q3,Adult
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Acidosis,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Cardiac failure,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Dehydration,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Diabetic metabolic decompensation,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Drug ineffective,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Drug interaction,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Eating disorder,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Fatigue,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Food refusal,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Hypernatraemia,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Metabolic acidosis,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Off label use,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
161403714,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2019,Q3,Urine ketone body present,,2019,Q3,4,F,,20190722.0,20190401,20190729,EXP,,PHHY2019PT072916,SANDOZ,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20190729.0,,OT,PT,PT,2019,Q3,Elderly
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Acute coronary syndrome,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Angina unstable,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Blood cholesterol increased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Blood creatine phosphokinase increased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Blood parathyroid hormone increased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Blood triglycerides increased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Coronary artery stenosis,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,High density lipoprotein decreased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Low density lipoprotein increased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Muscular weakness,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Myalgia,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Myopathy,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162547232,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q3,Total cholesterol/HDL ratio increased,,2019,Q3,2,F,,20190911.0,20190430,20190913,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20190913.0,,MD,CA,CA,2019,Q3,Adult
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Blood cholesterol increased,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Blood triglycerides increased,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Drug abuse,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Fatigue,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Hyperglycaemia,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Hypertension,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Intentional product misuse,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Overdose,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
162785083,16278508,15,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,D,,,,,1.0,DF,,BID,2019,Q3,Treatment noncompliance,,2019,Q3,3,F,,20190910.0,20190506,20190913,EXP,,ES-MYLANLABS-2017M1073678,MYLAN,,72.0,YR,,M,Y,,,20190913.0,,PH,ES,ES,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Anaemia,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Hypotension,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Mucosal inflammation,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Pneumonia,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Pruritus,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Thrombocytopenia,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Vertigo,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163854003,16385400,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Weight decreased,,2019,Q3,3,F,20190218.0,20190725.0,20190603,20190729,EXP,,PHHY2019DE122294,SANDOZ,,67.0,YR,,M,Y,81.0,KG,20190729.0,,OT,DE,DE,2019,Q3,Elderly
163982041,16398204,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q3,Condition aggravated,,2019,Q3,1,I,20190315.0,,20190605,20190605,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20190605.0,N,PH,US,US,2019,Q3,Adult
163982041,16398204,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q3,Foot amputation,,2019,Q3,1,I,20190315.0,,20190605,20190605,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20190605.0,N,PH,US,US,2019,Q3,Adult
163982041,16398204,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q3,Localised infection,,2019,Q3,1,I,20190315.0,,20190605,20190605,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20190605.0,N,PH,US,US,2019,Q3,Adult
163982041,16398204,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q3,Neuropathy peripheral,,2019,Q3,1,I,20190315.0,,20190605,20190605,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20190605.0,N,PH,US,US,2019,Q3,Adult
164042401,16404240,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,D,,,,10.0,MG,,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190214.0,,20190606,20190606,DIR,,,FDA-CTU,,61.0,YR,,M,N,102.8,KG,20190606.0,N,PH,US,US,2019,Q3,Adult
164453772,16445377,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q3,Death,,2019,Q3,2,F,20190521.0,20190628.0,20190618,20190701,EXP,,PHHY2019DE139144,SANDOZ,,70.0,YR,,M,Y,82.0,KG,20190701.0,,OT,DE,DE,2019,Q3,Elderly
164453772,16445377,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q3,Neutropenic sepsis,,2019,Q3,2,F,20190521.0,20190628.0,20190618,20190701,EXP,,PHHY2019DE139144,SANDOZ,,70.0,YR,,M,Y,82.0,KG,20190701.0,,OT,DE,DE,2019,Q3,Elderly
164453772,16445377,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q3,Pancytopenia,,2019,Q3,2,F,20190521.0,20190628.0,20190618,20190701,EXP,,PHHY2019DE139144,SANDOZ,,70.0,YR,,M,Y,82.0,KG,20190701.0,,OT,DE,DE,2019,Q3,Elderly
164531932,16453193,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Neutropenic sepsis,,2019,Q3,2,F,20190521.0,20190627.0,20190619,20190704,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201906007050,ELI LILLY AND CO,,70.0,YR,,M,Y,82.0,KG,20190704.0,,CN,DE,DE,2019,Q3,Elderly
164531932,16453193,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Pancytopenia,,2019,Q3,2,F,20190521.0,20190627.0,20190619,20190704,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201906007050,ELI LILLY AND CO,,70.0,YR,,M,Y,82.0,KG,20190704.0,,CN,DE,DE,2019,Q3,Elderly
165054261,16505426,17,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",,,,, UNK,,,1.0,DF,,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,GB-MHRA-TPP5410256C37451YC1546881454536,GB-MYLANLABS-2019M1059992,MYLAN,,58.0,YR,,F,Y,104.0,KG,20190701.0,,MD,GB,GB,2019,Q3,Adult
165054261,16505426,17,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",,,,, UNK,,,1.0,DF,,QD,2019,Q3,Wheezing,,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,GB-MHRA-TPP5410256C37451YC1546881454536,GB-MYLANLABS-2019M1059992,MYLAN,,58.0,YR,,F,Y,104.0,KG,20190701.0,,MD,GB,GB,2019,Q3,Adult
165199021,16519902,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,D,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Sudden death,,2019,Q3,1,I,20190625.0,20190627.0,20190702,20190702,EXP,,GB-ASTRAZENECA-2019SE94126,ASTRAZENECA,,20124.0,DY,,M,Y,,,20190702.0,,MD,GB,GB,2019,Q3,Elderly
165250441,16525044,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190522.0,20190627.0,20190703,20190703,EXP,,GB-ASTRAZENECA-2019SE93488,ASTRAZENECA,,36.0,YR,,F,Y,,,20190703.0,,OT,GB,GB,2019,Q3,Adult
165284481,16528448,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Fungal infection,,2019,Q3,1,I,2019.0,20190606.0,20190703,20190703,PER,,US-ASTRAZENECA-2019SE85617,ASTRAZENECA,,60.0,YR,,F,Y,,,20190703.0,,MD,US,US,2019,Q3,Adult
165297191,16529719,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"01 DF, QD",,,,,,,,1.0,DF,,QD,2019,Q3,Abdominal pain,,2019,Q3,1,I,20190109.0,20190117.0,20190704,20190704,PER,GB-MHRA-TPP1673979C3290997YC1547064375965,GB-LUPIN PHARMACEUTICALS INC.-2019-00320,LUPIN,,72.0,YR,,F,Y,59.0,KG,20190704.0,,CN,GB,GB,2019,Q3,Elderly
165338051,16533805,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Immune-mediated hepatitis,,2019,Q3,1,I,,20190622.0,20190704,20190704,EXP,,CA-APOTEX-2019AP017390,APOTEX,,65.0,YR,,M,Y,,,20190704.0,,CN,CA,CA,2019,Q3,Elderly
165342111,16534211,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,20190415.0,20190703.0,20190705,20190705,EXP,,GB-ASTRAZENECA-2019SE96677,ASTRAZENECA,,48.0,YR,,M,Y,141.0,KG,20190705.0,,,GB,GB,2019,Q3,Adult
165342111,16534211,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Tubulointerstitial nephritis,,2019,Q3,1,I,20190415.0,20190703.0,20190705,20190705,EXP,,GB-ASTRAZENECA-2019SE96677,ASTRAZENECA,,48.0,YR,,M,Y,141.0,KG,20190705.0,,,GB,GB,2019,Q3,Adult
165400581,16540058,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, EACH MORNING",,,U,,,,,10.0,MG,,QD,2019,Q3,Hypoglycaemia,,2019,Q3,1,I,20190520.0,20190628.0,20190708,20190708,EXP,GB-MHRA-ADR 24411937,GB-ELI_LILLY_AND_COMPANY-GB201907000457,ELI LILLY AND CO,,63.0,YR,,F,Y,123.0,KG,20190708.0,,CN,GB,GB,2019,Q3,Adult
165413251,16541325,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,34.958332,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Swelling face,,2019,Q3,1,I,201904.0,20190703.0,20190708,20190708,EXP,GB-MHRA-TPP2965958C4558548YC1555671163689,GB-TEVA-2019-GB-1074162,TEVA,,57.0,YR,,M,Y,110.0,KG,20190708.0,,MD,GB,GB,2019,Q3,Adult
165413251,16541325,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,34.958332,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Urticaria,,2019,Q3,1,I,201904.0,20190703.0,20190708,20190708,EXP,GB-MHRA-TPP2965958C4558548YC1555671163689,GB-TEVA-2019-GB-1074162,TEVA,,57.0,YR,,M,Y,110.0,KG,20190708.0,,MD,GB,GB,2019,Q3,Adult
165415951,16541595,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Myocardial infarction,,2019,Q3,1,I,,20190627.0,20190708,20190708,EXP,,BR-NOVOPROD-671139,NOVO NORDISK,,54.0,YR,,M,Y,,,20190708.0,,CN,BR,BR,2019,Q3,Adult
165425881,16542588,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,EACH MORNING.,,,U,,,,,10.0,MG,TABLET,QD,2019,Q3,Hypoglycaemia,,2019,Q3,1,I,20190520.0,20190703.0,20190709,20190709,EXP,GB-MHRA-ADR 24411937,GB-TORRENT-00021345,TORRENT,,63.0,YR,A,F,Y,123.0,KG,20190709.0,,MD,GB,GB,2019,Q3,Adult
165431851,16543185,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"EACH MORNING, 10 MG PER DAY",,,,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q3,Hypoglycaemia,,2019,Q3,1,I,20190520.0,20190703.0,20190709,20190709,EXP,GB-MHRA-ADR 24411937,GB-TEVA-2019-GB-1073951,TEVA,,63.0,YR,,F,Y,123.0,KG,20190709.0,,MD,GB,GB,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Blood creatinine increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Blood pressure diastolic decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Blood pressure diastolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Blood pressure systolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Glomerular filtration rate decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,54,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"2.5 MG, QD",,,,,,,,2.5,MG,,QD,2019,Q3,Wrong technique in product usage process,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood creatinine increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood pressure diastolic decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood pressure diastolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood pressure systolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Glomerular filtration rate decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,55,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Wrong technique in product usage process,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood creatinine increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood pressure diastolic decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood pressure diastolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Blood pressure systolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Glomerular filtration rate decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,56,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2019,Q3,Wrong technique in product usage process,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Blood creatinine increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Blood pressure diastolic decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Blood pressure diastolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Blood pressure systolic increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Glomerular filtration rate decreased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165512712,16551271,57,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q3,Wrong technique in product usage process,,2019,Q3,2,F,,20190702.0,20190710,20190716,EXP,,PHHY2019TH153666,NOVARTIS,,62.0,YR,,F,Y,,,20190716.0,,MD,TH,TH,2019,Q3,Adult
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Aortic valve calcification,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Aortic valve incompetence,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cardiac murmur,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cough,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Fatigue,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Heart rate irregular,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Hypertension,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Left atrial dilatation,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Left ventricular dysfunction,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Mitral valve incompetence,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Orthopnoea,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Pulmonary hypertension,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Rales,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Tricuspid valve incompetence,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165690032,16569003,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Ventricular hypokinesia,,2019,Q3,2,F,,20190706.0,20190713,20190713,EXP,,PHHY2019PT160715,NOVARTIS,,68.0,YR,,F,Y,,,20190713.0,,MD,PT,PT,2019,Q3,Elderly
165774481,16577448,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Immune-mediated hepatitis,,2019,Q3,1,I,,20190708.0,20190716,20190716,EXP,,CA-CELGENEUS-CAN-20190702673,CELGENE,,65.0,YR,,M,Y,,,20190716.0,,MD,CA,CA,2019,Q3,Elderly
165802031,16580203,1,PS,DAPAGLIFLOZINA/ METFORMINA,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,(5/1000)MG COMP,,,Y,,,,205649.0,,,TABLET,,2019,Q3,Metabolic acidosis,,2019,Q3,1,I,20190421.0,20190711.0,20190716,20190716,EXP,,ES-ASTRAZENECA-2019SE99657,ASTRAZENECA,,55.0,YR,,M,Y,61.0,KG,20190716.0,,MD,ES,ES,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Dehydration,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Insulin resistance,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Malaise,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Pancreatic disorder,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Polydipsia,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Polyuria,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821211,16582121,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,Y,,,,,10.0,MG,,,2019,Q3,Pyrexia,,2019,Q3,1,I,,20190712.0,20190717,20190717,EXP,,PHHY2019GB164258,NOVARTIS,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70",43.0,YR,,M,Y,,,20190717.0,,OT,GB,GB,2019,Q3,Adult
165821221,16582122,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,,GR-ASTRAZENECA-2019SF01527,ASTRAZENECA,,44.0,YR,,F,Y,,,20190717.0,,MD,GR,GR,2019,Q3,Adult
165821221,16582122,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q3,Off label use,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,,GR-ASTRAZENECA-2019SF01527,ASTRAZENECA,,44.0,YR,,F,Y,,,20190717.0,,MD,GR,GR,2019,Q3,Adult
165981441,16598144,2,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,TABLET,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190714.0,20190719,20190719,EXP,,GB-ASTRAZENECA-2019SF01213,ASTRAZENECA,,39.0,YR,,M,Y,,,20190719.0,,OT,GB,GB,2019,Q3,Adult
165981441,16598144,2,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,TABLET,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,,20190714.0,20190719,20190719,EXP,,GB-ASTRAZENECA-2019SF01213,ASTRAZENECA,,39.0,YR,,M,Y,,,20190719.0,,OT,GB,GB,2019,Q3,Adult
165981441,16598144,2,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,TABLET,,2019,Q3,Hypotension,,2019,Q3,1,I,,20190714.0,20190719,20190719,EXP,,GB-ASTRAZENECA-2019SF01213,ASTRAZENECA,,39.0,YR,,M,Y,,,20190719.0,,OT,GB,GB,2019,Q3,Adult
165981441,16598144,2,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,TABLET,,2019,Q3,Intentional overdose,,2019,Q3,1,I,,20190714.0,20190719,20190719,EXP,,GB-ASTRAZENECA-2019SF01213,ASTRAZENECA,,39.0,YR,,M,Y,,,20190719.0,,OT,GB,GB,2019,Q3,Adult
166070722,16607072,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,, UNKNOWN,,,10.0,MG,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,2,F,,20190808.0,20190722,20190813,EXP,,GB-CONCORDIA PHARMACEUTICALS INC.-E2B_00020369,CONCORDIA,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACTICAL DIABETES. 2019;36(2):69-70A. DOI: 10.1002/PDI.2217. DOI:10.1002/PDI.2217",43.0,YR,,M,Y,,,20190813.0,,MD,GB,GB,2019,Q3,Adult
166091622,16609162,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,,20190723.0,20190722,20190725,EXP,,GB-PFIZER INC-2019312831,PFIZER,"MCKEAG, C.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE. ENDOCRINE ABSTRACTS. 2019;10.1530/ENDOABS.62.P54",39.0,YR,,M,Y,,,20190725.0,,OT,GB,GB,2019,Q3,Adult
166091622,16609162,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q3,Hypotension,,2019,Q3,2,F,,20190723.0,20190722,20190725,EXP,,GB-PFIZER INC-2019312831,PFIZER,"MCKEAG, C.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE. ENDOCRINE ABSTRACTS. 2019;10.1530/ENDOABS.62.P54",39.0,YR,,M,Y,,,20190725.0,,OT,GB,GB,2019,Q3,Adult
166091622,16609162,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q3,Intentional overdose,,2019,Q3,2,F,,20190723.0,20190722,20190725,EXP,,GB-PFIZER INC-2019312831,PFIZER,"MCKEAG, C.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE. ENDOCRINE ABSTRACTS. 2019;10.1530/ENDOABS.62.P54",39.0,YR,,M,Y,,,20190725.0,,OT,GB,GB,2019,Q3,Adult
166136151,16613615,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190715.0,20190723,20190723,EXP,,GB-TEVA-2019-GB-1081495,TEVA,"AUNG ET, KOSHY RM, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACT-DIABETES 2019;36(2):69-70.",43.0,YR,,M,Y,,,20190723.0,,MD,GB,GB,2019,Q3,Adult
166138641,16613864,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Diarrhoea,,2019,Q3,1,I,20170908.0,20190718.0,20190723,20190723,EXP,,GB-ASTRAZENECA-2019SF03828,ASTRAZENECA,,53.0,YR,,F,Y,134.0,KG,20190723.0,,,GB,GB,2019,Q3,Adult
166138641,16613864,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Irritable bowel syndrome,,2019,Q3,1,I,20170908.0,20190718.0,20190723,20190723,EXP,,GB-ASTRAZENECA-2019SF03828,ASTRAZENECA,,53.0,YR,,F,Y,134.0,KG,20190723.0,,,GB,GB,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Acute coronary syndrome,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Angina unstable,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Blood cholesterol increased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Blood creatine phosphokinase increased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Blood parathyroid hormone increased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Blood triglycerides increased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Coronary artery stenosis,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,High density lipoprotein decreased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Low density lipoprotein increased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Muscular weakness,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Myalgia,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Myopathy,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166141431,16614143,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Total cholesterol/HDL ratio increased,,2019,Q3,1,I,,20190712.0,20190723,20190723,EXP,,CA-APOTEX-2019AP018594,APOTEX,,56.0,YR,,M,Y,82.0,KG,20190723.0,,CN,CA,CA,2019,Q3,Adult
166149191,16614919,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190714.0,20190723,20190723,EXP,,GB-ASTRAZENECA-2019SF01240,ASTRAZENECA,,51.0,YR,,F,Y,,,20190723.0,,OT,GB,GB,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Arthralgia,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Arthritis,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Blood glucose abnormal,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Blood pressure systolic decreased,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Cataract,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Ear discomfort,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Erythema,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Fatigue,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Headache,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Inappropriate schedule of product administration,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Joint stiffness,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Nausea,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166255131,16625513,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,,2019,Q3,Vomiting,,2019,Q3,1,I,,20190712.0,20190724,20190724,EXP,,CA-APOTEX-2019AP018593,APOTEX,,55.0,YR,,M,Y,,,20190724.0,,CN,CA,CA,2019,Q3,Adult
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Aortic valve calcification,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Aortic valve incompetence,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cardiac murmur,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cough,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Fatigue,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Heart rate irregular,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Hypertension,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Left atrial dilatation,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Mitral valve incompetence,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Orthopnoea,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Pulmonary hypertension,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Rales,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Tricuspid valve incompetence,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166259751,16625975,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Ventricular hypokinesia,,2019,Q3,1,I,,20190722.0,20190724,20190724,EXP,,PT-009507513-1907PRT012684,MERCK,,68.0,YR,,F,Y,,,20190724.0,,MD,PT,PT,2019,Q3,Elderly
166264581,16626458,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2019,Q3,Toe amputation,Toe amputation,2019,Q3,1,I,,20190710.0,20190724,20190724,EXP,,US-ALVOGEN-2019-ALVOGEN-100642,ALVOGEN,,62.0,YR,,M,Y,,,20190724.0,,OT,US,US,2019,Q3,Adult
166274601,16627460,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2019,Q3,Condition aggravated,,2019,Q3,1,I,,20190715.0,20190724,20190724,EXP,,GB-BAUSCH-BL-2019-020541,BAUSCH AND LOMB,"AUNG E, KOSHY R, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. CASE REPORT. 2019;36(2):69-70.",43.0,YR,,M,Y,,,20190724.0,,MD,GB,GB,2019,Q3,Adult
166274601,16627460,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190715.0,20190724,20190724,EXP,,GB-BAUSCH-BL-2019-020541,BAUSCH AND LOMB,"AUNG E, KOSHY R, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. CASE REPORT. 2019;36(2):69-70.",43.0,YR,,M,Y,,,20190724.0,,MD,GB,GB,2019,Q3,Adult
166274601,16627460,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2019,Q3,Insulin resistance,,2019,Q3,1,I,,20190715.0,20190724,20190724,EXP,,GB-BAUSCH-BL-2019-020541,BAUSCH AND LOMB,"AUNG E, KOSHY R, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. CASE REPORT. 2019;36(2):69-70.",43.0,YR,,M,Y,,,20190724.0,,MD,GB,GB,2019,Q3,Adult
166274601,16627460,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2019,Q3,Pancreatic disorder,,2019,Q3,1,I,,20190715.0,20190724,20190724,EXP,,GB-BAUSCH-BL-2019-020541,BAUSCH AND LOMB,"AUNG E, KOSHY R, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. CASE REPORT. 2019;36(2):69-70.",43.0,YR,,M,Y,,,20190724.0,,MD,GB,GB,2019,Q3,Adult
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Aortic valve calcification,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Aortic valve incompetence,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Cardiac murmur,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Cough,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Fatigue,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Heart rate irregular,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Hypertension,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Left atrial dilatation,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Mitral valve incompetence,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Orthopnoea,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Pulmonary hypertension,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Rales,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Tricuspid valve incompetence,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166304161,16630416,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Ventricular hypokinesia,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-BAUSCH-BL-2019-020675,BAUSCH AND LOMB,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Aortic valve calcification,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Aortic valve incompetence,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cardiac murmur,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cough,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Fatigue,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Heart rate irregular,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Hypertension,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Left atrial dilatation,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Mitral valve incompetence,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Orthopnoea,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Pulmonary hypertension,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Rales,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Tricuspid valve incompetence,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166320621,16632062,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Ventricular hypokinesia,,2019,Q3,1,I,,20190717.0,20190725,20190725,EXP,,PT-ASTRAZENECA-2019SF02648,ASTRAZENECA,,68.0,YR,,F,Y,,,20190725.0,,MD,PT,PT,2019,Q3,Elderly
166336621,16633662,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q3,Accidental overdose,,2019,Q3,1,I,2017.0,20190719.0,20190725,20190725,EXP,,CO-SA-2019SA199017,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20190725.0,,CN,CO,CO,2019,Q3,Elderly
166336621,16633662,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q3,Device operational issue,,2019,Q3,1,I,2017.0,20190719.0,20190725,20190725,EXP,,CO-SA-2019SA199017,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20190725.0,,CN,CO,CO,2019,Q3,Elderly
166336621,16633662,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q3,Drug administered in wrong device,,2019,Q3,1,I,2017.0,20190719.0,20190725,20190725,EXP,,CO-SA-2019SA199017,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20190725.0,,CN,CO,CO,2019,Q3,Elderly
166336621,16633662,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q3,Hypoglycaemic unconsciousness,,2019,Q3,1,I,2017.0,20190719.0,20190725,20190725,EXP,,CO-SA-2019SA199017,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20190725.0,,CN,CO,CO,2019,Q3,Elderly
166336621,16633662,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q3,Inappropriate schedule of product administration,,2019,Q3,1,I,2017.0,20190719.0,20190725,20190725,EXP,,CO-SA-2019SA199017,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20190725.0,,CN,CO,CO,2019,Q3,Elderly
166336621,16633662,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q3,Treatment noncompliance,,2019,Q3,1,I,2017.0,20190719.0,20190725,20190725,EXP,,CO-SA-2019SA199017,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20190725.0,,CN,CO,CO,2019,Q3,Elderly
166340261,16634026,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Blood creatine increased,,2019,Q3,1,I,,20190719.0,20190725,20190725,PER,,US-ASTRAZENECA-2019SF05837,ASTRAZENECA,,63.0,YR,,M,Y,,,20190726.0,,MD,US,US,2019,Q3,Adult
166340261,16634026,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Dehydration,,2019,Q3,1,I,,20190719.0,20190725,20190725,PER,,US-ASTRAZENECA-2019SF05837,ASTRAZENECA,,63.0,YR,,M,Y,,,20190726.0,,MD,US,US,2019,Q3,Adult
166340261,16634026,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Hypertension,,2019,Q3,1,I,,20190719.0,20190725,20190725,PER,,US-ASTRAZENECA-2019SF05837,ASTRAZENECA,,63.0,YR,,M,Y,,,20190726.0,,MD,US,US,2019,Q3,Adult
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Aortic valve calcification,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Aortic valve incompetence,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cardiac murmur,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cough,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Fatigue,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Heart rate irregular,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Hypertension,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Left atrial dilatation,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Mitral valve incompetence,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Orthopnoea,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Pulmonary hypertension,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Rales,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Tricuspid valve incompetence,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166380681,16638068,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Ventricular hypokinesia,,2019,Q3,1,I,,20190723.0,20190726,20190726,EXP,,PT-PFIZER INC-2019316597,PFIZER,,68.0,YR,,F,Y,,,20190726.0,,MD,PT,PT,2019,Q3,Elderly
166420191,16642019,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Acute kidney injury,Acute kidney injury,2019,Q3,1,I,,20190714.0,20190729,20190729,EXP,,GB-ALVOGEN-2019-ALVOGEN-100800,ALVOGEN,,39.0,YR,,M,Y,,,20190729.0,,OT,GB,GB,2019,Q3,Adult
166420191,16642019,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Euglycaemic diabetic ketoacidosis,Euglycaemic diabetic ketoacidosis,2019,Q3,1,I,,20190714.0,20190729,20190729,EXP,,GB-ALVOGEN-2019-ALVOGEN-100800,ALVOGEN,,39.0,YR,,M,Y,,,20190729.0,,OT,GB,GB,2019,Q3,Adult
166420191,16642019,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Hypotension,Hypotension,2019,Q3,1,I,,20190714.0,20190729,20190729,EXP,,GB-ALVOGEN-2019-ALVOGEN-100800,ALVOGEN,,39.0,YR,,M,Y,,,20190729.0,,OT,GB,GB,2019,Q3,Adult
166420191,16642019,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Intentional overdose,Intentional overdose,2019,Q3,1,I,,20190714.0,20190729,20190729,EXP,,GB-ALVOGEN-2019-ALVOGEN-100800,ALVOGEN,,39.0,YR,,M,Y,,,20190729.0,,OT,GB,GB,2019,Q3,Adult
166427202,16642720,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,,20190729.0,20190729,20190730,EXP,,PHHY2019GB170606,SANDOZ,,39.0,YR,,M,Y,,,20190731.0,,OT,GB,GB,2019,Q3,Adult
166427202,16642720,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,2,F,,20190729.0,20190729,20190730,EXP,,PHHY2019GB170606,SANDOZ,,39.0,YR,,M,Y,,,20190731.0,,OT,GB,GB,2019,Q3,Adult
166427202,16642720,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q3,Hypotension,,2019,Q3,2,F,,20190729.0,20190729,20190730,EXP,,PHHY2019GB170606,SANDOZ,,39.0,YR,,M,Y,,,20190731.0,,OT,GB,GB,2019,Q3,Adult
166427202,16642720,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q3,Intentional overdose,,2019,Q3,2,F,,20190729.0,20190729,20190730,EXP,,PHHY2019GB170606,SANDOZ,,39.0,YR,,M,Y,,,20190731.0,,OT,GB,GB,2019,Q3,Adult
166487021,16648702,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, NOT REPORTED,,202293.0,5.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190722.0,20190730,20190730,PER,,US-ASTRAZENECA-2019SF06147,ASTRAZENECA,,60.0,YR,,F,Y,,,20190730.0,,MD,US,US,2019,Q3,Adult
166487021,16648702,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, NOT REPORTED,,202293.0,5.0,MG,TABLET,QD,2019,Q3,Urinary tract infection,,2019,Q3,1,I,,20190722.0,20190730,20190730,PER,,US-ASTRAZENECA-2019SF06147,ASTRAZENECA,,60.0,YR,,F,Y,,,20190730.0,,MD,US,US,2019,Q3,Adult
166581931,16658193,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,170.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Pancreatitis acute,,2019,Q3,1,I,20190628.0,20190724.0,20190801,20190801,EXP,,ES-ASTRAZENECA-2019SF06023,ASTRAZENECA,,66.0,YR,,M,Y,90.0,KG,20190801.0,,MD,ES,ES,2019,Q3,Elderly
166607893,16660789,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Asthenia,,2019,Q3,3,F,20190626.0,20190906.0,20190802,20190917,EXP,,BR-TAIHO ONCOLOGY  INC-IM-2019-00401,TAIHO ONCOLOGY INC,,71.0,YR,,M,Y,83.0,KG,20190917.0,,MD,BR,BR,2019,Q3,Elderly
166607893,16660789,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Lung infection,,2019,Q3,3,F,20190626.0,20190906.0,20190802,20190917,EXP,,BR-TAIHO ONCOLOGY  INC-IM-2019-00401,TAIHO ONCOLOGY INC,,71.0,YR,,M,Y,83.0,KG,20190917.0,,MD,BR,BR,2019,Q3,Elderly
166674541,16667454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190624.0,20190726.0,20190805,20190805,EXP,,GB-ASTRAZENECA-2019SF07300,ASTRAZENECA,,50.0,YR,,F,Y,,,20190805.0,,,GB,GB,2019,Q3,Adult
166680551,16668055,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Cardiac arrest,,2019,Q3,1,I,,20190731.0,20190805,20190805,EXP,,GB-ASTRAZENECA-2019SF10289,ASTRAZENECA,,71.0,YR,,M,Y,,,20190805.0,,,GB,GB,2019,Q3,Elderly
166680551,16668055,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190731.0,20190805,20190805,EXP,,GB-ASTRAZENECA-2019SF10289,ASTRAZENECA,,71.0,YR,,M,Y,,,20190805.0,,,GB,GB,2019,Q3,Elderly
166680551,16668055,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Hypophagia,,2019,Q3,1,I,,20190731.0,20190805,20190805,EXP,,GB-ASTRAZENECA-2019SF10289,ASTRAZENECA,,71.0,YR,,M,Y,,,20190805.0,,,GB,GB,2019,Q3,Elderly
166680551,16668055,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Hypotension,,2019,Q3,1,I,,20190731.0,20190805,20190805,EXP,,GB-ASTRAZENECA-2019SF10289,ASTRAZENECA,,71.0,YR,,M,Y,,,20190805.0,,,GB,GB,2019,Q3,Elderly
166761131,16676113,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190724.0,20190807,20190807,EXP,,"GB-VISTAPHARM, INC.-VER201907-000702",VISTAPHARM,"AUNG E, KOSHY R, JACOB K. DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES PRECIPITATED BY INFECTION, STEROIDS AND SGLT2 INHIBITOR. PRACT DIABETES. 2019;36(2):69-70.",43.0,YR,,M,Y,,,20190807.0,,,COUNTRY NOT SPECIFIED,GB,2019,Q3,Adult
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Abdominal pain,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Asthenia,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Back pain,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Bile duct obstruction,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Cerebral atrophy,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Drug ineffective,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Hyperhidrosis,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Hyperlipidaemia,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Kidney angiomyolipoma,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Pancreatic atrophy,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Pancreatic duct obstruction,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
166799681,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q3,Vertigo,,2019,Q3,1,I,2018.0,20190730.0,20190807,20190807,EXP,,PHHY2019CZ181589,SANDOZ,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20190807.0,,OT,CZ,CZ,2019,Q3,Elderly
167048831,16704883,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG PER DAY,,,Y,,,,,,,TABLET,,2019,Q3,Blood pressure increased,,2019,Q3,1,I,201907.0,20190807.0,20190814,20190814,EXP,,RO-ASTRAZENECA-2019SF13023,ASTRAZENECA,,63.0,YR,,M,Y,85.0,KG,20190815.0,,MD,RO,RO,2019,Q3,Adult
167048831,16704883,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG PER DAY,,,Y,,,,,,,TABLET,,2019,Q3,Glomerular filtration rate increased,,2019,Q3,1,I,201907.0,20190807.0,20190814,20190814,EXP,,RO-ASTRAZENECA-2019SF13023,ASTRAZENECA,,63.0,YR,,M,Y,85.0,KG,20190815.0,,MD,RO,RO,2019,Q3,Adult
167048831,16704883,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG PER DAY,,,Y,,,,,,,TABLET,,2019,Q3,Palpitations,,2019,Q3,1,I,201907.0,20190807.0,20190814,20190814,EXP,,RO-ASTRAZENECA-2019SF13023,ASTRAZENECA,,63.0,YR,,M,Y,85.0,KG,20190815.0,,MD,RO,RO,2019,Q3,Adult
167048831,16704883,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG PER DAY,,,Y,,,,,,,TABLET,,2019,Q3,Ventricular arrhythmia,,2019,Q3,1,I,201907.0,20190807.0,20190814,20190814,EXP,,RO-ASTRAZENECA-2019SF13023,ASTRAZENECA,,63.0,YR,,M,Y,85.0,KG,20190815.0,,MD,RO,RO,2019,Q3,Adult
167077061,16707706,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,,,,QD,2019,Q3,Intentional dose omission,,2019,Q3,1,I,201801.0,20180524.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0243,BIODELIVERY SCIENCES INTERNATIONAL,,63.0,YR,,F,Y,99.88,KG,20190809.0,,CN,US,US,2019,Q3,Adult
167077061,16707706,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,,,,QD,2019,Q3,Oral administration complication,,2019,Q3,1,I,201801.0,20180524.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0243,BIODELIVERY SCIENCES INTERNATIONAL,,63.0,YR,,F,Y,99.88,KG,20190809.0,,CN,US,US,2019,Q3,Adult
167077061,16707706,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,,,,QD,2019,Q3,Product adhesion issue,,2019,Q3,1,I,201801.0,20180524.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0243,BIODELIVERY SCIENCES INTERNATIONAL,,63.0,YR,,F,Y,99.88,KG,20190809.0,,CN,US,US,2019,Q3,Adult
167077061,16707706,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,,,,QD,2019,Q3,Product solubility abnormal,,2019,Q3,1,I,201801.0,20180524.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0243,BIODELIVERY SCIENCES INTERNATIONAL,,63.0,YR,,F,Y,99.88,KG,20190809.0,,CN,US,US,2019,Q3,Adult
167080262,16708026,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Decreased appetite,,2019,Q3,2,F,20190710.0,20190819.0,20190815,20190828,EXP,GB-MHRA-EYC 00204747,GB-NOVOPROD-677801,NOVO NORDISK,,74.0,YR,,M,Y,86.0,KG,20190828.0,,MD,GB,GB,2019,Q3,Elderly
167080262,16708026,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Dehydration,,2019,Q3,2,F,20190710.0,20190819.0,20190815,20190828,EXP,GB-MHRA-EYC 00204747,GB-NOVOPROD-677801,NOVO NORDISK,,74.0,YR,,M,Y,86.0,KG,20190828.0,,MD,GB,GB,2019,Q3,Elderly
167080262,16708026,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Diarrhoea,,2019,Q3,2,F,20190710.0,20190819.0,20190815,20190828,EXP,GB-MHRA-EYC 00204747,GB-NOVOPROD-677801,NOVO NORDISK,,74.0,YR,,M,Y,86.0,KG,20190828.0,,MD,GB,GB,2019,Q3,Elderly
167080262,16708026,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Fluid intake reduced,,2019,Q3,2,F,20190710.0,20190819.0,20190815,20190828,EXP,GB-MHRA-EYC 00204747,GB-NOVOPROD-677801,NOVO NORDISK,,74.0,YR,,M,Y,86.0,KG,20190828.0,,MD,GB,GB,2019,Q3,Elderly
167080262,16708026,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Nausea,,2019,Q3,2,F,20190710.0,20190819.0,20190815,20190828,EXP,GB-MHRA-EYC 00204747,GB-NOVOPROD-677801,NOVO NORDISK,,74.0,YR,,M,Y,86.0,KG,20190828.0,,MD,GB,GB,2019,Q3,Elderly
167106861,16710686,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190808.0,20190816,20190816,EXP,,GB-ASTRAZENECA-2019SF13597,ASTRAZENECA,,49.0,YR,,F,Y,70.0,KG,20190816.0,,PH,GB,GB,2019,Q3,Adult
167106861,16710686,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Genital infection,,2019,Q3,1,I,,20190808.0,20190816,20190816,EXP,,GB-ASTRAZENECA-2019SF13597,ASTRAZENECA,,49.0,YR,,F,Y,70.0,KG,20190816.0,,PH,GB,GB,2019,Q3,Adult
167106861,16710686,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Sepsis,,2019,Q3,1,I,,20190808.0,20190816,20190816,EXP,,GB-ASTRAZENECA-2019SF13597,ASTRAZENECA,,49.0,YR,,F,Y,70.0,KG,20190816.0,,PH,GB,GB,2019,Q3,Adult
167140161,16714016,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",770.0,MG,,,,,,10.0,MG,,QD,2019,Q3,Pancreatic carcinoma,,2019,Q3,1,I,20190723.0,20190815.0,20190819,20190819,EXP,GB-MHRA-ADR 24424813,GB-TAKEDA-2019TEU009734,TAKEDA,,80.0,YR,,F,Y,70.0,KG,20190819.0,,OT,GB,GB,2019,Q3,Elderly
167148421,16714842,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U, NOT KNOWN,,,10.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190725.0,20190813.0,20190819,20190819,EXP,,GB-ASTRAZENECA-2019SF16208,ASTRAZENECA,,61.0,YR,,F,Y,70.6,KG,20190819.0,,PH,GB,GB,2019,Q3,Adult
167243501,16724350,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190812.0,20190821,20190821,EXP,,US-ASTRAZENECA-2019SF15283,ASTRAZENECA,,61.0,YR,,M,Y,,,20190821.0,,MD,US,US,2019,Q3,Adult
167275401,16727540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10,,,U,U,,,,,,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20171023.0,20190822,20190822,EXP,GB-MHRA-ADR 24220049,GB-EMCURE PHARMACEUTICALS LTD-2017-EPL-0306,EMCURE,,70.0,YR,,F,Y,,,20190822.0,,MD,GB,GB,2019,Q3,Elderly
167288081,16728808,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190815.0,20190822,20190822,EXP,,GB-ASTRAZENECA-2019SF17560,ASTRAZENECA,,46.0,YR,,M,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Adult
167288081,16728808,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Dizziness,,2019,Q3,1,I,,20190815.0,20190822,20190822,EXP,,GB-ASTRAZENECA-2019SF17560,ASTRAZENECA,,46.0,YR,,M,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Adult
167288081,16728808,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Lethargy,,2019,Q3,1,I,,20190815.0,20190822,20190822,EXP,,GB-ASTRAZENECA-2019SF17560,ASTRAZENECA,,46.0,YR,,M,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Adult
167288081,16728808,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Vomiting,,2019,Q3,1,I,,20190815.0,20190822,20190822,EXP,,GB-ASTRAZENECA-2019SF17560,ASTRAZENECA,,46.0,YR,,M,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Adult
167340411,16734041,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190814.0,20190823,20190823,EXP,GB-EMA-DD-20190813-AGRAHARI_P-134612,GB-ACCORD-152576,ACCORD,,39.0,YR,,M,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Adult
167340411,16734041,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,,20190814.0,20190823,20190823,EXP,GB-EMA-DD-20190813-AGRAHARI_P-134612,GB-ACCORD-152576,ACCORD,,39.0,YR,,M,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Adult
167340411,16734041,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Hypotension,,2019,Q3,1,I,,20190814.0,20190823,20190823,EXP,GB-EMA-DD-20190813-AGRAHARI_P-134612,GB-ACCORD-152576,ACCORD,,39.0,YR,,M,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Adult
167340411,16734041,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2019,Q3,Intentional overdose,,2019,Q3,1,I,,20190814.0,20190823,20190823,EXP,GB-EMA-DD-20190813-AGRAHARI_P-134612,GB-ACCORD-152576,ACCORD,,39.0,YR,,M,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Adult
167348601,16734860,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,,20190815.0,20190823,20190823,EXP,,GB-ASTRAZENECA-2019SF17601,ASTRAZENECA,,56.0,YR,,F,Y,,,20190823.0,,,GB,GB,2019,Q3,Adult
167348601,16734860,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q3,Sepsis,,2019,Q3,1,I,,20190815.0,20190823,20190823,EXP,,GB-ASTRAZENECA-2019SF17601,ASTRAZENECA,,56.0,YR,,F,Y,,,20190823.0,,,GB,GB,2019,Q3,Adult
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Contusion,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Depressed mood,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Diarrhoea,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Drug interaction,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Petechiae,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Rash,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Urinary tract infection,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167357462,16735746,3,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Vomiting,,2019,Q3,2,F,20181009.0,20190912.0,20190823,20190919,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20190919.0,,OT,CO,CO,2019,Q3,Elderly
167392411,16739241,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2019,Q3,Ejaculation failure,,2019,Q3,1,I,20170201.0,20190818.0,20190826,20190826,EXP,GB-MHRA-EYC 00204906,GB-TEVA-2019-GB-1096091,TEVA,,54.0,YR,,M,Y,84.81,KG,20190826.0,,CN,GB,GB,2019,Q3,Adult
167392411,16739241,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2019,Q3,Retrograde ejaculation,,2019,Q3,1,I,20170201.0,20190818.0,20190826,20190826,EXP,GB-MHRA-EYC 00204906,GB-TEVA-2019-GB-1096091,TEVA,,54.0,YR,,M,Y,84.81,KG,20190826.0,,CN,GB,GB,2019,Q3,Adult
167421751,16742175,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U, UNK,,,10.0,MG,,QD,2019,Q3,Diabetic retinopathy,,2019,Q3,1,I,,20190820.0,20190826,20190826,EXP,,PT-MYLANLABS-2019M1078524,MYLAN,"AMARAL M., FERREIRA C. BACELAR C.. DIABETES MELLITUS: QUANDO.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1 SUPPL):80",58.0,YR,,F,Y,81.0,KG,20190826.0,,OT,PT,PT,2019,Q3,Adult
167421751,16742175,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U, UNK,,,10.0,MG,,QD,2019,Q3,Macular oedema,,2019,Q3,1,I,,20190820.0,20190826,20190826,EXP,,PT-MYLANLABS-2019M1078524,MYLAN,"AMARAL M., FERREIRA C. BACELAR C.. DIABETES MELLITUS: QUANDO.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1 SUPPL):80",58.0,YR,,F,Y,81.0,KG,20190826.0,,OT,PT,PT,2019,Q3,Adult
167499311,16749931,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5.0MG UNKNOWN,,,Y,,,,,5.0,MG,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190731.0,20190819.0,20190828,20190828,EXP,,GB-ASTRAZENECA-2019SF18395,ASTRAZENECA,,24.0,YR,,F,Y,,,20190828.0,,,GB,GB,2019,Q3,Young Adult
167505751,16750575,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Immune-mediated hepatitis,,2019,Q3,1,I,,20190821.0,20190828,20190828,EXP,,CA-PFIZER INC-2019365637,PFIZER,,65.0,YR,,M,Y,,,20190828.0,,MD,CA,CA,2019,Q3,Elderly
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Azotaemia,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Blood calcium decreased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Blood glucose fluctuation,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Blood pressure decreased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Blood pressure increased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Cardiovascular disorder,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Chronic kidney disease,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Cystitis,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Decreased appetite,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Diabetic nephropathy,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Dysuria,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,General physical health deterioration,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Hepatic steatosis,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Hypokinesia,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Hypotension,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Klebsiella infection,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Left ventricular dilatation,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Left ventricular dysfunction,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Lipids increased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Nausea,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Oliguria,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Pancreatic steatosis,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Pleural effusion,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Renal failure,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Sinus rhythm,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Somnolence,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Staphylococcal infection,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Urinary tract infection,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Vomiting,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,6,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,5.0,MG,,QD,2019,Q3,Weight increased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Azotaemia,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Blood calcium decreased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Blood glucose fluctuation,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Blood pressure decreased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Blood pressure increased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Cardiovascular disorder,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Chronic kidney disease,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Cystitis,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Decreased appetite,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Diabetic nephropathy,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Dysuria,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,General physical health deterioration,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Hepatic steatosis,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Hypokinesia,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Hypotension,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Klebsiella infection,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Left ventricular dilatation,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Left ventricular dysfunction,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Lipids increased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Nausea,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Oliguria,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Pancreatic steatosis,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Pleural effusion,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Renal failure,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Sinus rhythm,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Somnolence,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Staphylococcal infection,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Urinary tract infection,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Vomiting,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167556292,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Weight increased,,2019,Q3,2,F,201903.0,20190712.0,20190829,20190918,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20190918.0,,CN,DE,DE,2019,Q3,Adult
167562741,16756274,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Immune-mediated hepatitis,,2019,Q3,1,I,,20190821.0,20190829,20190829,EXP,,CA-PFIZER INC-2019364826,PFIZER,,65.0,YR,,M,Y,,,20190829.0,,MD,CA,CA,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Dehydration,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Diabetic metabolic decompensation,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Fatigue,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Food refusal,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Hypernatraemia,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Metabolic acidosis,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167678292,16767829,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10MG/DAY,,,U,U,,,,10.0,MG,,QD,2019,Q3,Urine ketone body present,,2019,Q3,2,F,,20190923.0,20190903,20190927,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T, S?LVA F, FERREIRA T, VILAVERDE J ET., AL.. P059 DIABETIC KETOACIDOSIS: A REALITY OF THE INHIBITORS OF SGLT2 TO BE CONSIDERED. REVISTA PORTUGUESA DE DIABETE. 2019;14 (1):47-122",69.0,YR,,F,Y,,,20190927.0,,OT,PT,PT,2019,Q3,Elderly
167868541,16786854,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Chest pain,,2019,Q3,1,I,,20190825.0,20190909,20190909,EXP,,"SG-UPSHER-SMITH LABORATORIES, LLC-2019USL00686",UPSHER-SMITH,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROC SINGAPORE HEALTHCARE. 2019;28(2):138-140",66.0,YR,,F,Y,,,20190909.0,,OT,SG,SG,2019,Q3,Elderly
167868541,16786854,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Drug interaction,,2019,Q3,1,I,,20190825.0,20190909,20190909,EXP,,"SG-UPSHER-SMITH LABORATORIES, LLC-2019USL00686",UPSHER-SMITH,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROC SINGAPORE HEALTHCARE. 2019;28(2):138-140",66.0,YR,,F,Y,,,20190909.0,,OT,SG,SG,2019,Q3,Elderly
167885031,16788503,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Chest pain,Chest pain,2019,Q3,1,I,,20190902.0,20190910,20190910,EXP,,SG-TEVA-2019-SG-1105250,TEVA,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEED-SINGAPORE-HEALTHC 2019;28(2):138-140.",66.0,YR,,F,Y,,,20190910.0,,MD,SG,SG,2019,Q3,Elderly
167885031,16788503,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Drug interaction,Drug interaction,2019,Q3,1,I,,20190902.0,20190910,20190910,EXP,,SG-TEVA-2019-SG-1105250,TEVA,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEED-SINGAPORE-HEALTHC 2019;28(2):138-140.",66.0,YR,,F,Y,,,20190910.0,,MD,SG,SG,2019,Q3,Elderly
167885031,16788503,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Myalgia,Myalgia,2019,Q3,1,I,,20190902.0,20190910,20190910,EXP,,SG-TEVA-2019-SG-1105250,TEVA,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEED-SINGAPORE-HEALTHC 2019;28(2):138-140.",66.0,YR,,F,Y,,,20190910.0,,MD,SG,SG,2019,Q3,Elderly
167901731,16790173,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",650.0,MG,Y,U,,,,10.0,MG,,QD,2019,Q3,Asthma,,2019,Q3,1,I,20190324.0,20190903.0,20190910,20190910,EXP,GB-MHRA-EYC 00197580,GB-MYLANLABS-2019M1083592,MYLAN,,68.0,YR,,M,Y,,,20190910.0,,PH,GB,GB,2019,Q3,Elderly
167901731,16790173,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",650.0,MG,Y,U,,,,10.0,MG,,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190324.0,20190903.0,20190910,20190910,EXP,GB-MHRA-EYC 00197580,GB-MYLANLABS-2019M1083592,MYLAN,,68.0,YR,,M,Y,,,20190910.0,,PH,GB,GB,2019,Q3,Elderly
167901731,16790173,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",650.0,MG,Y,U,,,,10.0,MG,,QD,2019,Q3,Metabolic acidosis,,2019,Q3,1,I,20190324.0,20190903.0,20190910,20190910,EXP,GB-MHRA-EYC 00197580,GB-MYLANLABS-2019M1083592,MYLAN,,68.0,YR,,M,Y,,,20190910.0,,PH,GB,GB,2019,Q3,Elderly
167901731,16790173,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",650.0,MG,Y,U,,,,10.0,MG,,QD,2019,Q3,Wheezing,,2019,Q3,1,I,20190324.0,20190903.0,20190910,20190910,EXP,GB-MHRA-EYC 00197580,GB-MYLANLABS-2019M1083592,MYLAN,,68.0,YR,,M,Y,,,20190910.0,,PH,GB,GB,2019,Q3,Elderly
167977041,16797704,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Atrioventricular block second degree,,2019,Q3,1,I,20130920.0,20131126.0,20190912,20190912,PER,,US-ASTRAZENECA-2013SE89638,ASTRAZENECA,,61.0,YR,,F,Y,,,20190912.0,,MD,US,US,2019,Q3,Adult
167992021,16799202,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DAILY,,,,,,,,5.0,MG,,,2019,Q3,Weight decreased,Weight decreased,2019,Q3,1,I,201906.0,20190716.0,20190912,20190912,PER,,US-ALVOGEN-2019-ALVOGEN-100966,ALVOGEN,,59.0,YR,,M,Y,100.24,KG,20190912.0,,MD,US,US,2019,Q3,Adult
168021911,16802191,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,CREST syndrome,,2019,Q3,1,I,,20190906.0,20190912,20190912,EXP,,ES-MYLANLABS-2019M1084661,MYLAN,"LUNA PEREIRA M, L?PEZ D?AZ J, RAM?REZ S?NCHEZ D.. AQU? ESTOY OTRA VEZ, SIGO SIN SENTIRME BIEN.. MEDICINA DE FAMILIA ANDALUC?A.. 2018;19(1SUP.2):207",50.0,YR,,F,Y,,,20190912.0,,OT,ES,ES,2019,Q3,Adult
168079341,16807934,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2019,Q3,Lip swelling,,2019,Q3,1,I,20190703.0,20190902.0,20190915,20190915,EXP,GB-MHRA-TPP34880416C965278YC1562156314163,"GB-COLLEGIUM PHARMACEUTICAL, INC.-GB-2019COL001064",COLLEGIUM PHARMACEUTICAL,,78.0,YR,,F,Y,70.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
168079341,16807934,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2019,Q3,Urticaria,,2019,Q3,1,I,20190703.0,20190902.0,20190915,20190915,EXP,GB-MHRA-TPP34880416C965278YC1562156314163,"GB-COLLEGIUM PHARMACEUTICAL, INC.-GB-2019COL001064",COLLEGIUM PHARMACEUTICAL,,78.0,YR,,F,Y,70.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
168094242,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,,,,,5.0,MG,TABLET,QD,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,,20190920.0,20190916,20190926,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"ANTONIO B, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20190926.0,,OT,IT,IT,2019,Q3,Adult
168094242,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,,,,,5.0,MG,TABLET,QD,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,2,F,,20190920.0,20190916,20190926,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"ANTONIO B, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20190926.0,,OT,IT,IT,2019,Q3,Adult
168123502,16812350,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,2,F,,20190924.0,20190916,20190930,EXP,,IT-MYLANLABS-2019M1085961,MYLAN,"VANCHERI F, BURGIO A, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITALIAN JOURNAL OF MEDICINE. 2019;13:54-58",47.0,YR,,F,Y,,,20190930.0,,OT,IT,IT,2019,Q3,Adult
168166821,16816682,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Chest pain,,2019,Q3,1,I,,20190903.0,20190917,20190917,EXP,,SG-MICRO LABS LIMITED-ML2019-02457,MICRO LABS,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEEDINGS OF SINGAPORE HEALTHCARE. 2019;28(2):138-140.",66.0,YR,,F,Y,,,20190917.0,,OT,SG,SG,2019,Q3,Elderly
168166821,16816682,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Drug interaction,,2019,Q3,1,I,,20190903.0,20190917,20190917,EXP,,SG-MICRO LABS LIMITED-ML2019-02457,MICRO LABS,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEEDINGS OF SINGAPORE HEALTHCARE. 2019;28(2):138-140.",66.0,YR,,F,Y,,,20190917.0,,OT,SG,SG,2019,Q3,Elderly
168166821,16816682,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Myalgia,,2019,Q3,1,I,,20190903.0,20190917,20190917,EXP,,SG-MICRO LABS LIMITED-ML2019-02457,MICRO LABS,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEEDINGS OF SINGAPORE HEALTHCARE. 2019;28(2):138-140.",66.0,YR,,F,Y,,,20190917.0,,OT,SG,SG,2019,Q3,Elderly
168249321,16824932,10,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7220.0,MG,U,U,,,,10.0,MG,,QD,2019,Q3,Ketoacidosis,,2019,Q3,1,I,20190824.0,20190912.0,20190918,20190918,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,19763.0,DY,,F,Y,84.5,KG,20190919.0,,MD,NL,NL,2019,Q3,Elderly
168262761,16826276,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,TABLET,QD,2019,Q3,Bladder transitional cell carcinoma,,2019,Q3,1,I,20140621.0,20140711.0,20190919,20190919,PER,,US-ASTRAZENECA-2014SE54152,ASTRAZENECA,,75.0,YR,,M,Y,,,20190919.0,,MD,US,US,2019,Q3,Elderly
168337721,16833772,6,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7220.0,MG,D,,,,,10.0,MG,,QD,2019,Q3,Ketoacidosis,,2019,Q3,1,I,20190824.0,20190916.0,20190920,20190920,EXP,,PHHY2019NL215353,SANDOZ,,54.0,YR,,F,Y,84.5,KG,20190920.0,,OT,NL,NL,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Anaphylactic shock,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Asthma,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Back pain,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Blood count abnormal,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Body mass index increased,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Cough,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Crepitations,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Diverticulum,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Dysphonia,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Dyspnoea,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Dyspnoea exertional,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Feeling hot,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Haemoptysis,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Headache,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Heart sounds,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Hypersensitivity,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Iron deficiency,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Obstructive airways disorder,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Productive cough,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Rash,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Sinus congestion,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Skin ulcer,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Sputum discoloured,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Swelling face,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Symptom recurrence,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Throat clearing,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Upper respiratory tract inflammation,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Urinary incontinence,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Urticaria,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Weight increased,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364651,16836465,10,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Wheezing,,2019,Q3,1,I,,20190906.0,20190921,20190921,EXP,,CA-AUROBINDO-AUR-APL-2019-060529,AUROBINDO,,57.0,YR,,F,Y,,,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364911,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q3,Asthenia,,2019,Q3,1,I,20190818.0,20190911.0,20190921,20190921,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364911,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q3,Blood count abnormal,,2019,Q3,1,I,20190818.0,20190911.0,20190921,20190921,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364911,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q3,Hypersomnia,,2019,Q3,1,I,20190818.0,20190911.0,20190921,20190921,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364911,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q3,Malaise,,2019,Q3,1,I,20190818.0,20190911.0,20190921,20190921,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364911,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q3,Nausea,,2019,Q3,1,I,20190818.0,20190911.0,20190921,20190921,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20190921.0,,CN,CA,CA,2019,Q3,Adult
168364911,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q3,Oedema peripheral,,2019,Q3,1,I,20190818.0,20190911.0,20190921,20190921,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20190921.0,,CN,CA,CA,2019,Q3,Adult
168410091,16841009,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,649.0,DF,,,,,,1.0,DF,,QD,2019,Q3,Bone pain,,2019,Q3,1,I,20190401.0,20190911.0,20190923,20190923,EXP,,"GB-US WORLDMEDS, LLC-E2B_00003071",US WORLDMEDS,,60.0,YR,,F,Y,,,20190923.0,,MD,GB,GB,2019,Q3,Adult
168410091,16841009,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,649.0,DF,,,,,,1.0,DF,,QD,2019,Q3,Urinary incontinence,,2019,Q3,1,I,20190401.0,20190911.0,20190923,20190923,EXP,,"GB-US WORLDMEDS, LLC-E2B_00003071",US WORLDMEDS,,60.0,YR,,F,Y,,,20190923.0,,MD,GB,GB,2019,Q3,Adult
168436361,16843636,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Drug interaction,,2019,Q3,1,I,,20190909.0,20190924,20190924,EXP,,SG-AUROBINDO-AUR-APL-2019-061789,AUROBINDO,"PANG T, ET AL. FLUVOXAMINE/SIMVASTATIN INTERACTION: LEFT-SIDED ATYPICAL CHEST PAIN SECONDARY TO SUSPECTED MYALGIA: CASE REPORT. REACTIONS WEEKLY. 2019;1769:P214",66.0,YR,,F,Y,,,20190924.0,,OT,SG,SG,2019,Q3,Elderly
168436361,16843636,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Myalgia,,2019,Q3,1,I,,20190909.0,20190924,20190924,EXP,,SG-AUROBINDO-AUR-APL-2019-061789,AUROBINDO,"PANG T, ET AL. FLUVOXAMINE/SIMVASTATIN INTERACTION: LEFT-SIDED ATYPICAL CHEST PAIN SECONDARY TO SUSPECTED MYALGIA: CASE REPORT. REACTIONS WEEKLY. 2019;1769:P214",66.0,YR,,F,Y,,,20190924.0,,OT,SG,SG,2019,Q3,Elderly
168436361,16843636,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Non-cardiac chest pain,,2019,Q3,1,I,,20190909.0,20190924,20190924,EXP,,SG-AUROBINDO-AUR-APL-2019-061789,AUROBINDO,"PANG T, ET AL. FLUVOXAMINE/SIMVASTATIN INTERACTION: LEFT-SIDED ATYPICAL CHEST PAIN SECONDARY TO SUSPECTED MYALGIA: CASE REPORT. REACTIONS WEEKLY. 2019;1769:P214",66.0,YR,,F,Y,,,20190924.0,,OT,SG,SG,2019,Q3,Elderly
168699181,16869918,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10,,,U,U,,,,,,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190924.0,20190930,20190930,EXP,GB-EMA-DD-20190513-CHOPRA_I-160314,GB-MYLANLABS-2019M1090367,MYLAN,,70.0,YR,,F,Y,,,20190930.0,,MD,GB,GB,2019,Q3,Elderly
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Abdominal pain,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Anaphylactic reaction,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Blood immunoglobulin E increased,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Drug hypersensitivity,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Drug intolerance,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Dyspnoea,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Skin test positive,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Type I hypersensitivity,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
136791572,13679157,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Urticaria,,2019,Q4,2,F,,20191125.0,20170622,20191129,EXP,,CA-APOTEX-2017AP013044,APOTEX,,62.0,YR,,M,Y,,,20191129.0,,CN,CA,CA,2019,Q4,Adult
147723172,14772317,4,C,DAPAGLIFLOZIN;METFORMIN,,2,,,,,U,,,,,,,,,2019,Q4,Incorrect dose administered by device,,2019,Q4,2,F,20191021.0,20191022.0,20180418,20191115,EXP,,US-ELI_LILLY_AND_COMPANY-US201804005093,ELI LILLY AND CO,,57.0,YR,,F,Y,,,20191115.0,,CN,US,US,2019,Q4,Adult
147723172,14772317,4,C,DAPAGLIFLOZIN;METFORMIN,,2,,,,,U,,,,,,,,,2019,Q4,Injection site bruising,,2019,Q4,2,F,20191021.0,20191022.0,20180418,20191115,EXP,,US-ELI_LILLY_AND_COMPANY-US201804005093,ELI LILLY AND CO,,57.0,YR,,F,Y,,,20191115.0,,CN,US,US,2019,Q4,Adult
147723172,14772317,4,C,DAPAGLIFLOZIN;METFORMIN,,2,,,,,U,,,,,,,,,2019,Q4,Injection site erythema,,2019,Q4,2,F,20191021.0,20191022.0,20180418,20191115,EXP,,US-ELI_LILLY_AND_COMPANY-US201804005093,ELI LILLY AND CO,,57.0,YR,,F,Y,,,20191115.0,,CN,US,US,2019,Q4,Adult
147723172,14772317,4,C,DAPAGLIFLOZIN;METFORMIN,,2,,,,,U,,,,,,,,,2019,Q4,Injection site pain,,2019,Q4,2,F,20191021.0,20191022.0,20180418,20191115,EXP,,US-ELI_LILLY_AND_COMPANY-US201804005093,ELI LILLY AND CO,,57.0,YR,,F,Y,,,20191115.0,,CN,US,US,2019,Q4,Adult
147723172,14772317,4,C,DAPAGLIFLOZIN;METFORMIN,,2,,,,,U,,,,,,,,,2019,Q4,Injection site swelling,,2019,Q4,2,F,20191021.0,20191022.0,20180418,20191115,EXP,,US-ELI_LILLY_AND_COMPANY-US201804005093,ELI LILLY AND CO,,57.0,YR,,F,Y,,,20191115.0,,CN,US,US,2019,Q4,Adult
151910275,15191027,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Hyponatraemia,,2019,Q4,5,F,20180718.0,20191212.0,20180724,20191218,EXP,,JP-ASTRAZENECA-2018SE93906,ASTRAZENECA,,28985.0,DY,,M,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Elderly
151910275,15191027,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Hyponatraemia,,2019,Q4,5,F,20180718.0,20191212.0,20180724,20191218,EXP,,JP-ASTRAZENECA-2018SE93906,ASTRAZENECA,,28985.0,DY,,M,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Elderly
151910275,15191027,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,5.0,MG,TABLET,QD,2019,Q4,Hyponatraemia,,2019,Q4,5,F,20180718.0,20191212.0,20180724,20191218,EXP,,JP-ASTRAZENECA-2018SE93906,ASTRAZENECA,,28985.0,DY,,M,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Elderly
154989722,15498972,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,,20191101.0,20181015,20191108,EXP,,GB-ASTRAZENECA-2018SF29395,ASTRAZENECA,,57.0,YR,,M,Y,76.8,KG,20191108.0,,,GB,GB,2019,Q4,Adult
1567028913,15670289,16,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Chest pain,,2019,Q4,13,F,,20190926.0,20181129,20191001,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20191001.0,,CN,PT,PT,2019,Q4,Adult
1567028913,15670289,16,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Headache,,2019,Q4,13,F,,20190926.0,20181129,20191001,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20191001.0,,CN,PT,PT,2019,Q4,Adult
1567028913,15670289,16,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Ischaemic stroke,,2019,Q4,13,F,,20190926.0,20181129,20191001,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20191001.0,,CN,PT,PT,2019,Q4,Adult
1567028913,15670289,25,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Chest pain,,2019,Q4,13,F,,20190926.0,20181129,20191001,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20191001.0,,CN,PT,PT,2019,Q4,Adult
1567028913,15670289,25,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Headache,,2019,Q4,13,F,,20190926.0,20181129,20191001,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20191001.0,,CN,PT,PT,2019,Q4,Adult
1567028913,15670289,25,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Ischaemic stroke,,2019,Q4,13,F,,20190926.0,20181129,20191001,EXP,,PT-MYLANLABS-2018M1088222,MYLAN,,54.0,YR,,F,Y,,,20191001.0,,CN,PT,PT,2019,Q4,Adult
161067822,16106782,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q4,Foot amputation,,2019,Q4,2,F,,20191112.0,20190322,20191120,EXP,,CA-ASTRAZENECA-2019SE42911,ASTRAZENECA,,50.0,YR,,M,Y,,,20191120.0,,MD,CA,CA,2019,Q4,Adult
162269962,16226996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Asthenia,,2019,Q4,2,F,201903.0,20190415.0,20190423,20191203,EXP,,CN-ASTRAZENECA-2019SE60339,ASTRAZENECA,,864.0,MON,,M,Y,103.0,KG,20191204.0,,OT,CN,CN,2019,Q4,Elderly
162269962,16226996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Cough,,2019,Q4,2,F,201903.0,20190415.0,20190423,20191203,EXP,,CN-ASTRAZENECA-2019SE60339,ASTRAZENECA,,864.0,MON,,M,Y,103.0,KG,20191204.0,,OT,CN,CN,2019,Q4,Elderly
162269962,16226996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Decreased appetite,,2019,Q4,2,F,201903.0,20190415.0,20190423,20191203,EXP,,CN-ASTRAZENECA-2019SE60339,ASTRAZENECA,,864.0,MON,,M,Y,103.0,KG,20191204.0,,OT,CN,CN,2019,Q4,Elderly
162691092,16269109,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,60.0,MG,Y,, KF2968,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,,20190424.0,20190503,20191119,EXP,,CN-ASTRAZENECA-2019SE65006,ASTRAZENECA,,20.0,YR,,F,Y,58.1,KG,20191120.0,,OT,CN,CN,2019,Q4,Youth
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Blood cholesterol increased,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Blood triglycerides increased,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Fatigue,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Hyperglycaemia,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Hypertension,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Overdose,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164226062,16422606,14,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, BID, DAPAGLIFLOZIN PROPANEDIOL/LINAGLIPTIN/METFORMIN HYDROCHLORIDE",,,U,, ASKQ,,,1.0,DF,,,2019,Q4,Treatment noncompliance,,2019,Q4,2,F,,20191201.0,20190612,20191210,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-TEVA-2019-ES-1060874,TEVA,,72.0,YR,,M,Y,,,20191210.0,,PH,ES,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Blood cholesterol increased,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Blood triglycerides increased,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Fatigue,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Hyperglycaemia,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Hypertension,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Overdose,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164305472,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2019,Q4,Treatment noncompliance,,2019,Q4,2,F,,20191120.0,20190614,20191205,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20191205.0,,OT,NL,ES,2019,Q4,Elderly
164519003,16451900,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Hypokalaemia,,2019,Q4,3,F,20180611.0,20191217.0,20190619,20191223,EXP,,GR-PFIZER INC-2019254944,PFIZER,,51.0,YR,,F,Y,98.0,KG,20191223.0,,MD,GR,GR,2019,Q4,Adult
166091623,16609162,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,3,F,,20191007.0,20190722,20191015,EXP,,GB-PFIZER INC-2019312831,PFIZER,"MCKEAG, C.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE. ENDOCRINE ABSTRACTS. 2019;10.1530/ENDOABS.62.P54",39.0,YR,,M,Y,,,20191015.0,,OT,GB,GB,2019,Q4,Adult
166091623,16609162,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Hypotension,,2019,Q4,3,F,,20191007.0,20190722,20191015,EXP,,GB-PFIZER INC-2019312831,PFIZER,"MCKEAG, C.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE. ENDOCRINE ABSTRACTS. 2019;10.1530/ENDOABS.62.P54",39.0,YR,,M,Y,,,20191015.0,,OT,GB,GB,2019,Q4,Adult
166091623,16609162,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,3,F,,20191007.0,20190722,20191015,EXP,,GB-PFIZER INC-2019312831,PFIZER,"MCKEAG, C.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE. ENDOCRINE ABSTRACTS. 2019;10.1530/ENDOABS.62.P54",39.0,YR,,M,Y,,,20191015.0,,OT,GB,GB,2019,Q4,Adult
166872911,16687291,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Ischaemic stroke,,2019,Q4,1,I,20190808.0,,20190808,20190808,DIR,,,FDA-CTU,,67.0,YR,,F,N,122.0,KG,20190808.0,N,PH,US,US,2019,Q4,Elderly
166872911,16687291,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Treatment failure,,2019,Q4,1,I,20190808.0,,20190808,20190808,DIR,,,FDA-CTU,,67.0,YR,,F,N,122.0,KG,20190808.0,N,PH,US,US,2019,Q4,Elderly
167239142,16723914,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Arrhythmia,,2019,Q4,2,F,20190725.0,20191112.0,20190821,20191121,EXP,,GB-ELI_LILLY_AND_COMPANY-GB201908006852,ELI LILLY AND CO,,68.0,YR,,M,Y,104.8,KG,20191121.0,,MD,GB,GB,2019,Q4,Elderly
167239142,16723914,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Dizziness,,2019,Q4,2,F,20190725.0,20191112.0,20190821,20191121,EXP,,GB-ELI_LILLY_AND_COMPANY-GB201908006852,ELI LILLY AND CO,,68.0,YR,,M,Y,104.8,KG,20191121.0,,MD,GB,GB,2019,Q4,Elderly
167239142,16723914,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Fatigue,,2019,Q4,2,F,20190725.0,20191112.0,20190821,20191121,EXP,,GB-ELI_LILLY_AND_COMPANY-GB201908006852,ELI LILLY AND CO,,68.0,YR,,M,Y,104.8,KG,20191121.0,,MD,GB,GB,2019,Q4,Elderly
167239142,16723914,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Headache,,2019,Q4,2,F,20190725.0,20191112.0,20190821,20191121,EXP,,GB-ELI_LILLY_AND_COMPANY-GB201908006852,ELI LILLY AND CO,,68.0,YR,,M,Y,104.8,KG,20191121.0,,MD,GB,GB,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Contusion,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Depressed mood,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Diarrhoea,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Drug interaction,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Incorrect dose administered,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Off label use,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Pain in extremity,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Petechiae,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Rash,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Urinary tract infection,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167357464,16735746,4,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q4,Vomiting,,2019,Q4,4,F,20181009.0,20191112.0,20190823,20191119,EXP,,CO-JNJFOC-20181035667,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,75.0,KG,20191119.0,,OT,CO,CO,2019,Q4,Elderly
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Azotaemia,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Blood calcium decreased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Blood glucose fluctuation,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Blood pressure decreased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Blood pressure increased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Cardiovascular disorder,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Chronic kidney disease,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Cystitis,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Decreased appetite,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Diabetic nephropathy,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Dysuria,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,General physical health deterioration,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Hepatic steatosis,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Hypokinesia,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Hypotension,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Klebsiella infection,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Left ventricular dilatation,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Left ventricular dysfunction,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Lipids increased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Oliguria,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Pancreatic steatosis,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Pleural effusion,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Renal failure,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Sinus rhythm,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Somnolence,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Staphylococcal infection,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Urinary tract infection,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2019,Q4,Weight increased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Azotaemia,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Blood calcium decreased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Blood glucose fluctuation,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Blood pressure decreased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Blood pressure increased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Cardiovascular disorder,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Chronic kidney disease,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Cystitis,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Decreased appetite,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Diabetic nephropathy,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Dysuria,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,General physical health deterioration,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Hepatic steatosis,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Hypokinesia,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Hypotension,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Klebsiella infection,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Left ventricular dilatation,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Left ventricular dysfunction,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Lipids increased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Oliguria,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Pancreatic steatosis,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Pleural effusion,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Renal failure,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Sinus rhythm,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Somnolence,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Staphylococcal infection,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Urinary tract infection,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167556293,16755629,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Weight increased,,2019,Q4,3,F,201903.0,20191120.0,20190829,20191126,EXP,,DE-GILEAD-2019-0425597,GILEAD,,64.0,YR,A,F,Y,88.0,KG,20191126.0,,CN,DE,DE,2019,Q4,Adult
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Acidosis,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Acute kidney injury,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Cardiac failure,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Dehydration,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Diabetic metabolic decompensation,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Drug ineffective,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Drug interaction,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Eating disorder,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Fatigue,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Hypernatraemia,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Intentional product misuse,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Metabolic acidosis,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Off label use,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
167678295,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Urine ketone body present,,2019,Q4,5,F,,20191130.0,20190903,20191206,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20191206.0,,OT,PT,PT,2019,Q4,Elderly
168080182,16808018,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Ketoacidosis,,2019,Q4,2,F,20190824.0,20190924.0,20190916,20191002,EXP,,NL-ASTRAZENECA-2019SF24716,ASTRAZENECA,,19763.0,DY,,F,Y,84.5,KG,20191002.0,,MD,NL,NL,2019,Q4,Elderly
168094243,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,U,,,,5.0,MG,TABLET,QD,2019,Q4,Asthenia,,2019,Q4,3,F,,20190930.0,20190916,20191007,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"BURGIO A, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20191007.0,,OT,IT,IT,2019,Q4,Adult
168094243,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,U,,,,5.0,MG,TABLET,QD,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,3,F,,20190930.0,20190916,20191007,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"BURGIO A, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20191007.0,,OT,IT,IT,2019,Q4,Adult
168094243,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,U,,,,5.0,MG,TABLET,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,3,F,,20190930.0,20190916,20191007,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"BURGIO A, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20191007.0,,OT,IT,IT,2019,Q4,Adult
168094243,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,U,,,,5.0,MG,TABLET,QD,2019,Q4,Nausea,,2019,Q4,3,F,,20190930.0,20190916,20191007,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"BURGIO A, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20191007.0,,OT,IT,IT,2019,Q4,Adult
168094243,16809424,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,U,,,,5.0,MG,TABLET,QD,2019,Q4,Vomiting,,2019,Q4,3,F,,20190930.0,20190916,20191007,EXP,,IT-MYLANLABS-2019M1085060,MYLAN,"BURGIO A, ALLETTO M, AMICO S, CASTIGLIONE U, FULCO G, GROPPUSO C, ET AL.. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2-DIABETES MELLITUS TREATED WITH SGLT2 INHIBITORS-A REPORT ON TWO CASES.. ITJM. 2019;13:54-58",50.0,YR,,F,Y,,,20191007.0,,OT,IT,IT,2019,Q4,Adult
168337722,16833772,6,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2019,Q4,Ketoacidosis,,2019,Q4,2,F,20190824.0,20191127.0,20190920,20191205,EXP,,PHHY2019NL215353,NOVARTIS,,54.0,YR,,F,Y,84.5,KG,20191205.0,,OT,NL,NL,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Asthenia,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Blood count abnormal,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,General physical health deterioration,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Hypersomnia,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Malaise,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168364912,16836491,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Oedema peripheral,,2019,Q4,2,F,20190818.0,20190930.0,20190921,20191007,EXP,,CA-ABBVIE-19K-028-2926890-00,ABBVIE,,56.0,YR,,M,Y,108.96,KG,20191007.0,,CN,CA,CA,2019,Q4,Adult
168555311,16855531,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q4,Fournier's gangrene,,2019,Q4,1,I,20190901.0,,20190926,20190926,DIR,,,FDA-CTU,,66.0,YR,,M,N,117.45,KG,20190926.0,N,MD,US,US,2019,Q4,Elderly
168739081,16873908,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5.0MG UNKNOWN,,,U,U,,,202293.0,5.0,MG,TABLET,,2019,Q4,Subarachnoid haemorrhage,,2019,Q4,1,I,20190824.0,20190923.0,20191001,20191001,EXP,,GB-ASTRAZENECA-2019SF35723,ASTRAZENECA,,49.0,YR,,F,Y,76.3,KG,20191001.0,,OT,GB,GB,2019,Q4,Adult
168743622,16874362,12,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,Y,,,,,10.0,MG,TABLET,QD,2019,Q4,Ketoacidosis,,2019,Q4,2,F,20190824.0,20191216.0,20191001,20191230,EXP,,NL-BAUSCH-BL-2019-054808,BAUSCH AND LOMB,,19763.0,DY,,F,Y,84.5,KG,20191230.0,,MD,NL,NL,2019,Q4,Elderly
168743622,16874362,13,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,Y,,,,,10.0,MG,TABLET,QD,2019,Q4,Ketoacidosis,,2019,Q4,2,F,20190824.0,20191216.0,20191001,20191230,EXP,,NL-BAUSCH-BL-2019-054808,BAUSCH AND LOMB,,19763.0,DY,,F,Y,84.5,KG,20191230.0,,MD,NL,NL,2019,Q4,Elderly
168847511,16884751,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20190927.0,20191004,20191004,EXP,,GB-MYLANLABS-2019M1091788,MYLAN,"KANDASWAMY L, AL-SALIHI A, SINGH K, RANGAN S, MOULIK K... KETOACIDOSIS IN PATIENTS ON SGLT2 INHIBITOR: EXPERIENCE FROM A DISTRICT GENERAL HOSITAL.. DIABETIC MEDICINE. 2019;36(1):174-174",63.0,YR,,F,Y,,,20191004.0,,OT,GB,GB,2019,Q4,Adult
168847511,16884751,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Pneumonia,,2019,Q4,1,I,,20190927.0,20191004,20191004,EXP,,GB-MYLANLABS-2019M1091788,MYLAN,"KANDASWAMY L, AL-SALIHI A, SINGH K, RANGAN S, MOULIK K... KETOACIDOSIS IN PATIENTS ON SGLT2 INHIBITOR: EXPERIENCE FROM A DISTRICT GENERAL HOSITAL.. DIABETIC MEDICINE. 2019;36(1):174-174",63.0,YR,,F,Y,,,20191004.0,,OT,GB,GB,2019,Q4,Adult
168922651,16892265,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20190913.0,20191002.0,20191007,20191007,EXP,,GB-ASTRAZENECA-2019SF40037,ASTRAZENECA,,42.0,YR,,F,Y,125.0,KG,20191007.0,,MD,GB,GB,2019,Q4,Adult
168922651,16892265,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Headache,,2019,Q4,1,I,20190913.0,20191002.0,20191007,20191007,EXP,,GB-ASTRAZENECA-2019SF40037,ASTRAZENECA,,42.0,YR,,F,Y,125.0,KG,20191007.0,,MD,GB,GB,2019,Q4,Adult
168922651,16892265,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Vomiting,,2019,Q4,1,I,20190913.0,20191002.0,20191007,20191007,EXP,,GB-ASTRAZENECA-2019SF40037,ASTRAZENECA,,42.0,YR,,F,Y,125.0,KG,20191007.0,,MD,GB,GB,2019,Q4,Adult
169000832,16900083,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,2,F,,20191025.0,20191009,20191108,EXP,,AU-JNJFOC-20190936913,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191108.0,,OT,AU,AU,2019,Q4,Adult
169000832,16900083,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Mental impairment,,2019,Q4,2,F,,20191025.0,20191009,20191108,EXP,,AU-JNJFOC-20190936913,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191108.0,,OT,AU,AU,2019,Q4,Adult
169000832,16900083,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Mitral valve incompetence,,2019,Q4,2,F,,20191025.0,20191009,20191108,EXP,,AU-JNJFOC-20190936913,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191108.0,,OT,AU,AU,2019,Q4,Adult
169000832,16900083,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Myocarditis,,2019,Q4,2,F,,20191025.0,20191009,20191108,EXP,,AU-JNJFOC-20190936913,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191108.0,,OT,AU,AU,2019,Q4,Adult
169000832,16900083,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Pulmonary valve incompetence,,2019,Q4,2,F,,20191025.0,20191009,20191108,EXP,,AU-JNJFOC-20190936913,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191108.0,,OT,AU,AU,2019,Q4,Adult
169000832,16900083,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Tricuspid valve incompetence,,2019,Q4,2,F,,20191025.0,20191009,20191108,EXP,,AU-JNJFOC-20190936913,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191108.0,,OT,AU,AU,2019,Q4,Adult
169000842,16900084,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2019,Q4,Drug ineffective,,2019,Q4,2,F,2009.0,20191025.0,20191009,20191111,EXP,,AU-JNJFOC-20190936984,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191111.0,,OT,AU,AU,2019,Q4,Adult
169000842,16900084,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2019,Q4,Mental impairment,,2019,Q4,2,F,2009.0,20191025.0,20191009,20191111,EXP,,AU-JNJFOC-20190936984,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191111.0,,OT,AU,AU,2019,Q4,Adult
169000842,16900084,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2019,Q4,Mitral valve incompetence,,2019,Q4,2,F,2009.0,20191025.0,20191009,20191111,EXP,,AU-JNJFOC-20190936984,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191111.0,,OT,AU,AU,2019,Q4,Adult
169000842,16900084,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2019,Q4,Myocarditis,,2019,Q4,2,F,2009.0,20191025.0,20191009,20191111,EXP,,AU-JNJFOC-20190936984,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191111.0,,OT,AU,AU,2019,Q4,Adult
169000842,16900084,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2019,Q4,Pulmonary valve incompetence,,2019,Q4,2,F,2009.0,20191025.0,20191009,20191111,EXP,,AU-JNJFOC-20190936984,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191111.0,,OT,AU,AU,2019,Q4,Adult
169000842,16900084,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2019,Q4,Tricuspid valve incompetence,,2019,Q4,2,F,2009.0,20191025.0,20191009,20191111,EXP,,AU-JNJFOC-20190936984,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,,,20191111.0,,OT,AU,AU,2019,Q4,Adult
169089411,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191008.0,20191011,20191011,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20191011.0,,OT,GB,GB,2019,Q4,Adult
169089411,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191008.0,20191011,20191011,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20191011.0,,OT,GB,GB,2019,Q4,Adult
169089411,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Hypotension,,2019,Q4,1,I,,20191008.0,20191011,20191011,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20191011.0,,OT,GB,GB,2019,Q4,Adult
169089411,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,,20191008.0,20191011,20191011,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20191011.0,,OT,GB,GB,2019,Q4,Adult
169150101,16915010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,U,,,202293.0,10.0,MG,,,2019,Q4,Abdominal pain,,2019,Q4,1,I,,20191010.0,20191014,20191014,EXP,,GB-ASTRAZENECA-2019SF44879,ASTRAZENECA,,70.0,YR,,M,Y,,,20191014.0,,,GB,GB,2019,Q4,Elderly
169150101,16915010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,U,,,202293.0,10.0,MG,,,2019,Q4,Nightmare,,2019,Q4,1,I,,20191010.0,20191014,20191014,EXP,,GB-ASTRAZENECA-2019SF44879,ASTRAZENECA,,70.0,YR,,M,Y,,,20191014.0,,,GB,GB,2019,Q4,Elderly
169150101,16915010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,U,,,202293.0,10.0,MG,,,2019,Q4,Nocturia,,2019,Q4,1,I,,20191010.0,20191014,20191014,EXP,,GB-ASTRAZENECA-2019SF44879,ASTRAZENECA,,70.0,YR,,M,Y,,,20191014.0,,,GB,GB,2019,Q4,Elderly
169150101,16915010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,U,,,202293.0,10.0,MG,,,2019,Q4,Polyuria,,2019,Q4,1,I,,20191010.0,20191014,20191014,EXP,,GB-ASTRAZENECA-2019SF44879,ASTRAZENECA,,70.0,YR,,M,Y,,,20191014.0,,,GB,GB,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Acute respiratory failure,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Cardiac arrest,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Hypoxia,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Oedema peripheral,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Pneumonia,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Sepsis,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169169903,16916990,22,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Septic shock,,2019,Q4,3,F,20191002.0,20191016.0,20191015,20191024,EXP,,US-ROCHE-2440348,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191024.0,,MD,US,US,2019,Q4,Elderly
169185711,16918571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, PW673,,202293.0,10.0,MG,TABLET,,2019,Q4,Abdominal pain,,2019,Q4,1,I,20190925.0,20191011.0,20191015,20191015,EXP,,GB-ASTRAZENECA-2019SF45584,ASTRAZENECA,,52.0,YR,,M,Y,73.0,KG,20191015.0,,,GB,GB,2019,Q4,Adult
169185711,16918571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, PW673,,202293.0,10.0,MG,TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190925.0,20191011.0,20191015,20191015,EXP,,GB-ASTRAZENECA-2019SF45584,ASTRAZENECA,,52.0,YR,,M,Y,73.0,KG,20191015.0,,,GB,GB,2019,Q4,Adult
169185711,16918571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, PW673,,202293.0,10.0,MG,TABLET,,2019,Q4,Nausea,,2019,Q4,1,I,20190925.0,20191011.0,20191015,20191015,EXP,,GB-ASTRAZENECA-2019SF45584,ASTRAZENECA,,52.0,YR,,M,Y,73.0,KG,20191015.0,,,GB,GB,2019,Q4,Adult
169185711,16918571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, PW673,,202293.0,10.0,MG,TABLET,,2019,Q4,Thirst,,2019,Q4,1,I,20190925.0,20191011.0,20191015,20191015,EXP,,GB-ASTRAZENECA-2019SF45584,ASTRAZENECA,,52.0,YR,,M,Y,73.0,KG,20191015.0,,,GB,GB,2019,Q4,Adult
169185711,16918571,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, PW673,,202293.0,10.0,MG,TABLET,,2019,Q4,Vomiting,,2019,Q4,1,I,20190925.0,20191011.0,20191015,20191015,EXP,,GB-ASTRAZENECA-2019SF45584,ASTRAZENECA,,52.0,YR,,M,Y,73.0,KG,20191015.0,,,GB,GB,2019,Q4,Adult
169228453,16922845,23,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Oedema peripheral,,2019,Q4,3,F,20191002.0,20191004.0,20191016,20191126,EXP,,US-ROCHE-2434533,ROCHE,,75.0,YR,,M,Y,120.2,KG,20191126.0,,MD,US,US,2019,Q4,Elderly
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Acute coronary syndrome,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Angina unstable,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Blood cholesterol increased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Blood creatine phosphokinase increased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Blood parathyroid hormone increased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Blood triglycerides increased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Coronary artery stenosis,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,High density lipoprotein decreased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Low density lipoprotein increased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Muscular weakness,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Myalgia,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Myopathy,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169255181,16925518,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,UNK,,,,,,,,,,,,2019,Q4,Total cholesterol/HDL ratio increased,,2019,Q4,1,I,,20191010.0,20191016,20191016,EXP,,CA-PFIZER INC-2019445506,PFIZER,,56.0,YR,,M,Y,80.0,KG,20191016.0,,MD,CA,CA,2019,Q4,Adult
169300981,16930098,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,550.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Decreased appetite,,2019,Q4,1,I,20190805.0,20191010.0,20191017,20191017,EXP,,GB-ASTRAZENECA-2019SF44732,ASTRAZENECA,,59.0,YR,,M,Y,84.0,KG,20191017.0,,,GB,GB,2019,Q4,Adult
169300981,16930098,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,550.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,1,I,20190805.0,20191010.0,20191017,20191017,EXP,,GB-ASTRAZENECA-2019SF44732,ASTRAZENECA,,59.0,YR,,M,Y,84.0,KG,20191017.0,,,GB,GB,2019,Q4,Adult
169300981,16930098,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,550.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Dizziness,,2019,Q4,1,I,20190805.0,20191010.0,20191017,20191017,EXP,,GB-ASTRAZENECA-2019SF44732,ASTRAZENECA,,59.0,YR,,M,Y,84.0,KG,20191017.0,,,GB,GB,2019,Q4,Adult
169300981,16930098,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,550.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190805.0,20191010.0,20191017,20191017,EXP,,GB-ASTRAZENECA-2019SF44732,ASTRAZENECA,,59.0,YR,,M,Y,84.0,KG,20191017.0,,,GB,GB,2019,Q4,Adult
169300981,16930098,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,550.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Nausea,,2019,Q4,1,I,20190805.0,20191010.0,20191017,20191017,EXP,,GB-ASTRAZENECA-2019SF44732,ASTRAZENECA,,59.0,YR,,M,Y,84.0,KG,20191017.0,,,GB,GB,2019,Q4,Adult
169300981,16930098,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,550.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Vomiting,,2019,Q4,1,I,20190805.0,20191010.0,20191017,20191017,EXP,,GB-ASTRAZENECA-2019SF44732,ASTRAZENECA,,59.0,YR,,M,Y,84.0,KG,20191017.0,,,GB,GB,2019,Q4,Adult
169379721,16937972,13,C,Dapagliflozin;Metformin,,2,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Suicidal ideation,,2019,Q4,1,I,20190920.0,20191011.0,20191019,20191019,EXP,ES-AEMPS-552291,ES-AUROBINDO-AUR-APL-2019-067669,AUROBINDO,,73.0,YR,,M,Y,,,20191019.0,,MD,ES,ES,2019,Q4,Elderly
169405111,16940511,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191014.0,20191021,20191021,EXP,,GB-ASTRAZENECA-2019SF45621,ASTRAZENECA,,51.0,YR,,M,Y,85.0,KG,20191021.0,,,GB,GB,2019,Q4,Adult
169431191,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,20190902.0,20190912.0,20191021,20191021,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20191022.0,,MD,GB,GB,2019,Q4,Adult
169431191,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Abdominal distension,,2019,Q4,1,I,20190902.0,20190912.0,20191021,20191021,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20191022.0,,MD,GB,GB,2019,Q4,Adult
169431191,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Constipation,,2019,Q4,1,I,20190902.0,20190912.0,20191021,20191021,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20191022.0,,MD,GB,GB,2019,Q4,Adult
169431191,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Diarrhoea,,2019,Q4,1,I,20190902.0,20190912.0,20191021,20191021,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20191022.0,,MD,GB,GB,2019,Q4,Adult
169431191,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Malaise,,2019,Q4,1,I,20190902.0,20190912.0,20191021,20191021,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20191022.0,,MD,GB,GB,2019,Q4,Adult
169458751,16945875,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q4,Acute hepatic failure,,2019,Q4,1,I,,20191014.0,20191022,20191022,EXP,,US-ASTRAZENECA-2019SF45956,ASTRAZENECA,,54.0,YR,,F,Y,,,20191022.0,,MD,US,US,2019,Q4,Adult
169458751,16945875,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,,20191014.0,20191022,20191022,EXP,,US-ASTRAZENECA-2019SF45956,ASTRAZENECA,,54.0,YR,,F,Y,,,20191022.0,,MD,US,US,2019,Q4,Adult
169458751,16945875,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2019,Q4,Drug-induced liver injury,,2019,Q4,1,I,,20191014.0,20191022,20191022,EXP,,US-ASTRAZENECA-2019SF45956,ASTRAZENECA,,54.0,YR,,F,Y,,,20191022.0,,MD,US,US,2019,Q4,Adult
169603911,16960391,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,,20191014.0,20191025,20191025,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-225273,RANBAXY,"KORZENIEWSKA-DYL, I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8",62.0,YR,,M,Y,81.0,KG,20191025.0,,OT,PL,PL,2019,Q4,Adult
169603911,16960391,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Tuberculosis,,2019,Q4,1,I,,20191014.0,20191025,20191025,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-225273,RANBAXY,"KORZENIEWSKA-DYL, I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8",62.0,YR,,M,Y,81.0,KG,20191025.0,,OT,PL,PL,2019,Q4,Adult
169610142,16961014,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,2018.0,20191021.0,20191025,20191025,EXP,,ES-ASTRAZENECA-2019SF50286,ASTRAZENECA,,67.0,YR,,M,Y,,,20191025.0,,MD,ES,ES,2019,Q4,Elderly
169610142,16961014,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q4,Off label use,,2019,Q4,2,F,2018.0,20191021.0,20191025,20191025,EXP,,ES-ASTRAZENECA-2019SF50286,ASTRAZENECA,,67.0,YR,,M,Y,,,20191025.0,,MD,ES,ES,2019,Q4,Elderly
169610142,16961014,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q4,Product use in unapproved indication,,2019,Q4,2,F,2018.0,20191021.0,20191025,20191025,EXP,,ES-ASTRAZENECA-2019SF50286,ASTRAZENECA,,67.0,YR,,M,Y,,,20191025.0,,MD,ES,ES,2019,Q4,Elderly
169618191,16961819,13,C,DAPAGLIFLOZIN/METFORMIN,,2,,UNK,,,,,,,,,,,,2019,Q4,Off label use,,2019,Q4,1,I,20190920.0,20191021.0,20191025,20191025,EXP,ES-AEMPS-552291,ES-PFIZER INC-2019455766,PFIZER,,73.0,YR,,M,Y,,,20191025.0,,MD,ES,ES,2019,Q4,Elderly
169618191,16961819,13,C,DAPAGLIFLOZIN/METFORMIN,,2,,UNK,,,,,,,,,,,,2019,Q4,Product use in unapproved indication,,2019,Q4,1,I,20190920.0,20191021.0,20191025,20191025,EXP,ES-AEMPS-552291,ES-PFIZER INC-2019455766,PFIZER,,73.0,YR,,M,Y,,,20191025.0,,MD,ES,ES,2019,Q4,Elderly
169618191,16961819,13,C,DAPAGLIFLOZIN/METFORMIN,,2,,UNK,,,,,,,,,,,,2019,Q4,Suicidal ideation,,2019,Q4,1,I,20190920.0,20191021.0,20191025,20191025,EXP,ES-AEMPS-552291,ES-PFIZER INC-2019455766,PFIZER,,73.0,YR,,M,Y,,,20191025.0,,MD,ES,ES,2019,Q4,Elderly
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Asthenia,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Discomfort,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Dyspepsia,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Gastrointestinal haemorrhage,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Oesophageal mucosal tear,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169680313,16968031,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Vomiting,,2019,Q4,3,F,201910.0,20191031.0,20191028,20191112,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201910011376,ELI LILLY AND CO,,36.0,YR,,M,Y,90.0,KG,20191112.0,,CN,CN,CN,2019,Q4,Adult
169690691,16969069,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191019.0,20191029,20191029,EXP,,DE-DRREDDYS-GER/GER/19/0115464,DR REDDYS,,78.0,YR,,F,Y,,,20191029.0,,MD,DE,DE,2019,Q4,Elderly
169690691,16969069,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191019.0,20191029,20191029,EXP,,DE-DRREDDYS-GER/GER/19/0115464,DR REDDYS,,78.0,YR,,F,Y,,,20191029.0,,MD,DE,DE,2019,Q4,Elderly
169690691,16969069,14,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191019.0,20191029,20191029,EXP,,DE-DRREDDYS-GER/GER/19/0115464,DR REDDYS,,78.0,YR,,F,Y,,,20191029.0,,MD,DE,DE,2019,Q4,Elderly
169690691,16969069,14,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191019.0,20191029,20191029,EXP,,DE-DRREDDYS-GER/GER/19/0115464,DR REDDYS,,78.0,YR,,F,Y,,,20191029.0,,MD,DE,DE,2019,Q4,Elderly
169701311,16970131,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Fungal infection,,2019,Q4,1,I,20191010.0,20191021.0,20191029,20191029,EXP,,IT-ASTRAZENECA-2019SF49777,ASTRAZENECA,,57.0,YR,,M,Y,81.0,KG,20191029.0,,MD,IT,IT,2019,Q4,Adult
169701311,16970131,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Phimosis,,2019,Q4,1,I,20191010.0,20191021.0,20191029,20191029,EXP,,IT-ASTRAZENECA-2019SF49777,ASTRAZENECA,,57.0,YR,,M,Y,81.0,KG,20191029.0,,MD,IT,IT,2019,Q4,Adult
169747211,16974721,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20190423.0,20191023.0,20191030,20191030,EXP,,GB-ASTRAZENECA-2019SF50769,ASTRAZENECA,,52.0,YR,,F,Y,80.0,KG,20191030.0,,OT,GB,GB,2019,Q4,Adult
169747221,16974722,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,2018.0,20191021.0,20191030,20191030,EXP,,ES-ASTRAZENECA-2019SF50867,ASTRAZENECA,,33.0,YR,,F,Y,,,20191030.0,,OT,ES,ES,2019,Q4,Young Adult
169747221,16974722,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,,10.0,MG,TABLET,,2019,Q4,Off label use,,2019,Q4,1,I,2018.0,20191021.0,20191030,20191030,EXP,,ES-ASTRAZENECA-2019SF50867,ASTRAZENECA,,33.0,YR,,F,Y,,,20191030.0,,OT,ES,ES,2019,Q4,Young Adult
169747221,16974722,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,,10.0,MG,TABLET,,2019,Q4,Product use in unapproved indication,,2019,Q4,1,I,2018.0,20191021.0,20191030,20191030,EXP,,ES-ASTRAZENECA-2019SF50867,ASTRAZENECA,,33.0,YR,,F,Y,,,20191030.0,,OT,ES,ES,2019,Q4,Young Adult
169824191,16982419,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,,20191028.0,20191101,20191101,EXP,,NVSC2019TH019211,NOVARTIS,,55.0,YR,,F,Y,,,20191101.0,,MD,TH,TH,2019,Q4,Adult
169824191,16982419,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q4,Genital infection,,2019,Q4,1,I,,20191028.0,20191101,20191101,EXP,,NVSC2019TH019211,NOVARTIS,,55.0,YR,,F,Y,,,20191101.0,,MD,TH,TH,2019,Q4,Adult
169824191,16982419,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q4,Gout,,2019,Q4,1,I,,20191028.0,20191101,20191101,EXP,,NVSC2019TH019211,NOVARTIS,,55.0,YR,,F,Y,,,20191101.0,,MD,TH,TH,2019,Q4,Adult
169824191,16982419,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q4,Hypotension,,2019,Q4,1,I,,20191028.0,20191101,20191101,EXP,,NVSC2019TH019211,NOVARTIS,,55.0,YR,,F,Y,,,20191101.0,,MD,TH,TH,2019,Q4,Adult
169824191,16982419,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q4,Neuropathy peripheral,,2019,Q4,1,I,,20191028.0,20191101,20191101,EXP,,NVSC2019TH019211,NOVARTIS,,55.0,YR,,F,Y,,,20191101.0,,MD,TH,TH,2019,Q4,Adult
169826931,16982693,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191006.0,20191023.0,20191101,20191101,EXP,,GB-ASTRAZENECA-2019SF50784,ASTRAZENECA,,64.0,YR,,F,Y,65.0,KG,20191101.0,,,GB,GB,2019,Q4,Adult
169828201,16982820,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Hypersensitivity,,2019,Q4,1,I,20180705.0,20191030.0,20191101,20191101,EXP,GB-MHRA-EYC 00182228,GB-GLAXOSMITHKLINE-GB2019198111,GLAXOSMITHKLINE,,71.0,YR,,M,Y,127.0,KG,20191101.0,,MD,GB,GB,2019,Q4,Elderly
169828201,16982820,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Lip swelling,,2019,Q4,1,I,20180705.0,20191030.0,20191101,20191101,EXP,GB-MHRA-EYC 00182228,GB-GLAXOSMITHKLINE-GB2019198111,GLAXOSMITHKLINE,,71.0,YR,,M,Y,127.0,KG,20191101.0,,MD,GB,GB,2019,Q4,Elderly
169828201,16982820,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Mouth swelling,,2019,Q4,1,I,20180705.0,20191030.0,20191101,20191101,EXP,GB-MHRA-EYC 00182228,GB-GLAXOSMITHKLINE-GB2019198111,GLAXOSMITHKLINE,,71.0,YR,,M,Y,127.0,KG,20191101.0,,MD,GB,GB,2019,Q4,Elderly
169828201,16982820,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Oral mucosal erythema,,2019,Q4,1,I,20180705.0,20191030.0,20191101,20191101,EXP,GB-MHRA-EYC 00182228,GB-GLAXOSMITHKLINE-GB2019198111,GLAXOSMITHKLINE,,71.0,YR,,M,Y,127.0,KG,20191101.0,,MD,GB,GB,2019,Q4,Elderly
169828201,16982820,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Paraesthesia oral,,2019,Q4,1,I,20180705.0,20191030.0,20191101,20191101,EXP,GB-MHRA-EYC 00182228,GB-GLAXOSMITHKLINE-GB2019198111,GLAXOSMITHKLINE,,71.0,YR,,M,Y,127.0,KG,20191101.0,,MD,GB,GB,2019,Q4,Elderly
169828201,16982820,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Swollen tongue,,2019,Q4,1,I,20180705.0,20191030.0,20191101,20191101,EXP,GB-MHRA-EYC 00182228,GB-GLAXOSMITHKLINE-GB2019198111,GLAXOSMITHKLINE,,71.0,YR,,M,Y,127.0,KG,20191101.0,,MD,GB,GB,2019,Q4,Elderly
169830371,16983037,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,201707.0,20191029.0,20191101,20191101,EXP,GB-MHRA-EYC 00173721,GB-MYLANLABS-2019M1103477,MYLAN,,71.0,YR,,M,Y,115.21,KG,20191101.0,,CN,GB,GB,2019,Q4,Elderly
169830371,16983037,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,201707.0,20191029.0,20191101,20191101,EXP,GB-MHRA-EYC 00173721,GB-MYLANLABS-2019M1103477,MYLAN,,71.0,YR,,M,Y,115.21,KG,20191101.0,,CN,GB,GB,2019,Q4,Elderly
169830371,16983037,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,201707.0,20191029.0,20191101,20191101,EXP,GB-MHRA-EYC 00173721,GB-MYLANLABS-2019M1103477,MYLAN,,71.0,YR,,M,Y,115.21,KG,20191101.0,,CN,GB,GB,2019,Q4,Elderly
169830371,16983037,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,,,2019,Q4,Thirst,,2019,Q4,1,I,201707.0,20191029.0,20191101,20191101,EXP,GB-MHRA-EYC 00173721,GB-MYLANLABS-2019M1103477,MYLAN,,71.0,YR,,M,Y,115.21,KG,20191101.0,,CN,GB,GB,2019,Q4,Elderly
169830371,16983037,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,,,2019,Q4,Vision blurred,,2019,Q4,1,I,201707.0,20191029.0,20191101,20191101,EXP,GB-MHRA-EYC 00173721,GB-MYLANLABS-2019M1103477,MYLAN,,71.0,YR,,M,Y,115.21,KG,20191101.0,,CN,GB,GB,2019,Q4,Elderly
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Anaphylactic shock,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Asthma,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Back pain,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Blood count abnormal,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Body mass index increased,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Cough,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Crepitations,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Diverticulum,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Dysphonia,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Dyspnoea,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Dyspnoea exertional,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Feeling hot,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Haemoptysis,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Headache,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Heart sounds,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Hyperglycaemia,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Hypersensitivity,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Iron deficiency,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Obstructive airways disorder,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Productive cough,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Rash,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Sinus congestion,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Skin ulcer,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Sputum discoloured,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Swelling face,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Symptom recurrence,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Throat clearing,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Upper respiratory tract inflammation,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Urinary incontinence,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Urticaria,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Weight increased,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169831071,16983107,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2019,Q4,Wheezing,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,CA-TEVA-2019-CA-1129039,TEVA,,57.0,YR,,F,Y,,,20191101.0,,CN,CA,CA,2019,Q4,Adult
169834052,16983405,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q4,Delirium,,2019,Q4,2,F,20191023.0,20191107.0,20191101,20191111,EXP,,ES-SA-2019SA296261,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20191111.0,,OT,ES,ES,2019,Q4,Elderly
169834052,16983405,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q4,Hypoaesthesia,,2019,Q4,2,F,20191023.0,20191107.0,20191101,20191111,EXP,,ES-SA-2019SA296261,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20191111.0,,OT,ES,ES,2019,Q4,Elderly
169834052,16983405,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q4,Hypoglycaemia,,2019,Q4,2,F,20191023.0,20191107.0,20191101,20191111,EXP,,ES-SA-2019SA296261,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20191111.0,,OT,ES,ES,2019,Q4,Elderly
169834052,16983405,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q4,Hypokinesia,,2019,Q4,2,F,20191023.0,20191107.0,20191101,20191111,EXP,,ES-SA-2019SA296261,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20191111.0,,OT,ES,ES,2019,Q4,Elderly
169834052,16983405,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q4,Pain in extremity,,2019,Q4,2,F,20191023.0,20191107.0,20191101,20191111,EXP,,ES-SA-2019SA296261,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20191111.0,,OT,ES,ES,2019,Q4,Elderly
169834052,16983405,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2019,Q4,Syncope,,2019,Q4,2,F,20191023.0,20191107.0,20191101,20191111,EXP,,ES-SA-2019SA296261,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20191111.0,,OT,ES,ES,2019,Q4,Elderly
169835731,16983573,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191029.0,20191101,20191101,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-MYLANLABS-2019M1103575,MYLAN,,79.0,YR,,M,Y,,,20191101.0,,PH,GB,GB,2019,Q4,Elderly
169835731,16983573,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191029.0,20191101,20191101,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-MYLANLABS-2019M1103575,MYLAN,,79.0,YR,,M,Y,,,20191101.0,,PH,GB,GB,2019,Q4,Elderly
169835731,16983573,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191029.0,20191101,20191101,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-MYLANLABS-2019M1103575,MYLAN,,79.0,YR,,M,Y,,,20191101.0,,PH,GB,GB,2019,Q4,Elderly
169835731,16983573,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191029.0,20191101,20191101,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-MYLANLABS-2019M1103575,MYLAN,,79.0,YR,,M,Y,,,20191101.0,,PH,GB,GB,2019,Q4,Elderly
169835731,16983573,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191029.0,20191101,20191101,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-MYLANLABS-2019M1103575,MYLAN,,79.0,YR,,M,Y,,,20191101.0,,PH,GB,GB,2019,Q4,Elderly
169921791,16992179,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, DAILY, EVERY MORNING",116.0,DF,,,,,,1.0,DF,,,2019,Q4,Gastric ulcer,,2019,Q4,1,I,20190902.0,20191022.0,20191105,20191105,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-225771,RANBAXY,,50.0,YR,,M,Y,91.0,KG,20191105.0,,OT,NL,GB,2019,Q4,Adult
169939391,16993939,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,,,,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191010.0,20191030.0,20191105,20191105,EXP,,GB-ASTRAZENECA-2019SF56824,ASTRAZENECA,,38.0,YR,,F,Y,94.0,KG,20191105.0,,,GB,GB,2019,Q4,Adult
169947461,16994746,23,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q4,Nephrolithiasis,,2019,Q4,1,I,20190911.0,20191030.0,20191105,20191105,EXP,,GB-CELGENEUS-GBR-20191011143,CELGENE,,60.0,YR,,M,Y,93.2,KG,20191105.0,,OT,GB,GB,2019,Q4,Adult
169987091,16998709,9,C,Metformina + Dapagliflozina,,2,,2 DOSAGE FORMS,,,,, UNKNOWN,,,2.0,DF,,,2019,Q4,Upper gastrointestinal haemorrhage,,2019,Q4,1,I,20191013.0,20191029.0,20191106,20191106,EXP,PT-INFARMED-F201910-432,PT-TEVA-2019-PT-1131267,TEVA,,65.0,YR,,M,Y,,,20191106.0,,MD,PT,PT,2019,Q4,Elderly
170037191,17003719,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191101.0,20191107,20191107,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TAKEDA-2019TEU013147,TAKEDA,,79.0,YR,,M,Y,,,20191107.0,,OT,GB,GB,2019,Q4,Elderly
170037191,17003719,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191101.0,20191107,20191107,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TAKEDA-2019TEU013147,TAKEDA,,79.0,YR,,M,Y,,,20191107.0,,OT,GB,GB,2019,Q4,Elderly
170037191,17003719,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191101.0,20191107,20191107,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TAKEDA-2019TEU013147,TAKEDA,,79.0,YR,,M,Y,,,20191107.0,,OT,GB,GB,2019,Q4,Elderly
170037191,17003719,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191101.0,20191107,20191107,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TAKEDA-2019TEU013147,TAKEDA,,79.0,YR,,M,Y,,,20191107.0,,OT,GB,GB,2019,Q4,Elderly
170037191,17003719,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191101.0,20191107,20191107,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TAKEDA-2019TEU013147,TAKEDA,,79.0,YR,,M,Y,,,20191107.0,,OT,GB,GB,2019,Q4,Elderly
170041471,17004147,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Arthralgia,,2019,Q4,1,I,,20191030.0,20191107,20191107,EXP,,GB-ASTRAZENECA-2019SF54270,ASTRAZENECA,,56.0,YR,,F,Y,,,20191107.0,,,GB,GB,2019,Q4,Adult
170041471,17004147,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Constipation,,2019,Q4,1,I,,20191030.0,20191107,20191107,EXP,,GB-ASTRAZENECA-2019SF54270,ASTRAZENECA,,56.0,YR,,F,Y,,,20191107.0,,,GB,GB,2019,Q4,Adult
170041471,17004147,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191030.0,20191107,20191107,EXP,,GB-ASTRAZENECA-2019SF54270,ASTRAZENECA,,56.0,YR,,F,Y,,,20191107.0,,,GB,GB,2019,Q4,Adult
170041471,17004147,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Pain in extremity,,2019,Q4,1,I,,20191030.0,20191107,20191107,EXP,,GB-ASTRAZENECA-2019SF54270,ASTRAZENECA,,56.0,YR,,F,Y,,,20191107.0,,,GB,GB,2019,Q4,Adult
170076981,17007698,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191105.0,20191108,20191108,EXP,,DE-009507513-1911DEU001370,MERCK,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170076981,17007698,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191105.0,20191108,20191108,EXP,,DE-009507513-1911DEU001370,MERCK,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170076981,17007698,14,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191105.0,20191108,20191108,EXP,,DE-009507513-1911DEU001370,MERCK,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170076981,17007698,14,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191105.0,20191108,20191108,EXP,,DE-009507513-1911DEU001370,MERCK,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170084751,17008475,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, UNK",,,U,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191101.0,20191108,20191108,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-SA-2019SA305102,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20191108.0,,PH,GB,GB,2019,Q4,Elderly
170084751,17008475,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, UNK",,,U,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191101.0,20191108,20191108,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-SA-2019SA305102,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20191108.0,,PH,GB,GB,2019,Q4,Elderly
170084751,17008475,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, UNK",,,U,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191101.0,20191108,20191108,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-SA-2019SA305102,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20191108.0,,PH,GB,GB,2019,Q4,Elderly
170084751,17008475,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, UNK",,,U,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191101.0,20191108,20191108,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-SA-2019SA305102,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20191108.0,,PH,GB,GB,2019,Q4,Elderly
170084751,17008475,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, UNK",,,U,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191101.0,20191108,20191108,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-SA-2019SA305102,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20191108.0,,PH,GB,GB,2019,Q4,Elderly
170086671,17008667,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191029.0,20191108,20191108,EXP,,RO-ELI_LILLY_AND_COMPANY-RO201910015423,ELI LILLY AND CO,,42.0,YR,,,Y,,,20191108.0,,MD,RO,RO,2019,Q4,Adult
170095091,17009509,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ONCE/SINGLE ADMINISTRATION,,,U,," UNKNOWN,UNKNOWN",,202293.0,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191031.0,20191108,20191108,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170095091,17009509,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ONCE/SINGLE ADMINISTRATION,,,U,," UNKNOWN,UNKNOWN",,202293.0,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191031.0,20191108,20191108,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170095091,17009509,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191031.0,20191108,20191108,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170095091,17009509,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191031.0,20191108,20191108,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20191108.0,,MD,DE,DE,2019,Q4,Elderly
170096511,17009651,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191011.0,20191030.0,20191108,20191108,EXP,,GB-ASTRAZENECA-2019SF54005,ASTRAZENECA,,47.0,YR,,F,Y,60.3,KG,20191108.0,,,GB,GB,2019,Q4,Adult
170098901,17009890,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,95.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q4,Dizziness,,2019,Q4,1,I,,20191031.0,20191108,20191108,EXP,,GB-ASTRAZENECA-2019SF54936,ASTRAZENECA,,41.0,YR,,F,Y,,,20191108.0,,,GB,GB,2019,Q4,Adult
170098901,17009890,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,95.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q4,Fatigue,,2019,Q4,1,I,,20191031.0,20191108,20191108,EXP,,GB-ASTRAZENECA-2019SF54936,ASTRAZENECA,,41.0,YR,,F,Y,,,20191108.0,,,GB,GB,2019,Q4,Adult
170098901,17009890,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,95.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2019,Q4,Nausea,,2019,Q4,1,I,,20191031.0,20191108,20191108,EXP,,GB-ASTRAZENECA-2019SF54936,ASTRAZENECA,,41.0,YR,,F,Y,,,20191108.0,,,GB,GB,2019,Q4,Adult
170102233,17010223,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,3,F,,20191107.0,20191108,20191115,EXP,,PL-ASTRAZENECA-2019SF55126,ASTRAZENECA,,62.0,YR,,M,Y,81.0,KG,20191115.0,,OT,PL,PL,2019,Q4,Adult
170102233,17010223,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Tuberculosis,,2019,Q4,3,F,,20191107.0,20191108,20191115,EXP,,PL-ASTRAZENECA-2019SF55126,ASTRAZENECA,,62.0,YR,,M,Y,81.0,KG,20191115.0,,OT,PL,PL,2019,Q4,Adult
170104551,17010455,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2019,Q4,Pruritus,,2019,Q4,1,I,20180222.0,20191031.0,20191108,20191108,EXP,,GB-ASTRAZENECA-2019SF55036,ASTRAZENECA,,53.0,YR,,F,Y,83.0,KG,20191108.0,,,GB,GB,2019,Q4,Adult
170145201,17014520,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191030.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-LUPIN PHARMACEUTICALS INC.-2019-07205,LUPIN,,79.0,YR,,M,Y,,,20191111.0,,CN,GB,GB,2019,Q4,Elderly
170145201,17014520,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191030.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-LUPIN PHARMACEUTICALS INC.-2019-07205,LUPIN,,79.0,YR,,M,Y,,,20191111.0,,CN,GB,GB,2019,Q4,Elderly
170145201,17014520,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191030.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-LUPIN PHARMACEUTICALS INC.-2019-07205,LUPIN,,79.0,YR,,M,Y,,,20191111.0,,CN,GB,GB,2019,Q4,Elderly
170145201,17014520,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191030.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-LUPIN PHARMACEUTICALS INC.-2019-07205,LUPIN,,79.0,YR,,M,Y,,,20191111.0,,CN,GB,GB,2019,Q4,Elderly
170145201,17014520,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191030.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-LUPIN PHARMACEUTICALS INC.-2019-07205,LUPIN,,79.0,YR,,M,Y,,,20191111.0,,CN,GB,GB,2019,Q4,Elderly
170145571,17014557,19,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK 1 TOTAL,,,D,,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191029.0,20191111,20191111,EXP,,DE-AUROBINDO-AUR-APL-2019-071353,AUROBINDO,,78.0,YR,,F,Y,,,20191111.0,,MD,DE,DE,2019,Q4,Elderly
170145571,17014557,19,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK 1 TOTAL,,,D,,,,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191029.0,20191111,20191111,EXP,,DE-AUROBINDO-AUR-APL-2019-071353,AUROBINDO,,78.0,YR,,F,Y,,,20191111.0,,MD,DE,DE,2019,Q4,Elderly
170145571,17014557,20,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191029.0,20191111,20191111,EXP,,DE-AUROBINDO-AUR-APL-2019-071353,AUROBINDO,,78.0,YR,,F,Y,,,20191111.0,,MD,DE,DE,2019,Q4,Elderly
170145571,17014557,20,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191029.0,20191111,20191111,EXP,,DE-AUROBINDO-AUR-APL-2019-071353,AUROBINDO,,78.0,YR,,F,Y,,,20191111.0,,MD,DE,DE,2019,Q4,Elderly
170155241,17015524,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191101.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-EMD SERONO-E2B_90072198,EMD SERONO INC,,79.0,YR,,M,Y,,,20191111.0,,PH,GB,GB,2019,Q4,Elderly
170155241,17015524,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191101.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-EMD SERONO-E2B_90072198,EMD SERONO INC,,79.0,YR,,M,Y,,,20191111.0,,PH,GB,GB,2019,Q4,Elderly
170155241,17015524,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191101.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-EMD SERONO-E2B_90072198,EMD SERONO INC,,79.0,YR,,M,Y,,,20191111.0,,PH,GB,GB,2019,Q4,Elderly
170155241,17015524,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191101.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-EMD SERONO-E2B_90072198,EMD SERONO INC,,79.0,YR,,M,Y,,,20191111.0,,PH,GB,GB,2019,Q4,Elderly
170155241,17015524,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191101.0,20191111,20191111,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-EMD SERONO-E2B_90072198,EMD SERONO INC,,79.0,YR,,M,Y,,,20191111.0,,PH,GB,GB,2019,Q4,Elderly
170176441,17017644,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK, SINGLE",,,,,,,,,,TABLET,QD,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191031.0,20191111,20191111,EXP,,DE-TOPROL ACQUISITION LLC-2019-TOP-001374,UNKNOWN,,78.0,YR,,F,Y,,,20191111.0,,OT,DE,DE,2019,Q4,Elderly
170176441,17017644,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK, SINGLE",,,,,,,,,,TABLET,QD,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191031.0,20191111,20191111,EXP,,DE-TOPROL ACQUISITION LLC-2019-TOP-001374,UNKNOWN,,78.0,YR,,F,Y,,,20191111.0,,OT,DE,DE,2019,Q4,Elderly
170176441,17017644,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191031.0,20191111,20191111,EXP,,DE-TOPROL ACQUISITION LLC-2019-TOP-001374,UNKNOWN,,78.0,YR,,F,Y,,,20191111.0,,OT,DE,DE,2019,Q4,Elderly
170176441,17017644,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191031.0,20191111,20191111,EXP,,DE-TOPROL ACQUISITION LLC-2019-TOP-001374,UNKNOWN,,78.0,YR,,F,Y,,,20191111.0,,OT,DE,DE,2019,Q4,Elderly
170187921,17018792,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071747,AUROBINDO,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170187921,17018792,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071747,AUROBINDO,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170187921,17018792,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071747,AUROBINDO,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170187921,17018792,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071747,AUROBINDO,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170187921,17018792,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071747,AUROBINDO,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170189751,17018975,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Tremor,,2019,Q4,1,I,20180201.0,20191028.0,20191112,20191112,EXP,GB-MHRA-ADR 24286556,GB-EMCURE PHARMACEUTICALS LTD-2019-EPL-1035,EMCURE,,49.0,YR,,F,Y,,,20191111.0,,CN,GB,GB,2019,Q4,Adult
170189901,17018990,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,201707.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071115,AUROBINDO,,71.0,YR,,M,Y,115.21,KG,20191112.0,,CN,GB,GB,2019,Q4,Elderly
170189901,17018990,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,201707.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071115,AUROBINDO,,71.0,YR,,M,Y,115.21,KG,20191112.0,,CN,GB,GB,2019,Q4,Elderly
170189901,17018990,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,201707.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071115,AUROBINDO,,71.0,YR,,M,Y,115.21,KG,20191112.0,,CN,GB,GB,2019,Q4,Elderly
170189901,17018990,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Thirst,,2019,Q4,1,I,201707.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071115,AUROBINDO,,71.0,YR,,M,Y,115.21,KG,20191112.0,,CN,GB,GB,2019,Q4,Elderly
170189901,17018990,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Vision blurred,,2019,Q4,1,I,201707.0,20191029.0,20191112,20191112,EXP,,GB-AUROBINDO-AUR-APL-2019-071115,AUROBINDO,,71.0,YR,,M,Y,115.21,KG,20191112.0,,CN,GB,GB,2019,Q4,Elderly
170212521,17021252,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,TOTAL,,,U,,,,,,,,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191031.0,20191112,20191112,EXP,,DE-BAUSCH-BL-2019-059881,BAUSCH AND LOMB,,78.0,YR,,F,Y,,,20191112.0,,MD,DE,DE,2019,Q4,Elderly
170212521,17021252,13,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,TOTAL,,,U,,,,,,,,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191031.0,20191112,20191112,EXP,,DE-BAUSCH-BL-2019-059881,BAUSCH AND LOMB,,78.0,YR,,F,Y,,,20191112.0,,MD,DE,DE,2019,Q4,Elderly
170212521,17021252,14,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q4,Intentional overdose,,2019,Q4,1,I,20191019.0,20191031.0,20191112,20191112,EXP,,DE-BAUSCH-BL-2019-059881,BAUSCH AND LOMB,,78.0,YR,,F,Y,,,20191112.0,,MD,DE,DE,2019,Q4,Elderly
170212521,17021252,14,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2019,Q4,Suicide attempt,,2019,Q4,1,I,20191019.0,20191031.0,20191112,20191112,EXP,,DE-BAUSCH-BL-2019-059881,BAUSCH AND LOMB,,78.0,YR,,F,Y,,,20191112.0,,MD,DE,DE,2019,Q4,Elderly
170212541,17021254,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191031.0,20191112,20191112,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-BAUSCH-BL-2019-060021,BAUSCH AND LOMB,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170212541,17021254,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191031.0,20191112,20191112,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-BAUSCH-BL-2019-060021,BAUSCH AND LOMB,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170212541,17021254,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191031.0,20191112,20191112,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-BAUSCH-BL-2019-060021,BAUSCH AND LOMB,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170212541,17021254,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191031.0,20191112,20191112,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-BAUSCH-BL-2019-060021,BAUSCH AND LOMB,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170212541,17021254,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191031.0,20191112,20191112,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-BAUSCH-BL-2019-060021,BAUSCH AND LOMB,,79.0,YR,,M,Y,,,20191112.0,,PH,GB,GB,2019,Q4,Elderly
170246761,17024676,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191107.0,20191113,20191113,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TORRENT-00022244,TORRENT,,79.0,YR,E,M,Y,,,20191113.0,,PH,GB,GB,2019,Q4,Elderly
170246761,17024676,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191107.0,20191113,20191113,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TORRENT-00022244,TORRENT,,79.0,YR,E,M,Y,,,20191113.0,,PH,GB,GB,2019,Q4,Elderly
170246761,17024676,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191107.0,20191113,20191113,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TORRENT-00022244,TORRENT,,79.0,YR,E,M,Y,,,20191113.0,,PH,GB,GB,2019,Q4,Elderly
170246761,17024676,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191107.0,20191113,20191113,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TORRENT-00022244,TORRENT,,79.0,YR,E,M,Y,,,20191113.0,,PH,GB,GB,2019,Q4,Elderly
170246761,17024676,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191107.0,20191113,20191113,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TORRENT-00022244,TORRENT,,79.0,YR,E,M,Y,,,20191113.0,,PH,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Off label use,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Product use in unapproved indication,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Thirst,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170270911,17027091,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Vision blurred,,2019,Q4,1,I,201707.0,20191107.0,20191113,20191113,EXP,GB-MHRA-EYC 00173721,GB-PFIZER INC-2019484635,PFIZER,,71.0,YR,,M,Y,115.0,KG,20191113.0,,CN,GB,GB,2019,Q4,Elderly
170354171,17035417,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,DAILY,,,Y,,,,,10.0,MG,,,2019,Q4,Fungal infection,Fungal infection,2019,Q4,1,I,201811.0,20190515.0,20191115,20191115,PER,,US-ALVOGEN-2019-ALVOGEN-100981,ALVOGEN,,62.0,YR,,M,Y,108.86,KG,20191115.0,,OT,US,US,2019,Q4,Adult
170354171,17035417,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,DAILY,,,Y,,,,,10.0,MG,,,2019,Q4,Muscular weakness,Muscular weakness,2019,Q4,1,I,201811.0,20190515.0,20191115,20191115,PER,,US-ALVOGEN-2019-ALVOGEN-100981,ALVOGEN,,62.0,YR,,M,Y,108.86,KG,20191115.0,,OT,US,US,2019,Q4,Adult
170354171,17035417,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,DAILY,,,Y,,,,,10.0,MG,,,2019,Q4,Rash,Rash,2019,Q4,1,I,201811.0,20190515.0,20191115,20191115,PER,,US-ALVOGEN-2019-ALVOGEN-100981,ALVOGEN,,62.0,YR,,M,Y,108.86,KG,20191115.0,,OT,US,US,2019,Q4,Adult
170355001,17035500,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,201707.0,20191112.0,20191115,20191115,EXP,GB-MHRA-EYC 00173721,GB-TEVA-2019-GB-1137219,TEVA,,71.0,YR,,M,Y,115.21,KG,20191115.0,,CN,GB,GB,2019,Q4,Elderly
170355001,17035500,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,201707.0,20191112.0,20191115,20191115,EXP,GB-MHRA-EYC 00173721,GB-TEVA-2019-GB-1137219,TEVA,,71.0,YR,,M,Y,115.21,KG,20191115.0,,CN,GB,GB,2019,Q4,Elderly
170355001,17035500,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,201707.0,20191112.0,20191115,20191115,EXP,GB-MHRA-EYC 00173721,GB-TEVA-2019-GB-1137219,TEVA,,71.0,YR,,M,Y,115.21,KG,20191115.0,,CN,GB,GB,2019,Q4,Elderly
170355001,17035500,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2019,Q4,Thirst,,2019,Q4,1,I,201707.0,20191112.0,20191115,20191115,EXP,GB-MHRA-EYC 00173721,GB-TEVA-2019-GB-1137219,TEVA,,71.0,YR,,M,Y,115.21,KG,20191115.0,,CN,GB,GB,2019,Q4,Elderly
170355001,17035500,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2019,Q4,Vision blurred,,2019,Q4,1,I,201707.0,20191112.0,20191115,20191115,EXP,GB-MHRA-EYC 00173721,GB-TEVA-2019-GB-1137219,TEVA,,71.0,YR,,M,Y,115.21,KG,20191115.0,,CN,GB,GB,2019,Q4,Elderly
170369811,17036981,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191016.0,20191106.0,20191115,20191115,EXP,,GB-ASTRAZENECA-2019SF58832,ASTRAZENECA,,47.0,YR,,F,Y,,,20191115.0,,,GB,GB,2019,Q4,Adult
170376731,17037673,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Ketosis,,2019,Q4,1,I,20191012.0,20191107.0,20191115,20191115,EXP,,CN-ASTRAZENECA-2019SF61982,ASTRAZENECA,,16383.0,DY,,F,Y,71.0,KG,20191115.0,,OT,CN,CN,2019,Q4,Elderly
170376731,17037673,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Ketosis,,2019,Q4,1,I,20191012.0,20191107.0,20191115,20191115,EXP,,CN-ASTRAZENECA-2019SF61982,ASTRAZENECA,,16383.0,DY,,F,Y,71.0,KG,20191115.0,,OT,CN,CN,2019,Q4,Elderly
170383061,17038306,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,,,,,5.0,MG,TABLET,QD,2019,Q4,Adrenal disorder,,2019,Q4,1,I,20181206.0,20191001.0,20191115,20191115,EXP,,JP-009507513-1910JPN000523J,MERCK,,73.0,YR,,F,Y,47.0,KG,20191115.0,,CN,JP,JP,2019,Q4,Elderly
170383061,17038306,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,,,,,5.0,MG,TABLET,QD,2019,Q4,Interstitial lung disease,,2019,Q4,1,I,20181206.0,20191001.0,20191115,20191115,EXP,,JP-009507513-1910JPN000523J,MERCK,,73.0,YR,,F,Y,47.0,KG,20191115.0,,CN,JP,JP,2019,Q4,Elderly
170399371,17039937,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191107.0,20191116,20191116,EXP,GB-MHRA-ADR 24331157,GB-ACCORD-161117,ACCORD,,79.0,YR,,M,Y,,,20191116.0,,PH,GB,GB,2019,Q4,Elderly
170399371,17039937,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191107.0,20191116,20191116,EXP,GB-MHRA-ADR 24331157,GB-ACCORD-161117,ACCORD,,79.0,YR,,M,Y,,,20191116.0,,PH,GB,GB,2019,Q4,Elderly
170399371,17039937,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191107.0,20191116,20191116,EXP,GB-MHRA-ADR 24331157,GB-ACCORD-161117,ACCORD,,79.0,YR,,M,Y,,,20191116.0,,PH,GB,GB,2019,Q4,Elderly
170399371,17039937,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191107.0,20191116,20191116,EXP,GB-MHRA-ADR 24331157,GB-ACCORD-161117,ACCORD,,79.0,YR,,M,Y,,,20191116.0,,PH,GB,GB,2019,Q4,Elderly
170399371,17039937,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191107.0,20191116,20191116,EXP,GB-MHRA-ADR 24331157,GB-ACCORD-161117,ACCORD,,79.0,YR,,M,Y,,,20191116.0,,PH,GB,GB,2019,Q4,Elderly
170400891,17040089,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"30 MG, QD",,,U,,,,,30.0,MG,TABLET,QD,2019,Q4,Blood creatinine increased,,2019,Q4,1,I,,20191108.0,20191116,20191116,EXP,,NVSC2019CN036285,NOVARTIS,,69.0,YR,,F,Y,,,20191116.0,,MD,CN,CN,2019,Q4,Elderly
170400891,17040089,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"30 MG, QD",,,U,,,,,30.0,MG,TABLET,QD,2019,Q4,Blood urea increased,,2019,Q4,1,I,,20191108.0,20191116,20191116,EXP,,NVSC2019CN036285,NOVARTIS,,69.0,YR,,F,Y,,,20191116.0,,MD,CN,CN,2019,Q4,Elderly
170400891,17040089,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"30 MG, QD",,,U,,,,,30.0,MG,TABLET,QD,2019,Q4,Blood uric acid abnormal,,2019,Q4,1,I,,20191108.0,20191116,20191116,EXP,,NVSC2019CN036285,NOVARTIS,,69.0,YR,,F,Y,,,20191116.0,,MD,CN,CN,2019,Q4,Elderly
170400891,17040089,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"30 MG, QD",,,U,,,,,30.0,MG,TABLET,QD,2019,Q4,Renal impairment,,2019,Q4,1,I,,20191108.0,20191116,20191116,EXP,,NVSC2019CN036285,NOVARTIS,,69.0,YR,,F,Y,,,20191116.0,,MD,CN,CN,2019,Q4,Elderly
170428061,17042806,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191021.0,20191107.0,20191118,20191118,EXP,,DE-ASTRAZENECA-2019SF59529,ASTRAZENECA,,44.0,YR,,M,Y,94.4,KG,20191118.0,,MD,DE,DE,2019,Q4,Adult
170509041,17050904,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,U,,,,,10.0,MG,,QD,2019,Q4,Cellulitis,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073755,AUROBINDO,,48.0,YR,,M,Y,151.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170509041,17050904,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,U,,,,,10.0,MG,,QD,2019,Q4,Drug titration error,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073755,AUROBINDO,,48.0,YR,,M,Y,151.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170509041,17050904,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,U,,,,,10.0,MG,,QD,2019,Q4,Hypoglycaemia,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073755,AUROBINDO,,48.0,YR,,M,Y,151.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170509041,17050904,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,U,,,,,10.0,MG,,QD,2019,Q4,Limb injury,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073755,AUROBINDO,,48.0,YR,,M,Y,151.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170509041,17050904,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,U,,,,,10.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073755,AUROBINDO,,48.0,YR,,M,Y,151.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170509041,17050904,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,U,,,,,10.0,MG,,QD,2019,Q4,Oedema peripheral,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073755,AUROBINDO,,48.0,YR,,M,Y,151.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170574591,17057459,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,1,I,20190201.0,20191111.0,20191121,20191121,EXP,,SG-ROCHE-2471203,ROCHE,,51.0,YR,,,Y,,,20191121.0,,OT,SG,SG,2019,Q4,Adult
170574591,17057459,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Hepatitis C,,2019,Q4,1,I,20190201.0,20191111.0,20191121,20191121,EXP,,SG-ROCHE-2471203,ROCHE,,51.0,YR,,,Y,,,20191121.0,,OT,SG,SG,2019,Q4,Adult
170581951,17058195,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Blood glucose abnormal,,2019,Q4,1,I,2016.0,20190919.0,20191121,20191121,PER,,US-ALVOGEN-2019-ALVOGEN-101554,ALVOGEN,,53.0,YR,,F,Y,90.72,KG,20191121.0,,CN,US,US,2019,Q4,Adult
170581951,17058195,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Insomnia,,2019,Q4,1,I,2016.0,20190919.0,20191121,20191121,PER,,US-ALVOGEN-2019-ALVOGEN-101554,ALVOGEN,,53.0,YR,,F,Y,90.72,KG,20191121.0,,CN,US,US,2019,Q4,Adult
170581951,17058195,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Muscle spasms,,2019,Q4,1,I,2016.0,20190919.0,20191121,20191121,PER,,US-ALVOGEN-2019-ALVOGEN-101554,ALVOGEN,,53.0,YR,,F,Y,90.72,KG,20191121.0,,CN,US,US,2019,Q4,Adult
170581951,17058195,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Restless legs syndrome,,2019,Q4,1,I,2016.0,20190919.0,20191121,20191121,PER,,US-ALVOGEN-2019-ALVOGEN-101554,ALVOGEN,,53.0,YR,,F,Y,90.72,KG,20191121.0,,CN,US,US,2019,Q4,Adult
170581951,17058195,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Thyroid disorder,,2019,Q4,1,I,2016.0,20190919.0,20191121,20191121,PER,,US-ALVOGEN-2019-ALVOGEN-101554,ALVOGEN,,53.0,YR,,F,Y,90.72,KG,20191121.0,,CN,US,US,2019,Q4,Adult
170638301,17063830,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191027.0,20191115.0,20191122,20191122,EXP,,GB-ASTRAZENECA-2019SF63019,ASTRAZENECA,,61.0,YR,,M,Y,,,20191122.0,,,GB,GB,2019,Q4,Adult
170678011,17067801,2,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20191014.0,20191113.0,20191122,20191122,EXP,NL-LRB-00360448,NL-NOVOPROD-696481,NOVO NORDISK,,52.0,YR,,M,Y,98.0,KG,20191122.0,,MD,NL,NL,2019,Q4,Adult
170678011,17067801,2,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,1,I,20191014.0,20191113.0,20191122,20191122,EXP,NL-LRB-00360448,NL-NOVOPROD-696481,NOVO NORDISK,,52.0,YR,,M,Y,98.0,KG,20191122.0,,MD,NL,NL,2019,Q4,Adult
170678011,17067801,2,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q4,Renal tubular necrosis,,2019,Q4,1,I,20191014.0,20191113.0,20191122,20191122,EXP,NL-LRB-00360448,NL-NOVOPROD-696481,NOVO NORDISK,,52.0,YR,,M,Y,98.0,KG,20191122.0,,MD,NL,NL,2019,Q4,Adult
170678011,17067801,2,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,20191014.0,20191113.0,20191122,20191122,EXP,NL-LRB-00360448,NL-NOVOPROD-696481,NOVO NORDISK,,52.0,YR,,M,Y,98.0,KG,20191122.0,,MD,NL,NL,2019,Q4,Adult
170681941,17068194,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 MG,,,,, UNKNOWN,,,5.0,MG,TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20180712.0,20191114.0,20191123,20191123,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TEVA-2019-GB-1139555,TEVA,,79.0,YR,,M,Y,,,20191123.0,,PH,GB,GB,2019,Q4,Elderly
170681941,17068194,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 MG,,,,, UNKNOWN,,,5.0,MG,TABLET,,2019,Q4,Confusional state,,2019,Q4,1,I,20180712.0,20191114.0,20191123,20191123,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TEVA-2019-GB-1139555,TEVA,,79.0,YR,,M,Y,,,20191123.0,,PH,GB,GB,2019,Q4,Elderly
170681941,17068194,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 MG,,,,, UNKNOWN,,,5.0,MG,TABLET,,2019,Q4,Hyperlactacidaemia,,2019,Q4,1,I,20180712.0,20191114.0,20191123,20191123,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TEVA-2019-GB-1139555,TEVA,,79.0,YR,,M,Y,,,20191123.0,,PH,GB,GB,2019,Q4,Elderly
170681941,17068194,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 MG,,,,, UNKNOWN,,,5.0,MG,TABLET,,2019,Q4,Infection,,2019,Q4,1,I,20180712.0,20191114.0,20191123,20191123,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TEVA-2019-GB-1139555,TEVA,,79.0,YR,,M,Y,,,20191123.0,,PH,GB,GB,2019,Q4,Elderly
170681941,17068194,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 MG,,,,, UNKNOWN,,,5.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20180712.0,20191114.0,20191123,20191123,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,GB-TEVA-2019-GB-1139555,TEVA,,79.0,YR,,M,Y,,,20191123.0,,PH,GB,GB,2019,Q4,Elderly
170726121,17072612,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Chest pain,Chest pain,2019,Q4,1,I,,20191125.0,20191125,20191125,EXP,,SG-ANIPHARMA-2019-SG-000014,ANI,"PANG T, GUDI A.CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION..PROCEEDINGS OF SINGAPORE HEALTHCARE.2019;28(2):138-140.",66.0,YR,,F,Y,,,20191125.0,,MD,SG,SG,2019,Q4,Elderly
170726121,17072612,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Drug interaction,Drug interaction,2019,Q4,1,I,,20191125.0,20191125,20191125,EXP,,SG-ANIPHARMA-2019-SG-000014,ANI,"PANG T, GUDI A.CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION..PROCEEDINGS OF SINGAPORE HEALTHCARE.2019;28(2):138-140.",66.0,YR,,F,Y,,,20191125.0,,MD,SG,SG,2019,Q4,Elderly
170738791,17073879,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,,5.0,MG,,,2019,Q4,Asthenia,,2019,Q4,1,I,,20190612.0,20191126,20191126,PER,,US-ALVOGEN-2019-ALVOGEN-101328,ALVOGEN,,75.0,YR,,M,Y,,,20191125.0,,OT,US,US,2019,Q4,Elderly
170738791,17073879,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,,5.0,MG,,,2019,Q4,Back pain,,2019,Q4,1,I,,20190612.0,20191126,20191126,PER,,US-ALVOGEN-2019-ALVOGEN-101328,ALVOGEN,,75.0,YR,,M,Y,,,20191125.0,,OT,US,US,2019,Q4,Elderly
170738791,17073879,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,,5.0,MG,,,2019,Q4,Lethargy,,2019,Q4,1,I,,20190612.0,20191126,20191126,PER,,US-ALVOGEN-2019-ALVOGEN-101328,ALVOGEN,,75.0,YR,,M,Y,,,20191125.0,,OT,US,US,2019,Q4,Elderly
170738791,17073879,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,,5.0,MG,,,2019,Q4,Pain in extremity,,2019,Q4,1,I,,20190612.0,20191126,20191126,PER,,US-ALVOGEN-2019-ALVOGEN-101328,ALVOGEN,,75.0,YR,,M,Y,,,20191125.0,,OT,US,US,2019,Q4,Elderly
170822561,17082256,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,,20191118.0,20191127,20191127,EXP,,CZ-EMD SERONO-9130687,EMD SERONO INC,UNKNOWN. EXPERIENCE WITH GLIFLOZIN. KAZUISTIKY V DIABETOLOGII - SUPPLEMENT. 2019;17 (3):2-3.,72.0,YR,,M,Y,94.0,KG,20191127.0,,MD,CZ,CZ,2019,Q4,Elderly
170929961,17092996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,,, 1904105/KP3063,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Blood glucose increased,,2019,Q4,1,I,20191026.0,20191121.0,20191129,20191129,EXP,,CN-ASTRAZENECA-2019SF70206,ASTRAZENECA,,66.0,YR,,F,Y,69.0,KG,20191129.0,,OT,CN,CN,2019,Q4,Elderly
170929961,17092996,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,,, 1904105/KP3063,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Renal injury,,2019,Q4,1,I,20191026.0,20191121.0,20191129,20191129,EXP,,CN-ASTRAZENECA-2019SF70206,ASTRAZENECA,,66.0,YR,,F,Y,69.0,KG,20191129.0,,OT,CN,CN,2019,Q4,Elderly
170930101,17093010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20191023.0,20191125.0,20191129,20191129,EXP,,GB-ASTRAZENECA-2019SF69373,ASTRAZENECA,,54.0,YR,,M,Y,,,20191129.0,,,GB,GB,2019,Q4,Adult
170930101,17093010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Malaise,,2019,Q4,1,I,20191023.0,20191125.0,20191129,20191129,EXP,,GB-ASTRAZENECA-2019SF69373,ASTRAZENECA,,54.0,YR,,M,Y,,,20191129.0,,,GB,GB,2019,Q4,Adult
170957671,17095767,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191111.0,20191126.0,20191201,20191201,EXP,,GB-ASTRAZENECA-2019SF69419,ASTRAZENECA,,61.0,YR,,M,Y,,,20191202.0,,,GB,GB,2019,Q4,Adult
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Blood cholesterol increased,Blood cholesterol increased,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Blood triglycerides increased,Blood triglycerides increased,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Fatigue,Fatigue,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Hyperglycaemia,Hyperglycaemia,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Hypertension,Hypertension,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Overdose,Overdose,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
170970781,17097078,16,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE/METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,,2019,Q4,Treatment noncompliance,Treatment noncompliance,2019,Q4,1,I,,20191118.0,20191202,20191202,EXP,ES-EMA-DD-20190524-TANEJA_C-170028,ES-ALVOGEN-2019-ALVOGEN-101978,ALVOGEN,,72.0,YR,,M,Y,,,20191202.0,,PH,ES,ES,2019,Q4,Elderly
171107691,17110769,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191128.0,20191204,20191204,EXP,,GB-ASTRAZENECA-2019SF70643,ASTRAZENECA,,52.0,YR,,M,Y,70.0,KG,20191204.0,,MD,GB,GB,2019,Q4,Adult
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Aortic valve calcification,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Aortic valve incompetence,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Arrhythmia,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Cardiac failure,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Cardiac murmur,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Cough,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Fatigue,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Heart rate irregular,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Hypertension,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Left atrial dilatation,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Left ventricular dysfunction,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Mitral valve incompetence,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Orthopnoea,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Pulmonary hypertension,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Rales,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Tricuspid valve incompetence,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171164561,17116456,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q4,Ventricular hypokinesia,,2019,Q4,1,I,,20191129.0,20191205,20191205,EXP,,PT-MYLANLABS-2019M1118908,MYLAN,,68.0,YR,,F,Y,,,20191205.0,,MD,PT,PT,2019,Q4,Elderly
171173401,17117340,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5180.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191113.0,20191127.0,20191205,20191205,EXP,,GB-ASTRAZENECA-2019SF70087,ASTRAZENECA,,71.0,YR,,M,Y,,,20191205.0,,,GB,GB,2019,Q4,Elderly
171173401,17117340,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5180.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Malaise,,2019,Q4,1,I,20191113.0,20191127.0,20191205,20191205,EXP,,GB-ASTRAZENECA-2019SF70087,ASTRAZENECA,,71.0,YR,,M,Y,,,20191205.0,,,GB,GB,2019,Q4,Elderly
171277251,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2019,Q4,Depression,,2019,Q4,1,I,20170330.0,20170202.0,20191209,20191209,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20191209.0,,CN,US,US,2019,Q4,Adult
171277251,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2019,Q4,Fatigue,,2019,Q4,1,I,20170330.0,20170202.0,20191209,20191209,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20191209.0,,CN,US,US,2019,Q4,Adult
171277251,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2019,Q4,Myocardial infarction,,2019,Q4,1,I,20170330.0,20170202.0,20191209,20191209,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20191209.0,,CN,US,US,2019,Q4,Adult
171277251,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2019,Q4,Somnolence,,2019,Q4,1,I,20170330.0,20170202.0,20191209,20191209,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20191209.0,,CN,US,US,2019,Q4,Adult
171279713,17127971,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLETS,,2019,Q4,Hypoglycaemia,,2019,Q4,3,F,20191201.0,20191223.0,20191209,20191230,PER,,BR-EISAI MEDICAL RESEARCH-EC-2019-066649,EISAI,,63.0,YR,,F,Y,56.8,KG,20191230.0,,MD,BR,BR,2019,Q4,Adult
171296711,17129671,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Headache,,2019,Q4,1,I,,20191127.0,20191209,20191209,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C ET.AL.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20191209.0,,OT,PT,PT,2019,Q4,Adult
171296711,17129671,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Mouth ulceration,,2019,Q4,1,I,,20191127.0,20191209,20191209,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C ET.AL.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20191209.0,,OT,PT,PT,2019,Q4,Adult
171296711,17129671,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Myalgia,,2019,Q4,1,I,,20191127.0,20191209,20191209,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C ET.AL.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20191209.0,,OT,PT,PT,2019,Q4,Adult
171296711,17129671,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Neutropenia,,2019,Q4,1,I,,20191127.0,20191209,20191209,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C ET.AL.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20191209.0,,OT,PT,PT,2019,Q4,Adult
171296711,17129671,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Pyrexia,,2019,Q4,1,I,,20191127.0,20191209,20191209,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C ET.AL.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20191209.0,,OT,PT,PT,2019,Q4,Adult
171502541,17150254,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Ketoacidosis,,2019,Q4,1,I,20191111.0,20191204.0,20191213,20191213,EXP,,GB-ASTRAZENECA-2019SF75190,ASTRAZENECA,,63.0,YR,,F,Y,85.0,KG,20191213.0,,,GB,GB,2019,Q4,Adult
171502541,17150254,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Malaise,,2019,Q4,1,I,20191111.0,20191204.0,20191213,20191213,EXP,,GB-ASTRAZENECA-2019SF75190,ASTRAZENECA,,63.0,YR,,F,Y,85.0,KG,20191213.0,,,GB,GB,2019,Q4,Adult
171508721,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Creatinine renal clearance decreased,,2019,Q4,1,I,,20191204.0,20191213,20191213,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20191213.0,,CN,CA,CA,2019,Q4,Adult
171508721,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,,20191204.0,20191213,20191213,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20191213.0,,CN,CA,CA,2019,Q4,Adult
171508721,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Injection site pain,,2019,Q4,1,I,,20191204.0,20191213,20191213,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20191213.0,,CN,CA,CA,2019,Q4,Adult
171508721,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Pancreatitis,,2019,Q4,1,I,,20191204.0,20191213,20191213,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20191213.0,,CN,CA,CA,2019,Q4,Adult
171508721,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Product use issue,,2019,Q4,1,I,,20191204.0,20191213,20191213,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20191213.0,,CN,CA,CA,2019,Q4,Adult
171569581,17156958,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORMS,672.0,DF,,, UNKNOWN,,,1.0,DF,TABLET,,2019,Q4,Malaise,,2019,Q4,1,I,20191113.0,20191209.0,20191216,20191216,EXP,GB-MHRA-TPP18123756C7025916YC1573647137326,GB-TEVA-2019-GB-1151900,TEVA,,52.0,YR,,F,Y,118.0,KG,20191216.0,,MD,GB,GB,2019,Q4,Adult
171569581,17156958,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORMS,672.0,DF,,, UNKNOWN,,,1.0,DF,TABLET,,2019,Q4,Mouth ulceration,,2019,Q4,1,I,20191113.0,20191209.0,20191216,20191216,EXP,GB-MHRA-TPP18123756C7025916YC1573647137326,GB-TEVA-2019-GB-1151900,TEVA,,52.0,YR,,F,Y,118.0,KG,20191216.0,,MD,GB,GB,2019,Q4,Adult
171655961,17165596,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191102.0,20191211.0,20191217,20191217,EXP,,GB-ASTRAZENECA-2019SF79445,ASTRAZENECA,,59.0,YR,,M,Y,,,20191217.0,,,GB,GB,2019,Q4,Adult
171657641,17165764,12,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q4,Bladder tamponade,,2019,Q4,1,I,20191006.0,20191205.0,20191217,20191217,EXP,,DE-JNJFOC-20191209452,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,93.0,KG,20191217.0,,MD,DE,DE,2019,Q4,Elderly
171657641,17165764,12,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,"5 MG, QD",,,,,,,,5.0,MG,,QD,2019,Q4,Haematuria,,2019,Q4,1,I,20191006.0,20191205.0,20191217,20191217,EXP,,DE-JNJFOC-20191209452,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,93.0,KG,20191217.0,,MD,DE,DE,2019,Q4,Elderly
171658931,17165893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20191115.0,20191212.0,20191217,20191217,EXP,,GB-ASTRAZENECA-2019SF80485,ASTRAZENECA,,40.0,YR,,M,Y,,,20191217.0,,PH,GB,GB,2019,Q4,Adult
171658931,17165893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Fournier's gangrene,,2019,Q4,1,I,20191115.0,20191212.0,20191217,20191217,EXP,,GB-ASTRAZENECA-2019SF80485,ASTRAZENECA,,40.0,YR,,M,Y,,,20191217.0,,PH,GB,GB,2019,Q4,Adult
171658931,17165893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,20191115.0,20191212.0,20191217,20191217,EXP,,GB-ASTRAZENECA-2019SF80485,ASTRAZENECA,,40.0,YR,,M,Y,,,20191217.0,,PH,GB,GB,2019,Q4,Adult
171674901,17167490,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Fournier's gangrene,,2019,Q4,1,I,20191014.0,20191210.0,20191217,20191217,EXP,,GB-ASTRAZENECA-2019SF78837,ASTRAZENECA,,72.0,YR,,M,Y,121.0,KG,20191218.0,,,GB,GB,2019,Q4,Elderly
171674901,17167490,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Necrosis,,2019,Q4,1,I,20191014.0,20191210.0,20191217,20191217,EXP,,GB-ASTRAZENECA-2019SF78837,ASTRAZENECA,,72.0,YR,,M,Y,121.0,KG,20191218.0,,,GB,GB,2019,Q4,Elderly
171687101,17168710,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Pneumonia,,2019,Q4,1,I,20190407.0,20191206.0,20191218,20191218,EXP,,GB-ROCHE-2494850,ROCHE,,76.0,YR,,F,Y,,,20191218.0,,MD,GB,GB,2019,Q4,Elderly
171754821,17175482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Osteomyelitis acute,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79690,ASTRAZENECA,,58.0,YR,,M,Y,,,20191219.0,,,GB,GB,2019,Q4,Adult
171754921,17175492,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,/hr,2019,Q4,Dehydration,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79435,ASTRAZENECA,,77.0,YR,,F,Y,,,20191219.0,,,GB,GB,2019,Q4,Elderly
171754921,17175492,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,/hr,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79435,ASTRAZENECA,,77.0,YR,,F,Y,,,20191219.0,,,GB,GB,2019,Q4,Elderly
171754921,17175492,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,/hr,2019,Q4,Malaise,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79435,ASTRAZENECA,,77.0,YR,,F,Y,,,20191219.0,,,GB,GB,2019,Q4,Elderly
171754921,17175492,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,/hr,2019,Q4,Urosepsis,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79435,ASTRAZENECA,,77.0,YR,,F,Y,,,20191219.0,,,GB,GB,2019,Q4,Elderly
171768151,17176815,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Localised infection,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79684,ASTRAZENECA,,57.0,YR,,M,Y,,,20191219.0,,,GB,GB,2019,Q4,Adult
171768151,17176815,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Necrosis,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79684,ASTRAZENECA,,57.0,YR,,M,Y,,,20191219.0,,,GB,GB,2019,Q4,Adult
171768151,17176815,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Osteomyelitis,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79684,ASTRAZENECA,,57.0,YR,,M,Y,,,20191219.0,,,GB,GB,2019,Q4,Adult
171768151,17176815,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Skin ulcer,,2019,Q4,1,I,,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79684,ASTRAZENECA,,57.0,YR,,M,Y,,,20191219.0,,,GB,GB,2019,Q4,Adult
171768411,17176841,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Blood alkaline phosphatase increased,,2019,Q4,1,I,20190604.0,20191211.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF79624,ASTRAZENECA,,53.0,YR,,F,Y,85.0,KG,20191219.0,,,GB,GB,2019,Q4,Adult
171788261,17178826,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Gangrene,,2019,Q4,1,I,,20191212.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF80484,ASTRAZENECA,,69.0,YR,,F,Y,,,20191220.0,,,GB,GB,2019,Q4,Elderly
171788261,17178826,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Infected skin ulcer,,2019,Q4,1,I,,20191212.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF80484,ASTRAZENECA,,69.0,YR,,F,Y,,,20191220.0,,,GB,GB,2019,Q4,Elderly
171788261,17178826,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Pain,,2019,Q4,1,I,,20191212.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF80484,ASTRAZENECA,,69.0,YR,,F,Y,,,20191220.0,,,GB,GB,2019,Q4,Elderly
171788261,17178826,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Skin necrosis,,2019,Q4,1,I,,20191212.0,20191219,20191219,EXP,,GB-ASTRAZENECA-2019SF80484,ASTRAZENECA,,69.0,YR,,F,Y,,,20191220.0,,,GB,GB,2019,Q4,Elderly
171839111,17183911,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191125.0,20191211.0,20191220,20191220,EXP,,GB-ASTRAZENECA-2019SF79660,ASTRAZENECA,,36.0,YR,,F,Y,,,20191220.0,,,GB,GB,2019,Q4,Adult
171865781,17186578,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,40.0,MG,Y,, KL2822A,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Liver function test abnormal,,2019,Q4,1,I,20191208.0,20191213.0,20191220,20191220,EXP,,CN-ASTRAZENECA-2019SF83298,ASTRAZENECA,,24471.0,DY,,F,Y,,,20191220.0,,OT,CN,CN,2019,Q4,Elderly
172064471,17206447,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,Y,, KP3064,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Renal impairment,,2019,Q4,1,I,20191128.0,20191220.0,20191227,20191227,EXP,,CN-ASTRAZENECA-2019SF88268,ASTRAZENECA,,93.0,YR,,F,Y,60.0,KG,20191227.0,,OT,CN,CN,2019,Q4,Elderly
172100451,17210045,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,440.0,MG,Y,, 1903140,,202293.0,10.0,MG,TABLET,QD,2019,Q4,Renal impairment,,2019,Q4,1,I,20191211.0,20191220.0,20191227,20191227,EXP,,CN-ASTRAZENECA-2019SF87815,ASTRAZENECA,,77.0,YR,,M,Y,89.0,KG,20191227.0,,OT,CN,CN,2019,Q4,Elderly
172101091,17210109,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191207.0,20191223.0,20191227,20191227,EXP,,GB-ASTRAZENECA-2019SF86828,ASTRAZENECA,,60.0,YR,,M,Y,,,20191227.0,,,DE,DE,2019,Q4,Adult
172101091,17210109,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Hypotension,,2019,Q4,1,I,20191207.0,20191223.0,20191227,20191227,EXP,,GB-ASTRAZENECA-2019SF86828,ASTRAZENECA,,60.0,YR,,M,Y,,,20191227.0,,,DE,DE,2019,Q4,Adult
172101091,17210109,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2019,Q4,Hypoxia,,2019,Q4,1,I,20191207.0,20191223.0,20191227,20191227,EXP,,GB-ASTRAZENECA-2019SF86828,ASTRAZENECA,,60.0,YR,,M,Y,,,20191227.0,,,DE,DE,2019,Q4,Adult
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Abdominal pain,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Anaemia,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Blood pressure diastolic abnormal,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Blood pressure systolic abnormal,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Blood pressure systolic increased,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Chronic obstructive pulmonary disease,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Cough,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Eczema,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Gastritis,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Gastrointestinal disorder,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Gout,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Heart rate increased,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Oxygen saturation decreased,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172170841,17217084,6,C,Dapagliflozine,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Sleep disorder,,2019,Q4,1,I,,20191216.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-107136,AUROBINDO,,69.0,YR,,F,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Dyspepsia,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Feeding disorder,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Flatulence,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Heart rate irregular,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Herpes zoster,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Hyperhidrosis,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Nausea,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Pruritus,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Retching,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Syncope,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2019,Q4,Vomiting,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Dyspepsia,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Feeding disorder,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Flatulence,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Heart rate irregular,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Herpes zoster,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Hyperhidrosis,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Nausea,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Pruritus,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Retching,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Syncope,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172178871,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Vomiting,,2019,Q4,1,I,,20191220.0,20191231,20191231,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20191231.0,,OT,CA,CA,2019,Q4,Elderly
172190261,17219026,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Off label use,,2019,Q4,1,I,20170501.0,20191223.0,20191231,20191231,PER,,GB-AMGEN-GBRNI2019214066,AMGEN,,76.0,YR,E,F,Y,,,20191231.0,,MD,GB,GB,2019,Q4,Elderly
172190261,17219026,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Pneumonia,,2019,Q4,1,I,20170501.0,20191223.0,20191231,20191231,PER,,GB-AMGEN-GBRNI2019214066,AMGEN,,76.0,YR,E,F,Y,,,20191231.0,,MD,GB,GB,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Dyspepsia,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Feeding disorder,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Flatulence,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Heart rate irregular,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Herpes zoster,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Hyperhidrosis,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Nausea,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Pruritus,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Retching,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Syncope,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172208431,17220843,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,5.0,MG,,,2019,Q4,Vomiting,,2019,Q4,1,I,,20191227.0,20191231,20191231,EXP,,CA-CIPHER-2019-CA-003300,CIPHER,,69.0,YR,E,M,Y,,,20191231.0,,,CA,CA,2019,Q4,Elderly
172616681,17261668,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,1,I,2017.0,,20191217,20191217,DIR,,,FDA-CTU,,47.0,YR,,M,N,210.0,LBS,20191210.0,Y,CN,US,US,2019,Q4,Adult
172616681,17261668,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Product substitution issue,,2019,Q4,1,I,2017.0,,20191217,20191217,DIR,,,FDA-CTU,,47.0,YR,,M,N,210.0,LBS,20191210.0,Y,CN,US,US,2019,Q4,Adult
172620781,17262078,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,1,I,2017.0,,20191217,20191217,DIR,,,FDA-CTU,,47.0,YR,,M,N,95.25,KG,20191210.0,Y,CN,US,US,2019,Q4,Adult
172620781,17262078,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Manufacturing production issue,,2019,Q4,1,I,2017.0,,20191217,20191217,DIR,,,FDA-CTU,,47.0,YR,,M,N,95.25,KG,20191210.0,Y,CN,US,US,2019,Q4,Adult
172620781,17262078,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Product quality issue,,2019,Q4,1,I,2017.0,,20191217,20191217,DIR,,,FDA-CTU,,47.0,YR,,M,N,95.25,KG,20191210.0,Y,CN,US,US,2019,Q4,Adult
